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NEURODEGENERATIVE DISORDERS: I. THE CANINE MODEL OF HUMAN
AGING; II. INSIGHTS INTO SUCCESSFUL AGING; AND III. TRAUMATIC
BRAIN INJURY
The studies presented in this dissertation were conducted with the objective of
gaining greater understanding into the mechanisms of successful aging, the role of
mitochondria dysfunction in traumatic brain injury, and also on the mechanisms of
improved learning and cognitive function in the aging.
Aging is usually characterized by impairments in physiological functions
increasing its susceptibility to dementia and neurodegenerative disorders. In this
dissertation, the mechanisms of dementia-free aging were investigated. The use of an
antioxidant fortified diet and a program of behavioral enrichment in the canine model of
human aging was shown to result in a significant decrease in the levels of oxidative
stress. A proteomic analysis of these brains also demonstrated a significant decrease in
the oxidative modification of key brain proteins and an increase in the expression levels
of other key brain proteins associated with energy metabolism and antioxidant systems
which correlated with improved learning and memory.
We show that following TBI key mitochondrial-related proteins undergo
extensive oxidative modification, possibly contributing to the severe loss of
mitochondrial energetics and neuronal cell death previously observed in experimental
TBI.
Taken together, these findings support the role of oxidative stress in the
pathophysiology of aging and age-related neurodegenerative disorders and in CNS injury.
These studies also show that antioxidants and a program of behavioral enrichment
provide protection against oxidative stress-mediated cognitive impairments.
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CHAPTER ONE
Introduction and Research Aims
The studies presented in this dissertation research were geared towards
elucidating biochemical mechanisms associated with successful aging, improved learning
and memory following treatment with an antioxidant fortified diet and a program of
behavioral enrichment and also in gaining insights into mechanisms of protein oxidation
in traumatic brain injury. Aging is defined as the gradual alteration in structure and
function that occurs over time, eventually leading to an increased probability of death not
associated with disease or trauma (Ashok and Ali, 1999; Gonos, 2000). Aging, and agerelated disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are usually
accompanied by a significant increase in oxidative stress with an eventual decline in
memory and cognitive function (Butterfield and Kanski, 2001; Poon et al., 2004a).
Though various mechanisms for neurodegeneration have been put forth, the progressive
accumulation of oxidative damage has been thought to play a significant role in the
development or accumulation of neuropathology typically observed in these
neurodegenerative disorders.
The significant increase in oxidative stress and generation of free radicals
observed in these neurodegenerative disorders are mediated through a wide range of
mechanisms. Mitochondria play a key role through the generation of superoxide anion
O2· -, which undergoes various reactions leading to the production of key ROS such as
hydroxyl radical (OH·), peroxynitrite (OONO- ), and hydrogen peroxide (H2O2) among
many others (Melov, 2000). For AD, our laboratory has proposed that the significant
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increase in the levels of oxidative stress are mediated by amyloid-beta peptide (Aβ 1-42)
through methionine 35 (Met-35)-related chemistry (Varadarajan et al., 2000; Varadarajan
et al., 2001; Butterfield and Kanski, 2002). These ROS/RNS have been shown to mediate
oxidative modification of proteins, lipids and DNA as observed in AD brain when
compared to age-matched controls. Oxidative attack to peptides and proteins usually
leads to alteration in protein structure (Subramaniam et al., 1997), and a possible loss in
function contributing to the pernicious effects on cellular functions (Levine and
Stadtman, 2001; Halliwell, 2006).
The mechanisms involved in being able to achieve extended longevity while still
maintaining cognitive function are still unknown. However, it has been proposed that the
mechanism of successful aging is a product of an interaction between genetic,
environmental and lifestyle factors (Petropoulou et al., 2000; Perls et al., 2002a; Perls et
al., 2002b; Snowdon, 2003). Significantly, until the present dissertation research, the
protein profiles in these groups of individuals have not yet been established. As a result,
this dissertation research provides a proteomic expressional profile for the non-demented
nonagenarian compared to demented age-match controls, providing possible biochemical
pathways towards successful aging.
With an increase in age-related oxidative stress and cognitive dysfunction as
reported for neurodegenerative disorders such as AD and models thereof, the use of
antioxidants, antioxidant-related compounds and exercise programs have been found to
provide beneficial and protective effects against these age-related deficits (Mates et al.,
1999; Bickford et al., 2000; Milgram et al., 2002b; Drake et al., 2003b; Farr et al., 2003;
Adlard et al., 2005b). These beneficial effects include a reduction in the levels of
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oxidative stress, improvements in learning and memory and a delay in the development
of age-related cognitive deficits. However, the mechanisms that underlie these effects in
the aging brain are still not well established. It has been reported that there is a significant
improvement in cognitive function in the canine model of human aging undergoing a
program of behavioral enrichment and having a diet fortified with a broad range of
antioxidants (Milgram et al., 2004; Milgram et al., 2005). We propose in this dissertation
research that this improvement in cognitive function observed is due to a decrease in the
level of oxidative stress, up-regulation of key antioxidant enzymes and protection of key
brain proteins from oxidative damage. Therefore, this dissertation provides possible
mechanism for the improvement in learning and memory following a behavioral
enrichment program and an antioxidant fortified diet in a canine model of human aging.
This model is highly relevant to AD since Aβ (1-42) in both beagles and humans have the
same amino acid sequence.
One of the risk factors associated with developing age-related defects in learning
and memory as observed in AD is traumatic brain injury (TBI) (Jellinger, 2004b). TBI is
associated with a significant loss in mitochondrial bioenergetics, increased oxidative
stress and neuronal cell death mediated by necrosis and apoptosis (Sullivan et al., 2002;
Lifshitz et al., 2004a). Despite the well-established notion of increased oxidative stress
and decline in mitochondrial function reported in TBI, the identities of specific proteins
undergoing oxidative modification following TBI are yet to be established. As a result,
one central goal of this dissertation research is to identify specific mitochondria-related
proteins that have been oxidatively altered following TBI.
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In Summary, this dissertation addresses the following questions:
1. Which proteins are protected following the combined treatment of an antioxidant
fortified diet and a program of behavioral enrichment in the brains of the canine
(beagle) model of human aging? How do these proteins contribute to the
improved learning and memory in the aging canine model?
2. What proteins are differentially expressed in the brains of the canine model of
human aging after treatment with an antioxidant-fortified diet and a program
behavioral enrichment?
3. Which brain mitochondrial-related proteins are oxidatively modified following
experimental traumatic brain injury (TBI)?
4. What brain proteins play a role in the mechanism of successful aging as seen the
non-demented nonagenarians?
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CHAPTER TWO
Background
2.1 Neuronal structure and function
The central nervous system (CNS) represents the largest part of the nervous
system. The CNS is composed of the brain and the spinal cord, which is organized in a
network of billions of interconnected components, with the major class of cells being
neurons. In addition, this network is composed of glia and astrocytes that provide support
to the neurons. Neurons in conjunction with other specialized cells like the astrocytes or
microglia mediate the specialized function of the brain which involves the reception,
processing and transmission of information as well as neuroprotection.
The anatomy of nerve cells as shown in Fig 2.1 is composed of the cell body also
known as the soma or perikaryon, cellular extension process known as dendrites, and a
long tube-like projection known as the axon. Just like any other cellular structure, the
neuron consists of a cell membrane and organelles that perform specialized functions.
These include; the nucleus, mitochondria, Golgi apparatus, lysosomes, endoplasmic
reticulum and ribosomes among others. Due to their specialization, neurons can be
functionally classified as excitatory, inhibitory and modulatory. As already mentioned,
the main function of the neuron is the reception and transmission of information in the
form of nerve impulses. Nerve impulses are usually transmitted through electrochemical
interactions. Briefly, at rest, the intracellular potassium ions and extracellular sodium ions
generate and maintain a neuronal electrical potential of approximately -70 mV. This
movement of potassium and sodium ions is facilitated by membrane bound sodiumpotassium pumps. At rest, the cell membrane is approximately 100 times more permeable
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to potassium ions compared to sodium. In the presence of a stimulus, voltage-gated
sodium channels are opened, allowing sodium ions to diffuse into the cell hence making
the cell more positive, i.e., depolarizing the cell to about 40+ mV. Once this has
stabilized, the sodium channels close and the voltage -dependent potassium channels
open, allowing potassium to influx into the cell. This large outward current of potassium
ions hyperpolarizes the neuron. The voltage-sensitive potassium channels now close and
the continual movement of potassium through potassium leak channels again dominates
the membrane potential. Sodium-potassium pumps continue to pump sodium ions out and
potassium ions in, preventing any long-term loss of the ion gradients. The resting
potential of -70 mV is then re-established and the neuron is said to be repolarized. Fig 2.2
provides a summary of the action potential process.
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Figure 2.1 Schematic representation of the neuron and its various components.
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Figure 2.2 Summary of the action potential.
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Repolarization

2.2 Oxidative stress
2.2.1 Overview
Under normal physiological conditions, there exists a balance between the
amounts of oxidants and antioxidant defenses present in the body. However, as a result of
disease, trauma, or environmental factors, there is a shift towards an increase in the
production of pro-oxidants or a decline in the levels of antioxidants. Consequently, the
rate at which reactive species are generated exceeds the rate at which endogenous
antioxidant defenses can scavenge oxidants. This resulting imbalance is what is defined
as oxidative stress (Halliwell, 2006) (Fig. 2.3). It has been established that ROS/RNS
play a significant role in the normal aging process as well as in various age-related
diseases neurodegenerative disorders (Ames et al., 1993a; Markesbery, 1997; Lewen et
al., 2000; Poon et al., 2004a; Dalle-Donne et al., 2006). An increase in the levels of
oxidative stress has been reported in a number of conditions like: Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis
(ALS) among many others (Butterfield and Kanski, 2001).
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Figure 2.3 A representation of normal vs. oxidative stress conditions.
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2.2.2 Free radical production
2.2.2.1 Overview
Free radicals are defined as low molecular weight molecules that contain at least
one unpaired electron and have previously been shown to mediate the pathophysiology of
most neurodegenerative disorders (Nordberg and Arner, 2001; Droge, 2002). These
radical species can be dived into primary radical species of which some examples are
OH·, O2·- CO2·- NO· and non-radical species are H2O2, N2O2, O2, NO2, HO2, and HOCl
among many others (Halliwell, 2006).

2.2.2.2 Reactive oxygen species (ROS)
ROS are defined as a group of highly reactive molecules usually derived from
ground-state oxygen (O2) (Halliwell, 1996; Fridovich, 1999; Halliwell, 1999; Betteridge,
2000). Some common examples include superoxide anion (O2· -), hydroxyl radical (OH·),
and hydrogen peroxide H2O2 among many others. This single most important source of
ROS is the mitochondria. As a by-product of energy metabolism during normal cellular
respiration, there is a 1-2% leakage of electrons from the mitochondria leading to the
partial reduction of oxygen (reaction 1) to form a highly toxic free radical known as
superoxide (Turrens, 2003). A detailed discussion on mitochondria’s role in oxidative
stress is provided below (Section 2.4.5). Superoxide dismutase catalyzes the dismutation
of superoxide to hydrogen peroxide and water. However, in the presence of transition
metal ions in the reduced state, like Fe2+ or Cu+, H2O2 is further converted to hydroxyl
radical OH· (reaction 2). Superoxide can also be produced from the activity of enzymes
such as xanthine oxidase and NADPH oxidase. Fig 2.4 below provides a summary of the
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pathways to the generation of the ROS mentioned above. A detail discussion of these
pathways is provided below in Section (2.4 and 2.7.2).

Reaction 1: O2 + e-

O2·-

Reaction 2: H2O2 + Fe2+

HO· + OH- + Fe3+
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Figure 2.4 Pathways leading to the production of ROS/RNS and antioxidant systems.
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2.2.2.3 Reactive nitrogen species (RNS)
RNS represent a group of reactive nitrogen containing compounds with the most
common examples being NO, peroxynitrite (-OONO), and nitrogen dioxide (NO2). Nitric
oxide radical is produced from the activation of the enzyme nitric oxide synthase (NOS).
There are three isoforms of NOS, i.e., inducible NOS (iNOS), endothelial NOS (eNOS),
and neuronal NOS (nNOS) (Calabrese et al., 2000). Nitric oxide (NO) in the presence of
superoxide reacts to form peroxynitrite reaction 3. Nitric oxide regulates various cellular
processes that include vasodilatation, modulation of signaling cascades, and immune
responses among many others. On the other hand, it has also been shown that nitric oxide
is involved in tissue injury and the progression of various inflammatory pathways in
neurodegenerative disorders as reviewed in (Halliwell, 2006). A detailed discussion on
the reactions of OONO is provided in Section (2.2.1.3.2).

Reaction 3: NO + O2·-

-

OONO
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2.2.3 Targets of Reactive oxygen species
2.2.3.1 Protein oxidation
Protein oxidation is an important post-translational modification observed in a
number of neurodegenerative disorders. Proteins are highly sensitive to oxidative
modifications by ROS/RNS. Oxidative damage to proteins can have a wide range of
downstream functional consequences. These can include inhibition of enzymatic activity,
increased susceptibility to degradation among many others. In AD and other
neurodegenerative disorders, there is a significant increase in the levels of protein
oxidation (Aksenova et al., 1998; Levine and Stadtman, 2001; Butterfield and
Lauderback, 2002; Halliwell, 2006). It should be noted, however, that the progressive
accumulation of oxidative damage is a combination of multiple factors. These include; a)
rate of formation of ROS/RNS; b) sensitivity of proteins to these ROS/RNS; c)
availability of antioxidant defense mechanisms; and d) the effectiveness of the
mechanism involve in the repair or elimination of damaged proteins (Stadtman and
Berlett, 1997; Stadtman and Levine, 2003). Some examples of oxidative modifications
are discussed here.

2.2.3.1.1 Protein carbonyls
The levels of protein carbonyls can index protein oxidation. The levels of protein
carbonyls have been shown to be a good marker of oxidative stress (Levine et al., 1990).
There is a significant increase in the levels of protein carbonyls in aging and in agerelated neurodegenerative disorders (Hensley et al., 1996). Protein carbonyl formation
can be introduced into proteins through three major mechanisms (Levine et al., 1990;
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Butterfield and Stadtman, 1997; Stadtman and Levine, 2003). These are I) Oxidation of
specific amino acids present in protein residues (Fig 2.5) II); β-scission of peptide
backbone (Fig 2.6); and III); Covalent modification of amino acids by reactive aldehydes
like HNE and acrolein (Fig 2.7). It can therefore be seen that protein carbonyl formation
is orders of magnitude greater than other oxidative modifications making it a widely used
marker for protein oxidation. The levels of protein carbonyls can be analyzed
immunochemically. The details of this procedure will be discussed in Chapter 3.
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Diamide
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Figure 2.5 Peptide bond cleavage and formation of protein carbonyls through the
diamide and α-amidation pathways.
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Figure 2.6 Mechanism of protein carbonyl formation from β-scission.
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Figure 2.7. Covalent modification of key amino acids by HNE.
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2.2.3.1.2 3-Nitrotyrosine (3NT)
Protein oxidation also can be indexed by the levels of 3-nitrotyrosine (3NT). As
mentioned previously, the activity of nitric oxide synthase leads to the production of
nitric oxide. This is usually through the catalytic conversion of L-arginine to citrulline
(Calabrese et al., 2000). Nitric oxide in itself is not a strong oxidant, but the diffusion rate
limited reaction with superoxide anion leads to the production of a highly reactive species
known as peroxynitrite ONOO- (Reaction 3). This reaction leading to the formation of
peroxynitrite is regulated by the enzymatic activities of NOS and SOD, since they are the
two enzymes that produce the needed reactants. Peroxynitrite is highly reactive with a
half-life of less than one second and it can exist in two forms; either as the peroxynitrite
anion (ONOO-), or as the protonated peroxynitrous acid (ONOOH) (reaction 4). This
protonated form can undergo hemolytic cleavage to form the toxic species hydroxyl and
nitrite radicals (reaction 5). It should be noted however, that this reaction proceeds via
carbon dioxide as shown in Fig 2.8a
Reaction 4: ONOO- + H+
Reaction 5: HOONO

HOONO
OH + NO2 .

.

Under physiological conditions it has been proposed that peroxynitrite reacts
with carbon dioxide with the resulting reactive intermediates being responsible for the
nitration of proteins (Fig 2.8a) (Denicola et al., 1996). The initial reaction of peroxynitrite
and carbon dioxide produces an intermediate known as nitrosoperoxycarbonate (Lymar
and Hurst, 1996; Lymar et al., 1996). This species then undergoes rearrangement,
forming nitrocarbonate. The homolysis of nitrocarbonate can then generate a carbonate
anion and a nitrite radical, which can then react with tyrosine residues on proteins leading
20

to the formation of 3-nitrotyrosine (3NT) Fig 2.8b). It should be noted however, that in
certain cases (like the reaction of peroxynitrite with glutathione) the presence of carbon
dioxide inhibits peroxynitrite reaction (Zhang et al., 1997). The levels of 3NT can be
detected immunochemically, and it has been shown that in aging and age-related
disorders, there is a relative increase in the levels of 3NT, further confirming the notion
of increased oxidative stress in these neurodegenerative disorders (Schulz et al., 1997).
Though not discussed, it should be noted that there are other possible nitration end
products that can be produced from the reactions mentioned above. Some examples are
dityrosine and tyrosine peroxide as shown in Fig 2.8b (Ducrocq et al., 1999).
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Figure 2.8a: Formation of peroxynitrite and its reaction in the presence of carbon
dioxide.
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Figure 2.8b: Mechanism of 3NT formation.
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2.2.3.2 Lipid peroxidation
There is accumulating evidence implicating lipid peroxidation in the aging
process and also in age-related neurodegenerative disorders like AD among other
diseases (Butterfield and Lauderback, 2002; Dei et al., 2002). Lipids are particularly
vulnerable to oxidative attack due to the availability of unsaturated fatty acid β-chains
and the solubility of paramagnetic oxygen in the bilayer. Lipid peroxidation proceeds via
a free-radical mediated chain reaction that is initiated by the abstraction of labile
hydrogen by the radical forming a carbon centered radical (reaction 6). The lipid radical
then reacts rapidly with paramagnetic oxygen forming a peroxyl radical (reaction 7). This
peroxyl radical reacts with nearby lipids, abstracting another nearby allylic hydrogen
atom, forming lipid hydroperoxides and another carbon-centered radical. If not impeded
the chain reaction propagates (reaction 8). Lipid peroxidation is terminated by the
quenching reaction of two peroxyl radicals forming oxygen and a nonradical species
(Reaction 9). The presence of vitamin E (α- tocopherol), an endogenous lipid soluble
antioxidant can also terminate this chain reaction as a chain-breaking antioxidant. The
lipid peroxyl radical can abstract a labile hydrogen from α- tocopherol (TOH) forming a
tocopheroxyl radical TO·. This radical can be recycled back to TOH by ascorbic acid
(vitamin C). Hence, the use of both vitamin E and C as supplements against oxidative
stress-mediate disorders is often employed. This will be discussed in detail in Section
(2.7.3).
L. + XH

Reaction 6: LH + X·
Reaction 7: L. + O2

LOO.

Reaction 8: LOO. + LH

LOOH + L.
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Reaction 9: LOO. + LOO.

Nonradical + O2

2.2.3.2.1 Membrane composition
Biological cellular membranes occur in several locations including the plasma
membrane. Biological membranes are selectively permeable membranes composed of
lipid bilayers, proteins, cholesterol and carbohydrates (Fig 2.9). The fluid mosaic model
of lipid bilayer demonstrates that the cell membrane is composed of two “leaflets”. Each
leaflet is composed of glycerol-derived phospholipids that contain a polar phosphate head
and hydrophobic chains. The leaflets are oriented in such away that one polar phosphate
head is towards the cytosol while the other is towards the extracellular milieu. The brain
is particularly rich in peroxidizable polyunsaturated fatty acids (PUFA). Some common
examples are arachidonic (AA, 20:4n-6) (Fig 2.10), and decosahexaenoic acid (DCH,
22:6n-6) (Fig 2.11) among many others. In neurodegenerative disorders like AD, there is
a decline in the levels of PUFA, possibly due to their release from the cell membrane by
the actions of phospholipase A2 (Pratico et al., 1998). These free phospholipids in turn
can undergo either enzymatic or non-enzymatic oxidation leading to the generation of
reactive aldehydes, prostaglandin isomers and other key biomolecules that play a role in
the oxidative stress pathology of neurodegenerative disorders. Figure 2.12 shows the free
radical-mediated formation of 4-hydroxy-2-trans-nonenal (HNE) from arachidonic acid.
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Figure 2.9 Representation of the membrane bilayer.
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Fatty acyl
chains

Figure 2.10 Arachidonic acid (AA, 20:4n-6)

Figure 2.11 Decosahexaenoic acid (DCH, 22:6n-6)
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Figure 2.12: Free radical formation of HNE from arachidonic acid.
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2.2.3.2.2 Reactive aldehydes
Reactive aldehydes are considered to be the end products of lipid peroxidation.
Free radical attack on PUFA leads to the formation of reactive alkenals with varying
carbon chain lengths. The most common α, β-unsaturated aldehydes observed in
neurodegenerative disorders include: 4-hydroxy-2-nonenal (HNE), acrolein (2-propenal),
and malondialdehyde (MDA). Relative to free radicals, these reactive aldehydes have
longer half-lives that allow for their diffusion to distant sites from their site of formation.
These alkenals can readily react via Michael addition with proteins, leading to the
formation of stable covalent protein-bound adducts with cysteine, lysine, and histidine
residues (Butterfield and Stadtman, 1997; Subramaniam et al., 1997). These
modifications can lead to conformational and structural changes in proteins thereby
leading to loss of function and cytopathologic effects observed during oxidative stress.
These reactive aldehydes in themselves or as thiobabituric acid species have been used as
excellent biomarkers of lipid peroxidation in various neurodegenerative disorders. There
is an elevation in the concentrations of free HNE in the ventricular cerebral spinal fluid
CSF of AD patient, while the levels of protein-bound HNE are also increased (Lovell et
al., 1995; Markesbery and Lovell, 1998; Lauderback et al., 2001). HNE bound to proteins
is also elevated in brain of subjects with mild cognitive impairments (Butterfield et al.,
2006b) usually the milder form of AD. Acrolein is the most reactive of this group of
aldehydes. Acrolein adducts have been observed in the NFT of AD patients compared to
control (Lovell et al., 2001). Acrolein has also been shown to bind to NADH-dependent
mitochondrial enzymes, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase
leading to their inactivation (Pocernich and Butterfield, 2003). On the other hand, MDA
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can also undergo similar reactions like HNE. There is an increase in the levels of MDA in
the inferior temperal cortexes of aged human brain, (Palinski et al., 1990), and in
cytoplasm of neurons and astrocytes (Dei et al., 2002). In the canine model of human
aging, it was observed that lipid peroxidation as indexed by MDA was increased as a
function of age (Head et al., 2002). As a result, these studies and others continue to
provide support for the involvement of oxidative stress and lipid peroxidation in
neurodegenerative disorders.

2.2.3.2.3 Isoprostanes and Neuroprostanes
In addition to reactive aldehydes, iso-and neuroprostanes present another index
for lipid peroxidation and oxidative stress (Morrow and Roberts, 1999; Milne et al.,
2005). The free radical catalyzed non-enzymatic oxidation of the PUFA arachidonic acid
and docosahexanoic acid, results in the generation of biologically active prostaglandin
derivatives (Morrow, 2006). These prostaglandin isomers are referred to as isoprostanes
(IsoPs) and neuroprostanes (NP), respectively, and they represent a reliable index for
lipid peroxidation. The levels of isoprostanes and neuroprostanes have been reported to
be increased in AD patients, providing additional evidence for lipid peroxidation in AD
(Pratico et al., 1998; Montine et al., 2005). In addition, 8-isoprostaglandin F2 alpha has
also been used as a marker for lipid peroxidation after experimental brain injury
(Hoffman et al., 1996).
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2.2.3.3 DNA oxidation
Oxidative modification of DNA has been observed during normal brain aging and
also in AD (Mecocci et al., 1993). There is increased damage to both nuclear and
mitochondrial DNA. Mitochondrial DNA is particularly vulnerable to oxidative attack
when compared to nuclear DNA because of their proximity to the source of production of
ROS, the lack of protective histones and also their inability to perform repair mechanism
(Wallace, 1992; Ames et al., 1993b). Also, there is recent evidence in AD brains that Aβ
(1-42), which produces oxidative stress , resides in mitochondria (Beal, 2004). This
damage could probably lead to deleterious effects to the mitochondria and it has been
proposed that this is one of the mechanisms resulting to mitochondrial alterations in most
neurodegenerative disorders (Beal, 2005; Schapira, 2006). DNA oxidation has been
shown to be mediated through the oxidative attack of DNA by ROS particularly hydroxyl
radical (OH·). Oxidative attack on DNA by hydroxyl radical yields a large number of
possible base-adducts; for example, it could lead to modification of DNA bases, DNA
strand breaks, DNA-DNA or DNA-protein crosses links among many others. The most
common adduct is 8-hydroxy-2'-deoxyguanosine (8-OHdG), resulting from the
hydroxylation of guanine at the C8 position. The quantified levels of 8-OHdG have since
been used as the best biomarkers of DNA oxidative damage. During aging and agerelated disorders, there is a significant increase in the levels of 8-hydroxy-2'deoxyguanosine (8-OHdG) in AD patients compared to controls (Mecocci et al., 1993;
Lovell et al., 1999).
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2.3 Brain aging and oxidative stress
2.3.1 Overview
As noted above, aging is defined as the gradual alteration in structure and function
that occurs over time, eventually leading to an increased probability of death not
associated with disease or trauma. Aging can be considered to be a product of an
interaction between genetic, environmental and lifestyle factors (Ashok and Ali, 1999;
Gonos, 2000). Aging is usually characterized by impairments in physiological functions,
such as impairments in the brain, mitochondrial dysfunction, increased susceptibility to
dementia and neurodegenerative disorders, i.e., Alzheimer’s disease (AD) (Calabrese et
al., 2001; Lenaz et al., 2006). As was mentioned previously, the aging process usually
makes the brain susceptible to oxidative attack leading to neuronal cell death and loss of
memory and cognitive functions. The brain is particularly susceptible to oxidative
damage due to a number of factors. (a) The brain has one of the highest metabolic rates of
any organ and is solely dependent of the supply of oxygen for its function. This
characteristic therefore leads to the increased production of ROS through the
mitochondria. (b) The brain lacks a relative capacity of antioxidant defense systems. (c)
The brain has a high level of polyunsaturated fatty acids (PUFA) that can easily undergo
peroxidation leading to the formation of reactive aldehydes among others as discussed
previously and (d) There is a high level of redox metal ion (Fe2+), which can participate
in lipid peroxidation reaction (Poon et al., 2004a).
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2.3.2 Free radical theory of aging
The aging process is an interaction of a wide range of factors leading to the
proposition of various theories that try to define and elucidate the aging process. Among
these theories is the free radical theory of aging. This was first proposed by Harman in
1956 (Harman, 1956) and it postulates that the production of reactive free radicals leads
to the progressive damage of biomolecules such as proteins, lipids or DNA resulting into
a loss of cellular function leading to eventual cell death (Beckman and Ames, 1998;
Droge, 2002; Harman, 2003, 2006). This theory is supported not only by the
involvement of oxidative stress in age-related disorders like AD, but also with the
established notion that there is increased oxidative stress and altered antioxidant activity
in the aging process (Beckman and Ames, 1998).
2.3.3 Alzheimer’s disease
Alzheimer’s disease (AD), first reported by Alois Alzheimer in 1907, is one of the
most common forms of dementia affecting the elderly population and accounting for 5060% of all dementia cases. In the western world, the prevalence of AD in people aged 85
year and above is approximately 50% (Blennow et al., 2006). In 2001, it was estimated
that approximately 24 million people were affected with AD, and it is believed that due to
the increasing life expectancy, 81 million people will be affected by the year 2040 (Ferri
et al., 2005). The costs involved with AD in the USA are estimated at least $100 billion
annually and it has been suggested that AD has the potential to become an overwhelming
public health concern. Consequently, these facts create an urgent need for the
development of potential therapeutic interventions. The most common risk factors for
developing AD is aging, other risk factors include; a decreased reserve capacity of the
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brain, including reduced brain size, low educational and occupational attainment, low
mental ability in early life, reduced mental and physical activity during late life, traumatic
brain injury, and genetics among many others (Mayeux, 2003; Mortimer et al., 2003;
Jellinger, 2004a, b). Clinically, AD is marked by loss in memory and cognitive functions,
loss of language function and motor skills, altered behavior and ultimately death. Its
pathophysiological hallmarks include senile plaques (SP), neurofibrillary tangles (NFT),
and synapse loss starting in the entorhinal cortex and progressing into the hippocampus
and cortex (Markesbery, 1997). One underlying mechanism associated with AD is the
involvement of oxidative stress as indexed by the increase in the levels of protein
oxidation as indexed by protein carbonyls and 3-nitrotyrosine, and also by the levels of
lipid peroxidation indexed by levels of free and protein bound HNE among many other
indices.
2.3.3.1 Amyloid-beta peptide (Aβ)
Central to the mechanisms of increased oxidative stress in AD is amyloid-βpeptide (Aβ). Senile plaques primarily are composed of Aβ protein, which is a 39-43
amino acid peptide. Aβ is produced by the proteolytic cleavage of amyloid precursor
protein (APP) by β-secretase and γ-secretase at the amino terminus by and at the carboxy
terminus, respectively (Butterfield and Boyd-Kimball, 2005). The cleavage by γ secretase can occur at varying positions within the carboxy terminus, hence generating
Aβ peptides of varying length. The two main Aβ peptides found in human brain are Aβ
(1-40) and Aβ (1-42) with Aβ (1-42) being the main component of senile plaques and the
more toxic form (Figure 2.13).

34

Our laboratory and others have established a role for Aβ-induced oxidative stress
in AD. Support for this comes from the fact that Aβ (1-42) has been shown to induce
protein oxidation and lipid peroxidation in vitro and in vivo (Hensley et al., 1995;
Markesbery, 1997; Yatin et al., 1999; Butterfield and Lauderback, 2002; Drake et al.,
2003a). We have proposed that Aβ1-42 peptide, as a small oligomer, inserts itself in the
lipid bilayer in an α-helix conformation. A one-electron oxidation of methionine forms
the methionine sulfuranyl radical, which can then abstract a labile hydrogen atom from
neighboring unsaturated lipids forming a carbon-centered lipid radical (L.), which can
react with molecular oxygen to from a peroxyl radical (LOO.). This peroxyl radical can
abstract hydrogen from a neighboring lipid to form the lipid hydroperoxide LOOH and a
carbon centered radical L., which propagates the free radical chain reaction (Varadarajan
et al., 2001; Butterfield et al., 2005) (See reactions 6-9 above). It is this mechanism of
free radical generation that we believe is responsible for the increased levels of oxidative
stress leading to neurodegeneration and a decline in memory and cognitive function in
AD patients hence continuing to support the rationale of the free radical theory of aging
(Markesbery, 1997; Beckman and Ames, 1998).
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Figure 2.13 Proteolytic cleavage of APP by β-secretase and γ-secretase.
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2.3.4 Successful aging
Successful aging or normal aging can be defined as the ability to achieve
extreme old age while still maintaining intact cognitive function. Centenarians are the
fastest growing age-group in the USA, and it is projected that there will be more that
400,000 persons in the next 30 years over 100 years old (Silver et al., 2002). Studies have
shown that there is an increase in the incidence of dementia among people aged 85 years
and above (Silver et al., 2001; Perls, 2004b, a), and most people believe that dementia is
inevitable to people in this age group (Blansjaar et al., 2000; Snowdon, 2003; Perls,
2004a). However, various studies on nonagenarians and centenarians have shown that
approximately 30% of centenarians are cognitively intact and that among those who are
demented, 90% show a delay in the time they present signs of cognitive impairments well
into their 90’s (Hagberg et al., 2001; Silver et al., 2001; Perls, 2004b, a). As a result, the
increasing number of cognitively intact nonagenarians and centenarians disputes the
notion that the older one becomes that dementia is inevitable (Green et al., 2000; Perls,
2006). The mechanisms involved in the rising number of the dementia-free oldest-old
appear to be the result of a complex combination of various factors. These include
genetics, environment, and lifestyle among others. These factors, therefore, add to the
complexity of understanding the mechanisms involved in the process of successful aging
in the human population (Perls, 2005; Perls, 2006). In the current dissertation research,
we have sought to gain a better understanding of biochemical mechanisms involved in
successful aging.
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2.3.5 Animal models of aging
Studies that try to elucidate the mechanisms of human aging and age-related
disorders are usually hampered by the lack of a good animal model that can be easily
translated to the human population. However, huge strides have been made in developing
animal models, e.g. transgenic mice that have led to an increase in the understanding of
the mechanisms of human aging. The differences between the genomes of the human and
the animal species is one major setback in studying age-related neurodegenerative
disorders; moreover, the use of primates which are closer species to humans is not always
feasible for age-related studies, due to the length of time required to observe such agerelated effects. Recently, the use of the canine model of human aging has gained
considerable interest (Cummings et al., 1996b; Cummings et al., 1996a; Cummings et al.,
1996c; Head and Torp, 2002). As will be seen in Chapters 4 and 5, the aging canine
provides one of the best models for human aging due to a number of reasons. These are:
a) Aged canines develop aspects of neuropathology similar to that observed in aged
humans; (b) Canines exhibit a clinical syndrome of age-related cognitive dysfunction; (c)
Aged canines are deficient on a variety of neuropsychological tests of cognitive function;
and (d) Canines develop extensive β-amyloid deposition within neurons and their
synaptic fields which appears to give rise to senile plaques. This level of β-amyloid
deposition correlates with cognitive dysfunction, and the amino acid sequence of beagle
Aβ is the same as that in humans.
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2.4 Mitochondria
2.4.1 Overview
There is increasing evidence for mitochondrial involvement in the pathogenesis of
neuronal cell death in most neurodegenerative disorders. This evidence applies to aging,
age related-disorders like Alzheimer’s and Parkinson’s disease, amyotrophic lateral
sclerosis (ALS) hereditary spastic paraplegia, and cerebellar degenerations, multiple
sclerosis (MS) and also in various nervous system injuries like TBI. Oxidative stress and
excitotoxicity seem to play a key role in the mechanisms leading towards the observed
mitochondrial dysfunction (DiMauro et al., 1993; Melov, 2000; Calabrese et al., 2001;
Dalakas et al., 2001; Lenaz et al., 2002; Fiskum et al., 2003; Lifshitz et al., 2004a; Beal,
2005; Zeevalk et al., 2005).
2.4.2 Mitochondria structure
Mitochondria are organelles that evolved from a symbiotic relationship between
aerobic bacteria and primordial eukaryotic cells. Mitochondria still carry a functional
relic of their original genome (DiDonato et al., 1993; Wallace, 2005). They are
intracellular tubular organelles delimited by two membranes. The outer mitochondrial
membrane (OMM) is permeable to ions and small proteins of molecular weights < 10
kDa, while the inner mitochondrial membrane houses the multimeric enzyme complexes
of the electron transport chain (Schapira, 2002). Human mitochondrial DNA is a circular
double stranded molecule of about 16.6 Kb long with the genome containing 37 genes.
Of these, 13 genes encode protein subunits of respiratory chain complexes with a
significant amount of mitochondrial proteins being encoded by the nuclear genome and
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transported into the mitochondria. For example, complex II is solely composed of
proteins encoded by nuclear genes (Orth and Schapira, 2001; Schapira, 2006). The
varying mitochondrial density in various tissues is usually dictated by the need for
oxidative phosphorylation and energy production (Orth and Schapira, 2001) . For
example, it is considered that cardiac, skeletal muscles cells, and neurons have the
highest density of mitochondria; hence, their sensitivity to energy dependent defects
resulting from mitochondrial dysfunctions in aging, age-related disorders or injury are
elevated (Schapira, 2006).
2.4.3 Mitochondria and energy metabolism (Bioenergetics)
Central to the role of mitochondria is energy metabolism through the
production of ATP. This energy production is usually carried out at the level of the inner
mitochondrial membrane through oxidative phosphorylation involving the reduction of
oxygen to water by multimeric enzyme complexes (Green and Reed, 1998; Stavrovskaya
and Kristal, 2005). The electron transport chain (ETC) is composed of NADHubiquinone oxidoreductase (complex I), succinate dehydrogenase-CoQ oxidoreductase
(complex II), cytochrome reductase (complex III), cytochrome oxidase (complex IV),
and ATP synthase, which is sometimes referred to as complex V (Dudkina et al., 2005;
Schapira, 2006). These multimeric complexes are arranged in the inner mitochondrial
membrane according to their reduction potentials (Sullivan et al., 2005) (Fig 2.14).
During oxidative phosphorylation, ETC complexes are usually involved in reduction and
oxidation reactions through reducing equivalents such as NADH or succinate, which are
transported into the mitochondria from the cytosol. In the process, protons are pumped
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from the matrix into the intermembrane space terminating with the reduction of O2 to
H2O. The transfer of protons from the matrix to the inner mitochondrial membrane leads
to the generation of a mitochondrial membrane potential ∆Ψm of 150-180 mV, which
usually determines the energetic status of the mitochondria (Nicholls et al., 1999a). This
reserve of potential energy through the electrochemical gradient is then coupled to the
generation of ATP, from ADP and inorganic phosphate Pi through the ATP synthase
complex (complex V) (Dubinsky et al., 2004). There is a significant compromise in the
mitochondrial bioenergetics in aging and neurodegenerative disorders as mentioned
above. Since neurons solely depend on the ATP from glycolysis and mitochondria
metabolism, this loss in ATP production usually makes the neurons vulnerable to
oxidative stress, which eventually results into neuronal cell loss through necrosis or
apoptosis.
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Figure 2.14 Representation of the inner mitochondrial membrane and the ETC
complexes.
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2.4.4 Excitotoxicity and Ca 2+ regulation.
Mitochondria under normal conditions usually act as high capacity Ca2+ sinks
through a highly complex system for the regulation and the transportation of Ca2+
(Gunter and Gunter, 1994; Bianchi et al., 2004; Campanella et al., 2004; Szabadkai et al.,
2006). Through these processes, mitochondria sense and respond to changes in cytosolic
Ca2+ loads to maintain cellular Ca2+ homeostasis that is required for normal neuronal
function (Ichas and Mazat, 1998; Rizzuto et al., 1998; Gunter et al., 2000). Disruption in
Ca2+ homeostasis is one of the major factors that contribute to the neuropathology
following most neurodegenerative disorders like AD and in some CNS injury like
traumatic brain injury (Bianchi et al., 2004; Campanella et al., 2004). In
neurodegenerative disorders, mitochondrial dysfunction is primarily involved in
glutamate neurotoxicity (Globus et al., 1995; Azbill et al., 1997; Montal, 1998). In AD,
glutamate excitotoxicity and calcium dysregulation have been shown to be examples of
etiologies that follow in addition to oxidative stress. Glutamate excitotoxicity is usually
triggered by the excessive influx of calcium following activation and over-stimulation of
NMDA subtype of glutamate receptors (Lipton and Rosenberg, 1994; Nicholls and Budd,
1998a; Liu et al., 1999; McAdoo et al., 1999). The resulting increase in intracellular
calcium has been shown to lead to impaired function of the mitochondrial ETC,
formation of ROS/RNS, and in particular superoxide anion and hydrogen peroxide
(White and Reynolds, 1996; Brustovetsky et al., 2002; Brustovetsky et al., 2003; Sullivan
et al., 2005). In addition, extreme loads of Ca2+, as will be discussed later, lead to the
opening of the mitochondrial permeability transition pore (mPTP) and induction of
apoptotic pathways eventually leading to neuronal cell death following most CNS trauma
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(Kristal and Dubinsky, 1997; Hirsch et al., 1998; Brustovetsky et al., 2002; Halestrap et
al., 2002; Sullivan et al., 2005).

2.4.5 Mitochondria and oxidative stress
As mentioned earlier mitochondria are a key source of ROS. Through the
generation of ATP via oxidative phosphorylation by the ETC components, there is
always some leakage of electrons (1-2%) from the mitochondria resulting in the partial
reduction of O2 to form superoxide anion O2. - , a majority of which is generated from
complex I and complex III of the ETC (Kushnareva et al., 2002; Liu et al., 2002; Zeevalk
et al., 2005; Halliwell, 2006). The production of superoxide anion can occur when the
electron transport chain is impeded following mitochondrial injury or during
neurodegenerative disorders as seen in the case of aging, AD and PD (DiMauro et al.,
1993; Lenaz et al., 2002; Lenaz et al., 2006). It should be noted that the production of
ROS by mitochondria is tightly linked to the mitochondrial membrane potential, since
hyperpolarization or high mitochondrial membrane potential promotes the production of
ROS (Liu et al., 2002; Sullivan, 2005). With a high mitochondrial membrane potential,
the ETC cannot transfer protons against the electrochemical proton gradient from the
matrix. This, in essence, leads to a reduced state of electron carriers and an increase in the
half life of semiquinone (Green and Kroemer, 2004). The intermediates thus remain in a
prolonged reduced state therefore increasing the chances of electron leakage and partially
reduction of O2 to superoxide anion O2.- (Liu et al., 2002).
One major pathway predominantly involved in the production of ROS/RNS is the
secondary activation of glutamate receptors and excitotoxicity following injury to the
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nervous system (White and Reynolds, 1996; Nicholls and Budd, 1998b; Nicholls et al.,
1999b). As already mentioned, following elevated cytosolic levels of Ca2+ in
neurodegenerative disorders or in CNS injury, excess Ca2+ is sequestered into the
mitochondrial matrix through various transporters (Gunter et al., 1998; Bianchi et al.,
2004). However, excessive calcium loads result in the dysregulation of mitochondrial
Ca2+ homeostasis leading to the activation of nitric oxide synthase (iNOS) and the
production of nitric oxide radical (NO·). The presence of nitric oxide NO and superoxide
anion O2.- as earlier discussed leads to the formation of peroxynitrite ONOO-, another
significant RNS, which can lead to the oxidative modification of proteins through
nitration (Beckman et al., 1990). Elevated intracellular Ca2+ levels also activate
phospholipase A2 (PLA2). This enzyme liberates the unsaturated fatty acid arachidonic
acid initiating the formation of free radicals via cyclooxygenase-2 (COX-2) and
lipoxygenase pathways. Arachidonic acid can also be oxidized leading to the formation
of lipid peroxidation products such as HNE, MDA, acrolein among others (Butterfield
and Stadtman, 1997; Lipton, 1999; Mirjany et al., 2002). The activation of inflammatory
response following CNS injury also leads to the production of substances such as
cytokines, tumor necrosis factor α (TNFα), and interleukin 1 (IL-1β) that can damage
neurons. In addition, activation of microglia and astrocytes can also lead to the generation
of more ROS. For example, NADPH and xanthine oxidase significantly contribute to O2·production upon activation of microglia (Gabryel and Trzeciak, 2001; Zeevalk et al.,
2005). If the significant increase in ROS and RNS following CNS injury is not
controlled, damage to DNA, proteins or lipids would result, eventually leading to loss of
function and possibly neuronal cell death as observed in neurodegenerative disorders.
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2.4.6 Mitochondria permeability transition pore (mPTP)
The mitochondrial permeability transition (mPT) is defined as an increase in
the permeability of the inner mitochondrial membrane to solutes that have molecular
masses lower than 1.5 KDa (Sullivan et al., 2005). The induction of this transition has
since been demonstrated to involve the opening of a 2-3mm inner membrane mega
channel now referred to as the mitochondria permeability transition pore (mPTP) (Jacotot
et al., 1999; Halestrap et al., 2002). This pore is a voltage-dependent channel, which is
activated by the elevation of Ca2+ levels, oxidative stress and low inner mitochondrial
membrane potentials as observed in most nervous system injuries (Hunter and Haworth,
1979). The exact identity of this mega -channel is still under investigation. However,
recent progress has been made in trying to provide a logical model for its composition.
The minimum configuration of the mPTP requires the adenine nucleotide translocator
(ANT), which is located in the inner mitochondrial membrane, in association with outer
mitochondrial membrane proteins such as the voltage-dependent anion channel (VDAC)
and cyclophilin-D (CyP-D), a peptidyl–prolyl cis-trans isomerase whose activity is
usually inhibited by immunosuppressant cyclosporine A (CsA) (Bernardi, 1996;
Halestrap et al., 2002). In addition, other proteins such as Bcl-2 and Bax have been
shown to interact with the ANT, as a result providing a regulatory role for the mPTP
(Marzo et al., 1998b; Marzo et al., 1998a; Halestrap et al., 2002). The exact physiological
function of the mPTP has not been established, however, there seems to be a clear
consensus on its involvement in the induction of permeability transition in the
neuropathology of various CNS injuries such as TBI and spinal cord injury (SCI) (Kristal
and Dubinsky, 1997; Halestrap et al., 2004; Sullivan et al., 2005). This is particularly
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evident, since, it has been established that CNS injury triggers the opening of the mPTP,
resulting in a collapse of the electrochemical gradient, the swelling of mitochondria, the
inhibition of ATP synthesis, the release of apoptotic factors and the eventual initiation of
cell death pathways that are blocked by the use of cyclophilin-D binding
immunosuppressant drug cyclosporine A (CsA) (Bernardi, 1996; Sullivan et al., 1999;
Brustovetsky et al., 2002; Brustovetsky et al., 2003; Sullivan et al., 2005).

2.4.7 Role of mitochondria in apoptosis and necrosis
Mitochondria also play a central role in the regulation of both programmed cell
death (also known as apoptosis) and of uncontrolled cell death, i.e., necrosis (Zamzami et
al., 1996; Cai et al., 1998; Green and Reed, 1998; Springer, 2002). Evidence of apoptosis
in neurodegenerative disorders like AD and CNS trauma have been well established
(DiMauro et al., 1993; Budd and Nicholls, 1998; Hirsch et al., 1998; Lifshitz et al.,
2004a). CNS injury usually occur in a biphasic manner, i.e., through a primary necrotic
process that results in rapid and significant decline in the levels of ATP and in the
ensuing hours, days and weeks, a secondary injury that exacerbates the primary insult
occurs through apoptosis (Rabchevsky and Smith, 2001; Springer, 2002; Sullivan et al.,
2005). These two mechanisms of neurodegeneration differ in their morphological
features of general cell structure. Apoptosis is marked by cell shrinkage and DNA
fragmentation, while necrosis is marked by cellular swelling and uncontrolled cell lysis
(Hirsch et al., 1997; Green and Reed, 1998; Bras et al., 2005). Due to the duration in the
manifestation of pathologies in neurodegenerative disorders, it is believed that apoptosis
is the predominant cell death pathway in most neurodegenerative disorders.
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As noted above, there is increase in oxidative stress and excitotoxicity leading to
Ca2+ overload, which in turn triggers the induction of the permeability transition (Kruman
and Mattson, 1999; Brustovetsky et al., 2002; Brustovetsky et al., 2003) in most
neurodegenerative disorders and CNS injury. This usually leads to excessive
mitochondrial swelling and depolarization of the mitochondria and uncoupling of the
oxidative phosphorylation eventually leading to a rapid decline in ATP reserves which if
not restrained as seen in sever CNS injuries, would more often that not lead to necrotic
cell death (Halestrap et al., 2002). However, it has been shown that transient opening of
the mPTP is associated with the induction of apoptosis through the release of cytochrome
c and other pro-apoptotic proteins (Marchetti et al., 1996; Hirsch et al., 1998; Marzo et
al., 1998a; Sullivan et al., 2002). Released cytochrome c usually complexes with
apoptosis protease-activating factor 1 (Apaf-1), dATP, and procaspase-9 to form the high
molecular weight complex, the apoptosome. The apoptosome then activates down-stream
effector caspases, which then initiate the apoptotic cascade (Zamzami et al., 1996; Cai et
al., 1998; Green and Reed, 1998; Springer et al., 1999; Eldadah and Faden, 2000).
However, apoptotic events still can occur without the opening of the permeability
transition pore. Pro-apoptotic proteins, such as Bax and Bad also have been thought to be
capable of forming pores in the outer mitochondrial membrane, thereby influencing the
release of other pro-apoptotic proteins such as cytochrome c, apoptosis inducing factor
(AIF), endonuclease G and Smac/Diablo, thereby activating the apoptotic cascade (von
Ahsen et al., 2000; Springer, 2002; Bras et al., 2005). These various pathways have been
summarized in Fig 2.15.
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Figure 2.15 Role of mitochondria in glutamate induced excitotoxicity a) represents cell
death through necrosis b) depicts cell death through apoptosis. Adapted from
Trends Neurosci. (2000) 23, 298–304
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2.5 Traumatic brain injury and oxidative stress
Traumatic brain injury (TBI) is a serious health care problem in the United States,
with more than 400,000 individuals hospitalized each year and an estimated annual cost
of $25 billion (Tibbs et al., 1998; McNair, 1999; Adekoya et al., 2002; Hall and Sullivan,
2004). There is currently no therapeutic intervention for TBI. The pathophysiological
events in TBI occur in a biphasic manner. Following TBI the primary insult results in a
rapid and significant necrosis of cortical tissue at the site of injury and in the ensuring
hours and days, a secondary injury occurs that exacerbates the primary damage (Sullivan
et al., 1998b; Robertson, 2004; Sullivan et al., 2005). One underlying feature of this
secondary injury in both experimental and clinical TBI is the loss in mitochondrial
bioenergetics. This is usually characterized by mitochondrial dysfunction that include
exposure of neurons to excitotoxic levels of excitatory neurotransmitters with excessive
uptake of Ca2+ and eventual overload, generation of reactive oxygen species, induction of
the opening of the mitochondrial permeability transition pore (mPTP), release of
cytochrome C, inhibition of ATP production and ultimately neuronal cell death (Sullivan
et al., 1998b; Nicholls and Budd, 2000; Harris et al., 2001; Xiong et al., 2001; Sullivan et
al., 2002; Rego and Oliveira, 2003; Lifshitz et al., 2004b; Robertson, 2004; Sullivan et
al., 2005).
Oxidative stress has been shown to be one of the main mechanisms following
TBI. Due to the proximity to the source of ROS, the mitochondria are believed to be
extremely vulnerable to the effects of these ROS. In this dissertation we have proposed
that mitochondrial-related proteins are undergoing significant oxidative modifications
leading to their dysfunction hence the decline in mitochondrial related function.
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2.6 HIV and AIDS
2.6.1 Overview
Infection with Human Immunodeficiency Virus (HIV) results in the severe
compromise of the immune system and increased susceptibility to opportunistic
infections (Wang et al., 2006). This leads to the development of acquired
immunodeficiency syndrome (AIDS). The risk of developing AIDS after infection with
HIV increases over time. It has been established that after HIV infects a cell, it uses the
individual’s host cell machinery to replicate and produce toxic proteins that contribute to
the mechanisms that lead to cell death (Nath and Geiger, 1998; Mattson et al., 2005;
Wang et al., 2006). The rise in complications as a result of HIV infection has presented a
tremendous challenge to both virologist and immunologists. In recent years, the use of
highly active antiretroviral therapies (HAART) has revolutionized the treatment of AIDS,
with a suppression of viral load and consequent reduction in complications observed in
the late-stages of the disease (Gray et al., 2003). HAART can suppress the replication of
the virus in the long term, but this is often accompanied by significant toxicities that can
compromise treatment (Egger et al., 1997; Brinkman and Kakuda, 2000). One of the key
challenges resulting from HIV infection is the development of neurological disorders
resulting in the manifestation of HIV-related dementia (HIVD) (Nath and Geiger, 1998;
McArthur et al., 2003; Mattson et al., 2005; Pocernich et al., 2005; Nath and Sacktor,
2006). A detailed discussion of HIVD is provided below.
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2.6.2 Toxic HIV proteins and neurodegeneration
It had previously been thought that HIV encephalitis results from the direct
infection of the nervous system with the virus (Nath and Geiger, 1998). However,
neuronal cell loss occurs without the infection of the neurons (Nath, 2002). It has been
established that inflammatory mediators and toxic viral proteins known as “virotoxins”
released form activated glial cells following infection with virus mediate this neuronal
loss (Pocernich et al., 2005). This is through the release of a number of soluble factors
that are either toxic to neurons or cause chemotaxis. Some examples of these virotoxins
are gp120, gp41, tat, nef, and vpr among many others. When released, these virotoxins
then initiate a cascade of positive feedback loop cascade that cause neuronal cell death
(Nath, 2002). Moreover, antioxidants block the effect of tat (Pocernich et al., 2005). A
summary of this cascade is provided in (Fig 2.16).
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Figure 2.16 Mechanism of neuronal damage following HIV infection.
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2.6.3 HIV-Dementia (HIVD) and oxidative stress
Human immunodeficiency virus type-1 (HIV-1) infection is the most common
cause of dementia in adults less than 40 years of age. It is estimated that 20-30% of adults
infected with (HIV-1) develop HIV dementia (Nath, 2002; Mattson et al., 2005).
Currently in the United States, it is estimated that up to 500,000 individuals are affected
with HIV-associated brain disease (Wang et al., 2006). The HIV virotoxins-mediated
neuronal loss, leads to the development of a condition known as HIV dementia. HIV
infection of the brain is characterized by among others, the presence of multinucleated
giant cells which are infected macrophages that have fused together, and microglia
nodules which are collections of lymphocytes and macrophages (Nath and Geiger, 1998).
The cognitive effects are characterized mainly by psychomotor retardation while
behavioral manifestations include apathy, social withdrawal, depression, psychosis and
emotional incontinence. Motor manifestations include tremors, incoordination,
Parkinsonism and impaired balance (Nath et al., 1987). There have been various
hypothesis proposed for the entry of HIV into the CNS. One is as a free viral particle or
most likely through the migration of infected across the blood-brain barrier, the "Trojan
horse" hypothesis (Nath, 2002). The brain is particularly a good reservoir of HIV virus
since it as been shown that the incident of HIVD increases with prolonged survival
approaching 75% in patients with end-stage AIDS (McArthur et al., 2003; Wang et al.,
2006). As already noted, once in the brain, the virus then initiates a cascade of reactions
through “virotoxins”. Recent reports have confirmed the clinical significance and
involvement of free radicals and oxidative stress in HIV-dementia (Sacktor et al., 2004;
Mattson et al., 2005; Pocernich et al., 2005; Wang et al., 2006). This is evident from the
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increased oxidative stress as measured by protein oxidation in the brain and cerebrospinal
fluid (CSF) of HIVD patients, there is increased expression of iNOS in individuals with
server to moderate dementia compared to those with a milder impairments (Adamson et
al., 1996). In addition, an increase in the levels of peroxynitrite has been observed in
HIVD brains (Boven et al., 1999). It has also been showed that there is a significant
decrease in the concentration of the antioxidant glutathione and catalase in HIV-infected
patients, thus making them more vulnerable to free radical attack (Castagna et al., 1995;
Yano et al., 1998). With the advent of HAART, the incidence of HIVD has fallen, while
the cumulative prevalence of HIVD has risen (Neuenburg et al., 2002). Despite the
decline of HIVD incidence, neurological complications still remain an important cause of
disability and death associated with AIDS (Kandanearatchi et al., 2003; McArthur et al.,
2003). For example, in a recent study evaluating HIV-infected outpatients on HAART, it
was demonstrated that 9% died with HIVD and, of those, 92% were diagnosed with
HIVD within 12 months of death (Welch and Morse, 2002). As a result, from this
dissertation and other studies it is proposed that some drugs used in the highly active
antiretroviral therapy (HAART) could possibly be involved in the development of HIV
dementia through oxidative stress mechanism (Schweinsburg et al., 2005; Nath and
Sacktor, 2006).
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2.7 Antioxidant defense systems
2.7.1 Overview
As already mentioned increased levels of ROS/RNS can lead to oxidative
damage to proteins or enzyme, DNA, and lipids leading to a loss in function and possibly
cell death. As a result, cells are equipped with efficient strategies to control and maintain
the intracellular levels of ROS/RNS through the use of various endogenous antioxidant
systems. These antioxidants and antioxidant defense systems have been reported to be
significantly decreased in aging and age-related neurodegenerative disorders (Mates et
al., 1999). As a result, various strategies have been developed to modulate these levels of
antioxidants and reduce oxidative damage using exogenous antioxidant compounds. The
natural antioxidant defense system consists of endogenous antioxidant systems that
include glutathione and its related enzymes, superoxide dismutase (SOD), catalase,
among others. Other important non-enzymatic low-molecular-weight molecules including
vitamin C, vitamin E, lipoic acid, compounds rich in flavonoids, and carotenoids among
many others (Sen and Packer, 1996; Mates et al., 1999; Gutteridge and Halliwell, 2000;
Martin, 2003; Kahl et al., 2004). These are discussed here in relation to
neurodegenerative disorders.
2.7.2 Superoxide dismutase
Superoxide dismutase (SOD) provides the first line of defense against ROS.
There are two classes of SOD; manganese SOD (Mn-SOD) which is predominately
located in the mitochondrial matrix and copper/zinc SOD (Cu/ZnSOD, SOD1) which is
found in the cytosol, though recent studies have shown that Cu/Zn SOD can also be
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located in the intermembrane space of the, nucleus, peroxisomes, and mitochondrial
intermembrane space of human cells (Liochev and Fridovich, 2005; Selverstone
Valentine et al., 2005). SOD acts as an antioxidant enzyme by lowering the steady-state
concentration of superoxide. This enzyme catalyzes the disproportionation of O2.− to
H2O2 and H2O thus eliminating the cytotoxic superoxide anion from the cell (Chan, 1996;
Gutteridge and Halliwell, 2000; Kahl et al., 2004; Liochev and Fridovich, 2005).
It has been shown that there is a decline in the levels of SOD in neurodegenerative
disorders like AD, HIVD and also in normal aging. This thus increases the vulnerability
to attack by ROS/RNS. When mutated, SOD can also cause disease as in the case of
familial amyotrophic lateral sclerosis (fALS), another neurodegenerative disorder
(Selverstone Valentine et al., 2005). The toxic gain of function of mutant SOD (mSOD)
leads to the generation of reactive oxygen/nitrogen species (Valentine, 2002; Perluigi et
al., 2005a; Poon et al., 2005f). Some researchers believe that the elevated oxidative
activity associated with mSOD occurs by enzymes acting as peroxidases (Valentine,
2002) or as superoxide reductases (Liochev and Fridovich, 2000) or by producing O2.− to
form peroxynitrite (Rakhit et al., 2002).
2.7.3 Vitamin E and C
Vitamin E (α-tocopherol) and vitamin C (ascorbic acid) Fig 2.17a/b are key
endogenous low molecular weight antioxidants that play a significant role in the
protection against neurological disorders associated with oxidative stress. Vitamin E is
lipid soluble, thus it predominately provides its antioxidant activity in the lipid-bilayer.
On the other hand, vitamin C is predominantly found in the cystosol, where it is involved
in the recycling of the tocopheroxyl radical thus maintaining the cellular levels of vitamin
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E (Butterfield et al., 1999b; Butterfield et al., 2002c). The levels of vitamin E and C have
been reported to be in low concentrations in the CSF of AD patients (Butterfield et al.,
2002c). However, there was a significant increase in the levels of both vitamins in the
CSF of AD patients who were given both vitamin C and E. The beneficial effects of this
supplementation was observed only in the group that had a combination of the vitamins
compared to one that had only vitamin E (Morris et al., 1998; Morris et al., 2002b;
Martin, 2003). This was thought to be as a result of the need to recycle the tocopheroxyl
radical by a reducing agent, such as vitamin C. It has also been observed that dietary
intake of antioxidants vitamins E and C, especially vitamin E, is associated with a lower
risk of incident AD, though other studies have seen the contrary(Morris et al., 2002a;
Petersen et al., 2005). There has also been a significant association found between
vitamin E intake and cognitive decline and dementia (Engelhart et al., 2002). Vitamin E
has been shown to block in vitro, the toxic effects of Aβ-induced toxicity (Koppal et al.,
1998; Butterfield et al., 1999b; Yatin et al., 2000). Also, other than its role as an
antioxidant, vitamin E has been reported to be involved in the modulation of cellular
signaling and transcriptional regulation that play a key role in reducing the risk of
developing AD (Morris et al., 1998).
On the other hand, vitamin C another antioxidant has been shown to participate in
several enzymatic reactions essential to the synthesis of catecholamines (Launer, 2000).
It has been established that medications or vitamins that increase the levels of brain
catecholamines and protect against oxidative damage which may reduce the neuronal
damage and slow the progression of neurodegenerative disorders like AD (Diliberto et
al., 1982). As a result, these studies provided here establish that the use of antioxidants

58

vitamin C and E could be a potential source of therapeutic intervention against AD and
other neurodegenerative disorders. Vitamin E and C were among the antioxidants
included in the antioxidant fortified diet given to the aging canine in this dissertation.
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Figure 2.17 a Structure of Vitamin E.

Figure 2.17 b Structure of Vitamin C.
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2.7.4 Glutathione system
2.7.4.1 Overview
The glutathione antioxidant system is one of the most important antioxidant
defense mechanisms available in living organisms. Glutathione (GSH) is a tripeptide
composed of γ-glutamyl-cyteinyl-glycine present in milimolar concentrations in the brain
Fig 2.18. It can exist in its oxidized GSSG or reduced for GSH, the ratio of which
provides a good indicator of oxidative stress. It has been established that a decrease in
GSH concentration is associated with aging and the pathogenesis of most
neurodegenerative disorders (Pastore et al., 2003).

61

Figure 2.18 Structure of Glutathione.
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2.7.4.2 GSH synthesis
GSH is not synthesized in mitochondria. GSH is synthesized in the cytosol from
where it is then transported into the mitochondria (Dringen et al., 2000). GSH is
synthesized from L-glutamate with L-cysteine forming L-γ-glutamyl-L-cysteine the rate
limiting substrate Fig 2.18. This initial reaction is catalyzed by γ-glutamylcysteine
synthetase in the presence of Mg 2+ and ATP. The addition of glycine to L-γ-glutamyl-Lcysteine is catalyzed by GSH synthetase in the presence of Mg 2+ and ATP to yield GSH
(Figure 2.19). It should be noted that the L-cysteine concentration in the brain are in
micomolar while the concentration of both L-glutamate and glycine are in millimolar,
thus, L-cysteine is the limiting amino acid in the biosynthesis of GSH (Cooper, 1997).
Our laboratory and others have successfully modulated the levels of GSH by using
compounds that provide cysteine precursors such as N-acetyl-L-cysteine (NAC),
glutathione monoethyl ester or through the use of γ-glutamylcysteine ethyl ester (GCEE)
that provides the limiting substrate γ-glutamylcysteine of GSH synthesis in various
models of neurodegeneration (Pocernich et al., 2001; Drake et al., 2003b; Anderson et al.,
2004; Boyd-Kimball et al., 2005a; Boyd-Kimball et al., 2005b).
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Figure 2.19 Glutathione synthesis.
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2.7.4.3 Role of Glutathione
The glutathione system in conjunction with glutathione peroxidase (GPx) and
glutathione reductase (GR) are involved in a number of antioxidant defense reactions
(Brigelius-Flohe, 1999). As mentioned earlier, the disproportionation of O2. - generates
H2O2, another ROS. Though not toxic, H2O2 can also mediate oxidative damage through
various mechanisms. In the presence of redox transition metal ions such as Fe2+ or Cu+,
H2O2 can undergo a Fenton reaction resulting in the generation of hydroxyl radical OH·, a
much more toxic ROS that can exact excessive damage at distant sites from where H2O2
was generated (Butterfield and Stadtman, 1997). As a result, there is need for the cell to
regulate the intracellular levels of H2O2. H2O2 can be converted to water by glutathione
peroxidase GPx using GSH as the hydrogen donor. The oxidized glutathione (GSSG) is
then recycled back to GSH by the enzyme glutathione reductase (GR) that uses NADPH
as a cofactor. GSH through the enzyme glutathione-s-transferase (GST) can also form
conjugated with reactive aldehydes such as HNE or MDA, which if not eliminated from
the cell could lead to additional oxidative damage. With the aid of the multidrug resistant
protein-1 (MRP1), the GSH-aldehdye conjugate is exported out of the cell getting rid of
the toxic reactive aldehydes (Sultana and Butterfield, 2004). The activities of most of
these enzymes have been shown to be decreased in AD. In particular, it has been shown
that GST activity is significantly decreased in AD brain and ventricular fluid relative to
control (Lovell et al., 1998). Summaries of the glutathione-related reactions described
here are given in Fig 2.4 above.
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2.7.5 Heme-oxygenase-1 (HO-1)
Heme oxygenase or heat shock protein 32 (HSP 32) is a member of the heat shock
family of proteins. There are two key isoforms of heme oxygenase, i.e., the inducible
form HO-1 and the constitutive form HO-2. Though recent studies have discovered a
third isoforms, HO-3, its functions and role are still questionable and it is found only in
rat brains. HO catalyzes the degradation of heme to iron (Fe), carbon monoxide, and
biliverdin. Biliverdin is further converted to the potent antioxidant bilirubin by biliverdin
reductase (Calabrese et al., 2003a; Maines, 2005). The levels of HO-1 are regulated by
the activity of the antioxidant response element ARE, which is usually activated in events
of increased oxidative stress or a decline in the levels of glutathione as seen in most aging
and age-related neurodegenerative disorders. HO-1 levels in particular have been shown
to be significantly decreased with age and in age-related neurodegenerative disorders.
Interventions with antioxidant compounds that lead to its up-regulation have been found
to have cytoprotective effects providing possible leads for the intervention against
neurodegenerative disorders in which oxidative stress plays a key role (Calabrese et al.,
2003b; Calabrese et al., 2004b; Calabrese et al., 2004a).
2.7.6 Lipoic acid
Lipoic acid (LA) Fig 2.20a is an example of the low molecular antioxidants which
can also be found in its reduced form, i.e., dihydrolipoic acid (DHLA) (Fig 2.20b).
LA is a redox-active molecule capable of thiol-disulfide exchange, giving it its
antioxidant activity. This antioxidant activity is derived from its ability to a) Scavenge
ROS such as H2O2, HO·, NO and ONOO− ; b) LA has the ability to chelate ions such as,
Cu 2+ and Fe 2+ thereby inhibiting further Fenton reactions that could lead to the
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generation of additional ROS; c) Lastly, LA antioxidant activity is derived from its ability
to recycle endogenous antioxidants. It also protects membranes by interacting with
vitamin C and glutathione, which may in turn recycle vitamin E (Packer et al., 1995).
Lipoic acid is also known as an essential cofactor of key mitochondrial enzyme
complexes particularly pyruvate dehydrogenase (PDH) and alpha ketoglutarate
dehydrogenase complex (α-KDH) hence its involvement in energy metabolism (Bogaert
et al., 1994; Gibson et al., 2005). The use of lipoic acid by itself or in combination with
other antioxidants as a potential therapeutic, is gaining considerable interest. Studies of
aging rat have suggested that the use of lipoic acid results in improved memory
performance and delayed structural mitochondrial decay. In a study from our laboratory,
we have shown that aged SAMP8 mice treated with alpha lipoic acid show improvements
in cognitive function as a result of decreased oxidative stress (Farr et al., 2003). This thus
suggests that lipoic acid could be a potential therapeutic for those at risk of developing
age-related neurodegenerative disorders like AD. Lipoic acid was one of the antioxidants
include in the antioxidant fortified diet given to the aging canine.
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a)

b)

Figure 2.20 Structures of a) lipoic acid and b) dihydrolipoic acid.
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2.8 Exercise
It has been established that voluntary physical activity and exercise training can
favorably influence brain plasticity by facilitating neurogenerative, neuroadaptive, and
neuroprotective processes (Neeper et al., 1995; Cotman and Berchtold, 2002; Cotman and
Engesser-Cesar, 2002; Adlard and Cotman, 2004; Adlard et al., 2005a). Physical activity
in particular has been shown to be inversely related to cognitive decline as a function of
age. The mechanism leading to these beneficial effects of physical activity and exercise
on the central nervous system are still unknown, but it is believed that neurotrophic
factors like brain derived neurotrophic factor (BDNF) play a key role (Cotman and
Berchtold, 2002; Adlard et al., 2005a). BDNF is involved in neuronal survival, enhances
learning, and protects against cognitive decline. It has also been established that
voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease
(Adlard et al., 2005b). Also, it has been shown that exercise benefits recovery of
neuromuscular function from spinal cord injury (SCI) through the increase in the
expression of key protective gene expression in the spinal cord in rats (Perreau et al.,
2005). These studies among others continue to provide evidence for the beneficial effects
of exercise in delaying the deleterious effects associated with age-related
neurodegenerative disorders. The biochemical mechanisms that ensue following exercise
have been investigated in the current dissertation.
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2.9 Learning and memory
Learning can be defined as the acquisition of an altered behavioral response due
to an environmental stimulus. Memory on the other hand, is defined as the process of
storing and retrieving what has been learnt resulting from changes in synaptic structure
and function (Sweatt, 2003). Memory can further be defined as either short-term or longterm depending on how long it persists. There are various theories that have been put
forth to try and define and understand the mechanisms of molecular learning and
memory. The most current one being the Hebb’s theory that proposes that the
simultaneous activation of pre and post synaptic neurons leads to an increase in synaptic
efficacy leading to the formation of an associative link (Hebb, 1949).
Age-related neurodegenerative disorders and in particular AD are usually
manifested with significant loss in hippocampus-dependent cognitive function, marked
by loss in memory and the inability to learn and remember new names, events and spatial
information. The mechanisms underlying age-dependent loss in cognitive function are
still not well understood. However, using a canine model of human aging among others
its emerging that oxidative stress plays a key role since some of this loss in cognitive
function can be reversed with the use of antioxidants. The possible mechanisms leading
to improved learning and memory in the canine model of human aging will be discussed
in detail in Chapters 4 and 5.
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CHAPTER THREE
Methods
3.1 Experimental Traumatic Brain injury
3.1.1 Animal and surgical procedures
The University of Kentucky Animal Use and Care Committee approved all
procedures using animals. Male Sprague-Dawley rats (250–300 g), (Harlan Laboratories,
IN) were used. All animals were housed in group cages on a 12-h light/dark cycle with
free access to water and food. Animals were subjected to a moderate unilateral cortical
contusion as previously described (Sullivan et al., 1999; Sullivan et al., 2000). This
cortical contusion results in severe behavioral deficits, significant loss of cortical tissue,
blood–brain barrier disruption and a loss of hippocampal neurons (Sullivan et al., 2002),
mimicking some of the events that take place in human closed-head injury. Briefly, the
subjects were anesthetized using isoflurane (2%) and placed in a stereotaxic frame (Kopf
Instruments, Tujunga, CA). The head was positioned in the horizontal plane with the nose
bar set at negative 5. Using sterile procedures, the skin was retracted and a craniotomy
made with a hand-held trephine lateral to the sagittal suture and centered between
Bregma and lambda. The skullcap was carefully removed without disrupting the
underlying dura. The exposed brain was injured using a pneumatically controlled
impacting device with a 5-mm beveled tip, which compressed the cortex at 3.5 m/s to a
depth of 1.5 mm (Baldwin and Scheff, 1996; Sullivan et al., 1999). After injury, Surgicel
(Johnson and Johnson, Arlington, TX) was laid on the dura and the skullcap replaced. A
thin coat of dental acrylic was then spread over the craniotomy site and allowed to dry
before the wound was stapled closed.
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3.2 Mitochondria isolation
3.2.1 Overview
As discussed in Chapter two, mitochondria play a significant role in the
pathosphysiology of most neurodegenerative disorders. Despite being the “power house”
of the cell through the production of ATP, they are also known to be involved in the
production of ROS and regulation of cell death process through either apoptosis or
necrosis. As a result they are among the best organelles for the study of mechanism
involved in most neurodegenerative disorders.

3.2.2 Mitochondria isolation procedure
Total brain mitochondria were isolated by the method of Sullivan (Sullivan et al.,
2003; Sullivan et al., 2004b; Sullivan et al., 2004a). Desired tissues were dissected using
a cork punch (d=8 mm). The tissue minced, and then homogenized separately in a glass
dounce homogenizer containing approximately five times the volume of isolation buffer
with 1 mM EGTA (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1
mM EGTA, pH 7.2). The homogenate was spun twice at 1300 × g for 3 min in an
eppendorf microcentrifuge at 4◦C. The supernatant were then transferred to new tubes,
topped off with isolation buffer with EGTA and spun at 13,000 × g for 10 min. The
resulting supernatant was discarded and the pellet resuspended in 500 µL of isolation
buffer with EGTA; The resulting pellet was then resuspended in 0.5 ml of mitochondrial
isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% bovine serum albumin, 1 mM
EGTA, 20 mM HEPES, pH 7.2), and the plasma membranes were ruptured by nitrogen
decompression (Parr Cell Disruption Bomb) at 1000 p.s.i. for 5 min (Brown et al., 2004).
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The homogenized tissue and an equal volume of 30 % Percoll in isolation buffer was
added (~4 ml). The resultant homogenate was layered on a discontinuous Percoll gradient
with the bottom layer containing 40 % Percoll solution in isolation buffer, followed by a
24 % Percoll solution, and finally the sample in a 15 % Percoll solution. The density
gradients were spun in a Sorvall RC-5C plus super speed refrigerated centrifuge
(Asheville, NC) in a fixed angle SE-12 rotor at 30,400 x g for 10 minutes. Following
centrifugation, band 3 (Sims, 1990) were separately removed from the density gradient.
The samples were washed by centrifugation at 16,700 x g for 15 minutes. The
supernatant was discarded and the loose pellet was resuspended in the 1 ml of isolation
buffer. The mitochondrial fractions were then placed in separate 15 ml conical tubes and
an equal volume of 30 % Percoll was added to each sample and discontinuous Percoll
density gradient centrifugation was performed again as described above. Band 3 was
obtained from the gradients and 10 ml of isolation buffer without EGTA (215 mM
mannitol, 75 mM sucrose, 0.1 % BSA, 20 mM HEPES, pH is adjusted to 7.2 with KOH)
was added. The fractions were centrifuged at 16,700 x g for 15 minutes and subsequently
at 11,000 x g for 10 minutes. The resultant pellet was resuspended in 1 ml of isolation
buffer without EGTA and centrifuged at 10,000 x g for 10 minutes. The final
mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a protein
concentration of ~10mg/ml and stored on ice for respiration assays or resuspended in
lysis buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.6 mM
MgSO4 and 0.5 mg/mL leupeptin, 0.7 µg/mL pepstatin, 0.5 µg/mL trypsin inhibitor, and
40 µg/mL PMSF) for subsequent assays.
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3.3 Mitochondria respiration
3.3.1 Overview
Isolated mitochondria are a very useful model used for the in vivo analysis of
oxygen consumption in various paradigms. Isolated mitochondria are always depleted of
substrates needed for energy metabolism. As a result, to successfully study respiratory
control, mitochondria need to establish and maintain a chemiosmotic gradient unless they
are deliberately poisoned. This is usually accomplished by the addition an excess of
substrate depending on the state of respiration one is studying. Using an oxygen
electrode, the amount of oxygen the isolated mitochondria consumes can then be
analyzed. Thus, one can be able to determine how well isolated mitochondria can
consume oxygen and hence determine the state of mitochondria in various conditions.
3.3.2 Mitochondria respiration assay
Mitochondrial oxygen consumption was measured by using a Clark-type electrode in
a continuously stirred, thermostated sealed chamber (Oxytherm System; Hansatech
Instruments Ltd.) at 37°C as previously described (Brown et al., 2004; Jin et al., 2004;
Sullivan et al., 2004b). Isolated mitochondrial protein (~30 µg) was suspended in
respiration buffer (215 mM mannitol, 75 mM sucrose, 20 mM HEPES, 2 mM MgCl2, 2.5
mM inorganic phosphate, 0.1% BSA, Ph 7.2) in a final volume of 0.25 ml. The
respiratory control ratio (RCR) was calculated as the ratio of oxygen consumption in the
presence of 10 mM pyruvate and 5 mM malate or 10 mM succinate in the presence of
ADP (state III) and in the absence of ADP (State IV).
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3.4 Synaptosomes
3.4.1 Overview
Synaptosomes are used as models of functional synapse for the study of neuronal
terminal processes. They are usually cleaved from homogenized neurons through the use
of ultracentrifugation and a discontinuous sucrose gradient. Synaptosomes are composed
of a continuous plasma membrane that have functional pumps and channels capable of
ion exchange, and respond to depolarization. They also contain some mitochondria hence
are able to carry out respiratory activities. It has also recently been shown that
synaptosomes are capable of carrying out protein synthesis; hence they provide a
complete model of a functional synapse.

3.4.2 Synaptosomes preparation
The University of Kentucky Animal Care and Use Committee approved animal
protocols. Animals were housed in the University of Kentucky Central Animal Facility
in 12 hour light/dark conditions and fed standard Purina rodent laboratory chow.
During light phase Synaptosomes were isolated from three-month old male Mongolian
gerbils (100g) as previously described (Whittaker, 1993). Briefly, the gerbils sacrificed
by decapitation and the brain immediately isolated and dissected. The cortex was placed
in 0.32 M sucrose isolation buffer containing 4 µg/ml leupeptin, 4 µg /ml pepstatin, 5 µg
/ml aprotinin, 2 mM ethylene di-amine tetra-acetic acid (EDTA), 2 mM ethylene glycolbis-tetraacetic acid (EGTA), 20 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES), 20 µg/ml trypsin inhibitor, and 0.2 mM phenylmethanesulfonyl fluoride
(PMSF), pH 7.4. The tissue was homogenized by 20 passes with a Wheaton tissue
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homogenizer. The homogenate was centrifuged at 1500 g for 10 minutes. The
supernatant was retained and centrifuged at 20,000 g for 10 minutes. The resulting pellet
was resuspended in ~1 ml of 0.32 M sucrose isolation buffer and layered over
discontinuous sucrose gradients (0.85 M pH 8.0, 1.0 M pH 8.0, 1.18 M pH 8.5 sucrose
solutions each containing 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES) and spun at
82,500 g for 1 hr at 4oC. Synaptosomes were collected from the 1.0/1.18M sucrose
interfaces, and washed in Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2,
1.0 mM MgCl2, 3.6 mM NaHCO3, 5 mM glucose, 5 mM HEPES) twice for 10 minutes at
32,000 g. The synaptosomal preparation was relatively free of non-synaptic moieties
(Whittaker, 1993).
3.5 Protein concentration
The protein concentrations of all samples in this dissertation were performed using
the Bicinchoninic acid (BCA) protein assay. This method is based on the proteinmediated reduction of Cu2+ to Cu+ by the electron-rich peptide bond and amino acids (the
biuret reaction). Cu+ can then be complex with BCA to from a soluble purple complex
exhibits a strong absorbance at 562 nm (Figure 3.1). In this dissertation, bovine serum
albumin (BSA) was used as a standard and Beer’s law was used to calculate the
concentration of protein in sample solution.
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Figure 3.1 Reaction of Cu+ with BCA.
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3.6 Cytochrome c release
3.6.1 Overview
Cytochrome c usually resides in the inner mitochondrial membrane as a member
of the electron transport chain complexes. However, as mentioned in chapter two, its
release from the inner mitochondrial membrane to the cytosol marks a key event in the
initiation of the apoptotic cascade leading to cell death. As a result, analysis of the levels
of Cytochrome c usually serves as a good indicator of cell death processes as seen in
neurodegenerative disorders.

3.6.2 Cytochrome c release assay
Cytochrome c release was detected as previously described with slight
modifications (Yang et al., 1997). Briefly, after centrifugation of mitochondrial samples,
the cytosolic fraction which is the supernatant was used for Western blot analysis for
cytochrome c release. The membrane was blocked in blocking buffer (3% bovine serum
albumin) in PBS/Tween for 2 h and incubated with a 1:2000 dilution of anti-cytochrome
c polyclonal antibody (C-5723; anti-sheep; Sigma) in PBS/Tween for 2 h. The membrane
then was washed in PBS/Tween for 5 min three times after incubation. The membrane
was incubated for 1 h, after washing, with an anti-sheep IgG alkaline phosphatase
secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The membrane then was
washed three times in PBS/Tween for 5 min and developed in Sigma Fast tablets. Blots
were dried, scanned with Adobe PhotoShop, and quantified using Scion Image software.
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3.7 Bcl-2 protein levels
Bcl-2 family of proteins provides a link between apoptosis and mitochondrial
physiology. Bcl-2 and Bcl-xL are anti-apoptotic proteins that suppress release of
sequestered matrix Ca2+ induced by uncouplers of respiration (Vander Heiden et al.,
1999). In isolated mitochondria, Bcl-2 or Bcl-xL enhances proton extrusion from
mitochondria and increases mitochondrial Ca2+ buffering capacity. Bcl-2 is also thought
to regulate the opening of the mPTP hence regulating the possible induction of apoptosis
and eventual cell death. The levels of anti-apoptotic protein Bcl-2 were detected as
previously described (Yang et al., 1997) with slight modification as described above,
except a 1:2000 dilution of anti-Bcl-2 monoclonal antibody (AAM-072; anti- mouse;
stressgen) in PBS/Tween for 2 h was used.
3.8 Oxidative stress parameters
3.8.1 Protein carbonyls
As mentioned in Chapter 2, increased oxidative stress usually results in the
oxidative modification of proteins. The introduction of the carbonyl moiety in proteins
makes protein carbonyls to be a significant index of protein oxidation. The levels of
protein carbonyls in this dissertation were analyzed using the OxyBlot Protein Oxidation
Kit (Chemicon International, Temecula, CA, USA). Briefly, samples (5 µg of protein)
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C) forming a
Protein-DNP adduct (Fig 3.2). The samples were then neutralized with 7.5 µL of the
neutralization solution (2 M Tris in 30% glycerol). Derivatized protein samples were then
blotted onto a nitrocellulose membrane with a slot-blot apparatus (250 ng per lane). The
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membrane was then washed with wash buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.05% Tween 20) and blocked by incubation in the presence of 5% bovine serum
albumin, followed by incubation with rabbit polyclonal anti-DNPH antibody (1: 100
dilution) as the primary antibody for 1 h. The membranes were washed with wash buffer
and further incubated with alkaline phosphatase-conjugated goat anti-rabbit antibody as
the secondary antibody for 1 h. Blots were developed using fast tablet (BCIP/NBT;
Sigma-Aldrich) and densitometric levels quantified using Scion Image (PC version of
Macintosh-compatible NIH Image) software.
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Cabonylated Protein

DNPH

Cabonylated Protein-DNP
adducts

Figure 3.2 Protein carbonyl reactions with DNP forming the protein –DNP adduct.
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3.8.2 3-Nitrotyrosine (3NT)
Protein nitration is another form of protein oxidation and can be indexed
immunochemically by the levels of 3NT (Castegna et al., 2003). Briefly, samples were
incubated with Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma base, pH 6.8, 4%
sodium dodecyl sulfate, 20% glycerol) for 20 min. Protein (250 ng) was then blotted onto
the nitrocellulose paper using the slot-blot apparatus and immunochemical methods as
described above for protein carbonyls. The mouse anti-nitrotyrosine antibody (5: 1000
dilutions) was used as the primary antibody and alkaline phosphatase-conjugated antimouse secondary antibody was used for detection. Blots were then scanned using scion
imaging and densitometric analysis of bands in images of the blots was used to calculate
levels of 3-NT.
3.8.3 4-Hydroxy-2-nonenal (HNE)
The level of lipid peroxidation in this dissertation was determined by the analysis
of protein–bound HNE (Figure 2.7). Briefly, 10 µl of sample were incubated with 10 µl
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v)
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus
containing a nitrocellulose membrane under vacuum pressure. The membrane was
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in
PBST for 90 min. Following completion of the primary antibody incubation, the
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The
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membrane was washed in PBST three times and developed using Sigma fast Tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
with Scion Image.
3.8.4 Isoprostanes and Neuroprostanes
Another indicator of the levels lipid peroxidation used in this dissertation was
determined through the analysis of Isoprostanes and Neuroprostanes. F2-IsoPs and F4NPs were quantified in brain specimens using highly precise and accurate mass
spectrometric assays applying stable isotope dilution techniques, as described previously
(Morrow and Roberts, 1999; Musiek et al., 2004). Briefly, lipids were extracted from
specimens by the method of Folch and colleagues (Folch et al., 1957). F2-IsoP and F4NPs were esterified in tissue and hydrolyzed by chemical saponification, extracted using
C18 and silica Sep-Pak cartridges (Waters Corporation, Milford, MA), purified by thinlayer chromatography, converted to pentafluorobenzyl ester trimethylsilyl ether
derivatives, and quantified using gas chromatography/negative ion chemical
ionization/mass spectrometry. The stable isotope dilution techniques used [2H4]-8-isoPGF2a as an internal standard for F2-IsoPs and [18O2]17-F4c-NP as an internal standard for
F4-NPs.
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3.9 Enzyme assays
3.9.1Overview
One underlying hypothesis being fronted by our laboratory and others is that
oxidative stress leads to the oxidative modification of key proteins and enzymes. In
addition, supplementation with antioxidant and antioxidant related compounds has been
shown to result in an increase in expression and in some conditions, activity of various
protective enzymes. However, it is believed that oxidative modification of critical amino
especially those found in the active sites of enzymes it leads to their inactivation and
alteration in function. As a result, enzyme activity has particularly been used in this
dissertation to try and confirm the hypothesis that oxidative modification of
proteins/enzymes leads to their possible inactivation
3.9.2 Glutathione-S-transferase (GST)
The clearance of toxic reactive aldehydes is carried out through their conjugation
to GSH catalyzed by GST. In particular, it has been shown that GSTs catalyze the
conjugation of GSH to HNE 300 to 600 times faster than the uncatalyzed reaction. In this
dissertation, the activity of Glutathione-S-transferase was measured as previously
described using 1-chloro-2, 4-dinitrobenzene (CDNB) as substrate (Habig and Jakoby,
1981). Briefly, the standard assay mixture contained CDNB (1 mM), reduced glutathione
(1 mM), and potassium phosphate buffer (100 mM; pH = 6.5) in a volume of 100 µL.
The thioether formed was determined by reading the absorbance at 340 nm, and
quantification was performed by using a molar absorptivity of 9.6 M−1.
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3.9.3 Superoxide dismutase (SOD)
As mentioned earlier, the first line of defense against ROS is through the enzyme
SOD that catalyzes the disproportionation of superoxide anion to H2O2. In this
dissertation the activity of total superoxide dismutase (SOD) was measured. Briefly, the
reaction mixture of total volume 184 µL contained 160 µL of 50 mmol/l glycine buffers,
pH 10.4, and 20.0 µL sample. The reaction was initiated by the addition of 4.0 µL of a 20
mg/ml solution of (–)-epinephrine. Due to its poor solubility, (–)-epinephrine (40 mg)
was suspended in 2 ml water and was solubilized by adding 2–3 drops of 2N HCl. The
auto-oxidation of (–)-epinephrine was monitored at 480nm and the millimolar
absorptivity (4.02 mmol · l–1 · cm–1) was used for calculations.
3.9.4 Pyruvate dehydrogenase (PDH)
Pyruvate dehydrogenase (PDH) is a mitochondrial enzyme complex that catalyzes
the conversion of pyruvate to acetyl CoA, NADH and CO2, making this protein the
central link between glycolysis and the TCA cycle. In this dissertation, the activity of
PDHC was measured using increment in fluorescence measurement of NADH with
BioTek Synergy HT plate reader (Winooski, VT, USA). Briefly, mitochondria were
freeze thawed and sonicated for 3 cycles. About 8 µg of double ficoll gradient purified
mitochondrial protein were added into the buffer containing final concentration of 50mM
KCl, 10mM HEPES pH 7.4, 0.3mM thiamine pyrophosphate (TPP), 10µM CaCl2, 0.2mM
MgCl2, 5mM pyruvate, 1 µM rotenone and 0.2mM NAD+. Reactions were started by
addition of 0.14mM CoASH and assay was performed at Ex λ 340 nm/ Em λ 460nm and
increases in fluorescence were observed at 1 min intervals at 300C. The PDHC activity
was calculated and expressed as nmol/mg protein
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3.9.5 Complex I assay
Complex I activity was measured in isolated mitochondria as the rotenonesensitive decrease in NADH absorption at 340 nm with ubiquinone-1 as the final
acceptor, as previously described (Sriram et al., 1998) with some slight modifications
(Sullivan et al., 2004b). Briefly, mitochondria were freeze-thawed and sonicated three
times and diluted 1 µg/µl in 10 mM K3PO4 buffer. The assay was performed in 25 mM
K3PO4 buffer (pH 7.2) containing mitochondrial protein (6 µg), 5 mM MgCl2, 1 mM
KCN, 1 mg/ml BSA, and 150 µM NADH. The reaction was preincubated for 2 minutes
at 30°C, the baseline established, and the reaction initiated by addition of coenzyme Q-1
(50 µM). The activity was measured by monitoring NADH fluorescence (340 nm
excitation, >450 nm emission) over time under the same conditions as described above.
The assay was also performed in the presence of rotenone (10 µM) to determine the
rotenone-insensitive activity and the rotenone-sensitive complex I enzyme activity
calculated by subtracting the rotenone-insensitive activity from the total activity. All the
assay protocol for a 96-well plate performed with BioTek Synergy HT plate reader
(Winooski, VT, USA)

3.9.6 Complex IV activity assay
Cytochrome C Oxidase (Complex IV) of mitochondrial electron transport chain
component activity measured with method previously described (Wharton and Tzagoloff,
1967) with slight modification using BioTek Synergy HT plate reader (Winooski, VT,
USA). Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg
of double ficoll gradient purified mitochondrial protein were added into the 10mM K3PO4
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buffer pH 8.0, 50µM reduced cytochrome c and the decrease in absorbance was observed
with difference with and without addition of Cytochrome c at 1 min interval at 370C at
550nm. First the rate constant k was calculated for oxidation reaction of ferricytochrome
c calculated and the specific activity A were expressed as (k/mg protein) for cytochrome
c oxidase.
3.10 Proteomics
3.10.1 Overview
Proteomics is defined as the study of the entire protein complement of the
genome. The proteomic technique encompasses the analysis of complex protein mixtures
leading to their identification and detection of possible quantitative changes. This
separation of proteins is usually carried out in two dimensions.
In the first dimension, proteins are separated according to their isoelectric point.
This is the pH, at which the protein carries no net charge and is therefore immobilized in
the electric field (Fig 3.3a). This is carried out through isoelectric focusing (IEF) using
immobilized pH gradients (IPG). IPGs are formed by the copolymerization of buffering
and titrant groups of acrylamido derivatives into a polyacrylamide gel matrix hence
permitting the steady state focusing with high reproducibility of spot positions.
In the second dimension, proteins are separated according to the rate of migration,
which in most cases is similar to their molecular weight (Fig 3.3b). Here the low
molecular weigh proteins travel faster through the gel and are found on the lower end of
the gel. On the other hand, high molecular weight proteins will travel slowly through the
polyacrylamide matrix and will be found on the upper end of the gel slab.
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With the development of novel mass spectrometry techniques such as MALDI
and ESI mass analyzers have been able to better resolve the molecular ion to their mass
and charge ratio leading to the proper identification of proteins through various
databases. The proteomic techniques in our laboratory and that of others has revolved
around the identification of differentially expressed proteins in diseased verse control
states and also the identification of the redox status of a protein, specifically oxidatively
modified proteins. We have come to refer to the latter as redox proteomics.
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Figure 3.3a First dimension isoelectric focusing (IEF).

Figure 3.3b Second dimension polyacrylamide gel electrophoresis (PAGE).
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3.10.2 Sample preparation
Samples (200 µg) were incubated with 4 volumes of 2N HCl for electrophoresis
or 20mM DNPH for western blotting at room temperature for 20 min at room
temperature. Proteins were then precipitated by the addition of ice-cold 100%
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v)
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h.
3.10.3 First dimension electrophoresis
For the first-dimension electrophoresis, 200 µL of sample solution was applied to
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80
°C until the 2nd dimension electrophoresis was to be performed.
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3.10.4 Second dimension (2D) electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along
with the sample at 200 V for 65 min.
3.10.5 Western blotting and immunochemical detection
The identification of oxidatively modified proteins was carried out through redox
proteomics through the analysis of protein carbonyls levels. Here, the 200 µg proteins
incubated with 20mN DNPH described above were used. The strips and gels were run as
described above. After the second dimension, the proteins from the gels were transferred
onto nitrocellulose papers (Bio-Rad) using the Transblot-Blot® SD semi-Dry Transfer
Cell (Bio-Rad), at 15 V for 4 h. The 2,4-dinitrophenyl hydrazone (DNP) adduct of the
carbonyls of the proteins was detected on the nitrocellulose paper using a primary rabbit
antibody (Chemicon, CA) specific for DNP-protein adducts (1:100), and then a
secondary goat anti-rabbit IgG (Sigma, MO) antibody was applied. The resulting stain
was developed by application of Sigma-Fast (BCIP/NBT) tablets. In this dissertation
these blots have been referred to as 2D-Oxyblots.
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3.10.6 Image and statistical analysis
The spots on 2D gels were visualized using SYPRO™ Ruby stain, which is a
fluorescent dye with sensitive (1-2ng) detection limits and linear dynamic range over
three orders of magnitude (Molloy and Witzmann, 2002). Images from SYPRO Ruby
stained gels, were obtained using a UV transilluminator (λex=470 nm, λem=618 nm,
Molecular Dynamics, Sunnyvale, CA, USA). On the other hand, 2D Oxyblots were
scanned on a Microtek Scanmaker 4900 and saved in TIFF format for further analysis.
With the use of PD-Quest (Bio-Rad) imaging software, gel-gel, blot-blot, and gel-blot
analysis were performed, generating a large pool of data. After the completion of spot
matching, the normalized intensities of each protein spot from individual gels/blots are
compared between groups using statistical analysis. Those spots showing significant
differential expression or oxidation are then excised from the gel and processed for ingel digestion.
3.10.7 In-gel trypsin digestion
After the identification of the protein of interest and its excision from the gel, the
spot is then subjected to digestion using proteolytic enzymes. In this dissertation, the
digestive enzyme trypsin was used in all in gel digestion studies. Trypsin specifically
cleaves peptide bonds after positively charged residues amino acids. In-gel-digestion
reduces the mass of a protein into small peptides and also forms a collection of
proteolytically sequence-specific peptides that enable the identification of the protein.
These digested proteins are easily eluted from the gel and are ready for mass
spectrometry analysis. In this dissertation excised spots were washed with 0.1 M
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ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was
then added to the gel pieces and incubated at room temperature for 15 min. This solvent
mixture was then removed and gel pieces dried. The protein spots were then incubated
with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution
was removed and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The
solution was then incubated at room temperature for 30 min. The iodoacetamide was
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in
50 mM NH4HCO3 with the minimal volume enough to cover the gel pieces. The gel
pieces were incubated overnight at 37 °C in a shaking incubator.
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Figure 3.4 Schematic representation of the parallel analysis of 2D-PAGE and oxyblot for
the identification of specifically carbonylated or differentially expressed proteins.
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3.11 Mass Spectrometry
3.11.1 Overview
Mass spectrometry technique has recently emerged as very invaluable tool in the
rapid identification and characterization of proteins. This is particularly evident from the
presentation of the 2005 chemistry Nobel Prize for the development of two novel
ionization techniques i.e., matrix assisted laser desorption/ionization (MALDI) and
electrospray ionization (ESI). These softer ionization techniques have enabled the
identification of large biomolecules with fewer fragmentations.
3.11.2 Matrix Assisted Laser Desorption/Ionization (MALDI)
MALDI is a pulsed ionization technique; generally coupled with TOF (time-offlight) mass analyzer. In MALDI, the peptide sample is mixed with a matrix (commonly
α-cyano-4-hydroxycinnamic acid) and condensed on a plate that is subjected to laser
radiation. On application of a high-energy laser to the matrix, the peptides along with the
matrix particles are vaporized. This usually occurs in a vacuum to ensure the sublimation
of the matrix-peptides solid. Due to the acidic nature of the matrix, the positive ions of
the peptides are formed in the gas phase the mechanisms of these are however not well
described.
3.11.2.1 The MALDI method
All mass spectrometry data reported in this dissertation were acquired from the
Core Proteomic Laboratory, University of Louisville, Louisville, Kentucky headed by
Drs Jon. B. Klein and William Pierce. Briefly, MALDI-TOF mass spectrometer in the
reflectron mode was used to generate peptide mass fingerprints. Peptides resulting from
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in-gel digestion with trypsin were analyzed on a 384 position, 600 µm AnchorChipTM
Target (Bruker Daltonics, Bremen, Germany) and prepared according to AnchorChip
recommendations (AnchorChip Technology, Rev. 2, Bruker Daltonics, Bremen,
Germany). Briefly, 1 µL of digestate was mixed with 1 µL of alpha-cyano-4hydoxycinnamic acid (0.3 mg/mL in ethanol: acetone, 2:1 ratio) directly on the target and
allowed to dry at room temperature. The sample spot was washed with 1 µL of a 1% TFA
solution for approximately 60 seconds. The TFA droplet was gently blown off the
sample spot with compressed air. The resulting diffuse sample spot was recrystallized
(refocused) using 1 µL of a solution of ethanol: acetone: 0. 1 % TFA (6:3:1 ratio).
Reported spectra are a summation of 100 laser shots. External calibration of the mass
axis was used for acquisition and internal calibration using either trypsin autolysis ions or
matrix clusters was applied post acquisition for accurate mass determination.

3.11.3 Electrospray Ionization (ESI)
In ESI the peptide in the solution is sprayed through a narrow capillary tube
maintained at ~4000 volts and atmospheric pressure. The potential difference between the
outlet and the mass spectrometer leads to the generation of a repulsive columbic force
between the like charges on the droplets to extend the solution to form a cone (Taylor
cone) from the outlet, causing the solution to disperse into fine droplets (Taylor, 1964).
ESI can be coupled to other separation techniques such as HPLC making it more
versatile. However the high flow rates and short analysis time presents a drawback when
performing multiple analyses.
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3.11.4 Data base searching and bioinformatics
Mass spectrometry analysis usually results in a mass spectrum that consists of
peaks, which correlate to the mass of peptides obtained following protein digestion.
Using various software programs and performing data base searches through different
search algorithms, the identity of specific proteins can be obtained. This process is
referred to as peptide mass finger printing. The search engines (Table 3.1) provide a
theoretical digest of all known proteins, which can be compared with the experimental
masses obtained. These comparisons can also be done taking it account several other
factors, such as; molecular weight, pI, the probability of a single peptide to occur in the
whole database, knowledge of peptide modifications, among many others. For each entry,
a probability score is provided based on a mathematical algorithm specific to each search
engine. This score, represents the probability that the experimental peptides match those
of the theoretical digest. A hit with a probability score corresponding to p< 0.05 has a
legitimate chance of being the protein cut from a particular spot.
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Name
Mass Search
Peptide Search
Mascot
MOWSE
SEQUEST

Address
http://cbrg.inf.ethz.ch
http://www.mann.emblheidelberg.de
http://www.matrixscience.com
http://www.hgmp.ac.uk/Bioinformatics/Webapp/mowse
http://thompson.mbt.washington.edu/sequest

Table 3.1 Table of search engines.
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3.11.5 Analysis of peptide sequences
In the current dissertation the MASCOT search engine based on the entire NCBI
and SwissProt protein databases. Database searches were conducted allowing for up to
one missed trypsin cleavage and using the assumption that the peptides were
monoisotopic, oxidized at methionine residues, and carbamidomethylated at cysteine
residues. Mass tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation
tolerance was the window of error allowed for matching the peptide mass values
(Butterfield and Castegna, 2003b). Probability-based MOWSE scores were estimated by
comparison of search results against estimated random match population and were
reported as -10*log10 (p), where p is the probability that the identification of the protein
is a random event. MOWSE scores greater than 63 were considered to be significant (p <
0.05).
3.11.6 Protein Interacteome
The proteins identified through proteomics have been found to be involved in a
wide range of functions, and are also believed to interact with a plethora of molecules and
other proteins. To enable us obtain a consequential possibility that will result from their
alterations and how these affect various cellular process, the Interaction Explorer TM
Software Pathway Assist software package (Stratagene, La Jolla, CA) was used in the
current dissertation. Pathway Assist is software for functional interaction analysis. It
allows for the identification and visualization of pathways, gene regulation networks and
protein interaction maps (Donninger et al., 2004). The proteins are first imported as the
gene symbols as a set of data. This data set is then searched against ResNet, a database
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containing over 500,000 biological interactions built by applying the MedScan textmining algorithms to all PubMed abstracts. These interactions are then visualized by
building interaction networks with shortest-path algorithms. This process can graphically
identify all known interaction among the proteins. The information of the function of
these proteins and their relevance to diseases are then obtained by using the BIOBASE's
Proteome BioKnowledge Library form Incyte Corporation (Incyte, Wilmington, DE)
(Hodges et al., 2002).

Copyright © Wycliffe Omondi Opii 2006
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CHAPTER FOUR
Redox Proteomic Identification of Less Oxidized Brain Proteins Following a LongTerm Treatment with Antioxidants and a Program of Behavioral Enrichment in the
Canine Model of Human Aging

4.1 Overview
Oxidative stress may be one of the main mechanisms contributing to neurodegeneration
and cognitive decline observed in a number of age-related neurodegenerative disorders such as
Alzheimer’s disease (AD). The use of antioxidants results in reductions in oxidative damage and
in improvements in cognitive function in many animal models. In the present study, the effect of
a long-term treatment with an antioxidant fortified diet and a program of behavioral enrichment
on oxidative damage was studied in aged canines. The parietal cortex from 21 beagle dogs was
obtained from animals placed in one of four treatment groups: i.e., control food- control
behavioral enrichment (CC); control food - behavioral enrichment (CE); antioxidant food-control
behavioral enrichment (CA); and enriched environment - antioxidant fortified food (EA). We
analyzed the levels of the oxidative stress biomarkers, i.e., protein carbonyls, 3-nitrotyroine
(3NT), and the lipid peroxidation product, 4-hydroxynonenal (HNE), and observed a decrease in
their levels on all treatments paradigms compared to control. The most significant effects were
found in the combined treatment, EA. We also used a parallel redox proteomics approach to
identify proteins that were less oxidized from the parietal cortex of the beagle dog brain. The
specific protein carbonyl levels of glutamate dehydrogenase [NAD (P)], glyceraldehyde-3phosphate dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, glutathione Stransferase (GST) and fascin actin bundling protein were significantly reduced in EA treated
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dogs compared to control. In addition, we observed a significant increase in the activities of
glutathione-S-transferase (GST) and total superoxide dismutase (SOD), and significant increase
in the protein levels of heme oxygenase (HO-1) in EA treated dogs compared to control. In
addition, a subset of proteins and antioxidant enzymes were found to correlate with an
improvement in cognitive function. These results suggest that the combined treatment reduces
the levels of oxidative damage and improves the antioxidant reserve systems in the aging canine
brain, and may contribute to improvements in learning and memory, hence providing a possible
neurobiological mechanism underlying the effects of the combined treatment. These results
support combination treatments as a possible therapeutic approach that could be translated to the
aging human population who are at risk for age-related neurodegenerative disorders, including
Alzheimer’s disease.
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4.2 Introduction
Aged dogs naturally develop cognitive deficits and accumulate brain pathology
similar to aging humans, providing a useful model for studying the neurobiological
mechanisms underlying age- related cognitive dysfunction (Head et al., 2000; Head and
Torp, 2002). Aged canine show reduced cerebral volume, cortical atrophy, ventricular
widening by in vivo magnetic resonance imaging (Su et al., 1998; Tapp et al., 2004; Tapp
et al., 2006). The aging canine also shows impairment on visuospatial working memory
and executive function (Chan et al., 2002; Tapp et al., 2003c; Studzinski et al., 2006).
Aged beagle brain deposits amyloid-β-peptide (Aβ) that is of the same sequence as
humans (Selkoe et al., 1987; Johnstone et al., 1991) and is correlated with decline in
cognitive function with age (Cummings et al., 1996b; Head et al., 1998). Beagle dogs are
accessible, easy to handle, capable of learning a broad repertoire of cognitive tasks, do
not need food deprivation to be motivated and absorb dietary nutrients in similar ways as
humans, hence making them a good model for studying human aging (Cummings et al.,
1996a). The deposition of Aβ could play a significant role in molecular pathways
involving free radical generation and oxidative stress as previously shown in AD-related
studies from our laboratory (Butterfield and Lauderback, 2002; Butterfield and BoydKimball, 2004a).
The aging process is associated with a progressive accumulation of oxidative
damage that could play a role in the development or accumulation of neuropathology
typically observed in age-related neurodegenerative disorders like AD (Hensley et al.,
1996; Markesbery, 1997; Lovell et al., 1999; Butterfield and Kanski, 2001). When
compared to age-matched controls, the AD brain shows a higher levels of protein and
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DNA oxidation, and lipid peroxidation leading to loss of function of key enzymes (Smith
et al., 1991; Hensley et al., 1995; Lovell et al., 1999). In various AD studies from our
laboratory, we have shown that Aβ 1-42 plays a central role in the oxidative stress
observed and that the key to this link is a key amino acid residue methionine 35
(Butterfield and Lauderback, 2002; Butterfield and Boyd-Kimball, 2004a). Similar events
may also occur in the canine model of aging as deposits of Aβ1-42 may account for
increased oxidative damage, a decline in glutathione content and decreased glutamine
synthetase (GS) activity reported previously (Head et al., 2002).
The use of antioxidants and/or related compounds reduces the level of oxidative
damage and delays or reduces age-related cognitive decline in both animal models and in
humans (Joseph et al., 1998a; Bickford et al., 2000; Milgram et al., 2002c). Previous
studies in aged canines show that oxidative damage may be critically involved in the
maintenance of cognitive function and long-term treatment with antioxidants and a
program of behavioral enrichment reduces cognitive decline (Cotman et al., 2002; Head
et al., 2002; Milgram et al., 2004; Milgram et al., 2005). Further, an antioxidant enriched
diet alone leads to rapid improvements in complex learning ability in aging dogs
(Cotman et al., 2002; Milgram et al., 2002c). However, the neurobiological changes
elicited by these two interventions alone or in combination have yet to be established.
We show here that there is a significant reduction in the levels of oxidative damage as
measured by levels of protein carbonyls, 3NT and HNE, following a combination of the
treatments (EA). Using redox proteomics, we identified six proteins that were
significantly less oxidized in animal receiving the combined treatment relative to control
animals and these included: glutamate dehydrogenase (GDH), glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein,
glutathione-S-transferase (GST) and fascin actin bundling protein. This improvement
was also associated with increased activity of the antioxidant enzymes glutathione-Stransferase (GST) and superoxide dismutase (SOD) and an increase in the protein levels
of inducible heme oxygenase (HO-1), a well known neuroprotective chaperone of the
family of heat shock proteins (Poon et al., 2004b). A subset of proteins and antioxidant
enzymes analyzed were also found to correlate with an improvement in cognitive
function. As a result, the use of antioxidants composed of mitochondrial cofactors and
cellular antioxidants and a program of behavioral enrichment in the present study could
potentially protect proteins from oxidative damage and enhance mitochondrial function
leading to the observed improved memory and cognitive function in this model.
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4.3 Experimental procedures
The breeding and maintenance of the animals used in the studies described here
and in chapter 5 were done by our collaborators at the Lovelace Respiratory Research
Institute Albuquerque NM. In addition, behavioral and cognitive tasks and correlational
analysis were carried out by Dr Head and group.
4.3.1 Subjects
Twenty-four beagle dogs ranging in from 8.05-12.35 yrs at the start of the study
(Mean = 10.69 yrs SE=0.25) were obtained from the colony at the Lovelace Respiratory
Research Institute (Table 4.1). These study animals were bred and maintained in the
same environment and all had documented dates of birth and comprehensive medical
histories. At the time of euthanasia, 23 dogs had received the intervention and ranged in
age from 10.72-15.01 yrs (Mean=13.31 yrs, SE=0.26) with one animal not completing
the baseline phase of the study. All research was conducted in accordance with approved
IACUC protocols.
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4.3.2 Group Assignments and study timeline
All study dogs underwent extensive baseline cognitive testing as described
previously (Milgram et al., 2002a).

Animals were subsequently ranked based on

cognitive test scores and placed into 4 groups.

These four groups were randomly

assigned as one of the treatment conditions as follows: C/C – control enrichment/control
diet, E/C – behavioral enrichment /control diet, C/A – control enrichment/antioxidant
diet, E/A – behavioral enrichment /antioxidant diet.

4.3.3 Behavioral enrichment treatment
The behavioral enrichment protocol consisted of social enrichment, by housing
animals in pairs, environmental enrichment, by providing play toys, physical enrichment,
by providing two 20-minute outdoor walks per week, and cognitive enrichment, through
continuous cognitive testing. The cognitive enrichment consisted of a landmark
discrimination task, an oddity discrimination task (Milgram et al., 2002b), and size
concept learning (Tapp et al., 2003a). In addition, all animals, regardless of treatment
condition were evaluated annually on a test of visuospatial memory (Chan et al., 2002),
object recognition memory (Callahan, 2000) and either size discrimination and reversal
learning (Tapp et al., 2003b), or black/white discrimination and reversal on consecutive
years.
4.3.4 Diet treatment
The two foods were formulated to meet the adult maintenance nutrient profile for
the American Association of Feed Control Officials recommendations for adult dogs
(AAFCO 1999). Control and test foods were identical in composition, other than
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inclusion of a broad-based antioxidant and mitochondrial co-factor supplementation to
the test food. The control and enriched foods had the following differences on an as-fed
basis, respectively: dl-alpha-tocopherol acetate (vitamin E, approximately 100 vs. 1000
ppm), -carnitine (<20 ppm vs. approximately 250 ppm), dl-alpha-lipoic acid (<20 ppm
vs. approximately 120 ppm), ascorbic acid or vitamin C as Stay-C (<30 ppm vs.
approximately 80 ppm), and 1% inclusions of each of the following (1 to 1 exchange for
corn): spinach flakes, tomato pomace, grape pomace, carrot granules and citrus pulp. The
rationale for these inclusions were as follows: Vitamin E is lipid soluble and acts to
protect cell membranes from oxidative damage; vitamin C is essential in maintaining
oxidative protection for the soluble phase of cells as well as preventing vitamin E from
propagating free radical production (Butterfield et al., 2002c); alpha-lipoic acid is a
cofactor for the mitochondrial respiratory chain enzymes, pyruvate and alphaketoglutarate dehydrogenase, as well as an antioxidant capable of redox recycling other
antioxidants and raising intracellular glutathione levels (Pocernich and Butterfield, 2003);
L-carnitine is a precursor to acetyl-L-carnitine and is involved in mitochondrial lipid
metabolism and maintaining efficient function (Calabrese et al., 2006). Fruits and
vegetables are rich in flavonoids and carotenoids and other antioxidants (Joseph et al.,
1998b; Bickford et al., 2000). To define this further, added inclusions were measured for
oxygen radical absorbing capacity (ORAC) as well as carotenoid and flavonoid profiles
(Cao et al., 1995). Fruit and vegetables selected for inclusion were based on ORAC
content and general commercial availability. Results of this analysis revealed that ORAC
content of the individual fruit and vegetable inclusions were higher than the corn for
which they were substituted. In addition, inclusion of these ingredients, in combination
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with the vitamins, resulted in increased ORAC content of the finished product. The food
was produced by an extrusion process and a production batch was fed for no more than 6
months before a new lot was manufactured.

4.3.5 Cognitive testing
All animals were given annual tests of cognition to detect changes in response to
the different treatments. Within 8 months of euthanasia, animals were given an
black/white discrimination and reversal problem that is impaired in aged animals and is
significantly improved in both antioxidant treated and/or behaviorally enriched animals
(Milgram et al., 2005). Also within a year of the end of the study, spatial memory was
tested using a nonmatching to position paradigm described previously to be sensitive to
age in dogs (Chan et al., 2002). All of the testing procedures were described in previous
publications (Chan et al., 2002; Milgram et al., 2005).

4.3.6 Animal euthanasia
Twenty minutes before induction of general anesthesia, animals were sedated by
subcutaneous injection with 0.2 mg/kg acepromazine. General anesthesia was induced
by inhalation with 5% isoflurane. While being maintained under anesthesia, dogs were
exsanguinated by cardiac puncture and blood samples were collected to obtain plasma
and serum for future studies. Within 15 minutes, the brain was removed from the skull
and a cerebrospinal fluid sample was obtained from the lateral ventricles. The brain was
sectioned midsagitally, with the entire left hemisphere being immediately placed in 4%
paraformaldehyde for 48-72 hours at 4°C prior to long term storage in phosphate buffered
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saline with 0.05% sodium azide at 4°C. The remaining hemispheres were sectioned
coronally and flash frozen at -80°C and the parietal cortex was dissected for use in the
current studies. The dissection procedure was completed within 20 minutes. Thus, the
post mortem interval for all animals was 35-45 minutes.
4.3.7 Measurement of protein carbonyls

Protein carbonyls are an index of protein oxidation and were determined as
described (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein) were
derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5 µL of
12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples were
then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30% glycerol).
Derivatized protein samples were then blotted onto a nitrocellulose membrane with a
slot-blot apparatus (250 ng per lane). The membrane was then washed with wash buffer
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by incubation
in the presence of 5% bovine serum albumin, followed by incubation with rabbit
polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h. The
membranes were washed with wash buffer and further incubated with alkaline
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion
Image (PC version of Macintosh-compatible NIH Image) software. No non-specific
background binding of the primary or secondary antibodies was found.
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4.3.8 Measurement of 3-nitrotyrosine (3-NT)
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003;
Sultana et al., 2006b). The nitrotyrosine content was determined immunochemically as
previously described (Drake et al., 2003b). Briefly, samples were incubated with
Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl
sulfate, 20% glycerol) for 20 min. Protein (250 ng) was then blotted onto the
nitrocellulose paper using the slot-blot apparatus and immunochemical methods as
described above for protein carbonyls. The mouse anti-nitrotyrosine antibody (5: 1000
dilutions) was used as the primary antibody and alkaline phosphatase-conjugated antimouse secondary antibody was used for detection. Blots were then scanned using scion
imaging and densitometric analysis of bands in images of the blots was used to calculate
levels of 3-NT. No non-specific binding of the primary or secondary antibodies was
found.
4.3.9 Measurement of 4-hydoxynonenal (HNE)
HNE is a marker of lipid oxidation and the assay was performed as previously
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v)
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus
containing a nitrocellulose membrane under vacuum pressure. The membrane was
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in
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PBST for 90 min. Following completion of the primary antibody incubation, the
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The
membrane was washed in PBST three times and developed using Sigmafast Tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
by Scion Image. A small background of the primary antibody binding to the membrane
was found, but this was scattered from both control and subject blots.
4.3.10 Two-dimensional electrophoresis
Brain samples (200 µg) were incubated with 4 volumes of 2N HCl at room for
electrophoresis or 20mM 2, 4-dinitrophenyl hydrazine (DNPH) for western blotting at
room temperature for 20 min. Proteins were then precipitated by the addition of ice-cold
100% trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples
were then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) for 1 h.
4.3.11 First dimension electrophoresis
For the first-dimension electrophoresis, 200 µL of sample solution was applied to
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The
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isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80
°C until the second dimension electrophoresis was to be performed.
4.3.12 Second dimension electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along
with the sample at 200 V for 65 min.
4.3.13 SYPRO ruby staining
After the second dimension electrophoresis, the gels were incubated in fixing
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was
then removed and gels stored in DI water.
4.3.14 Western Blotting
Brain samples (200 µg) incubated with 20mM DNPH were used for western
blotting. The strips and gels were run as described above. After the second dimension, the
proteins from the gels were transferred onto nitrocellulose papers (Bio-Rad) using the
Transblot-Blot® SD semi-Dry Transfer Cell (Bio-Rad), at 15 V for 4 h. The 2,4-
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dinitrophenyl hydrazone (DNP) adduct of the carbonyls of the proteins was detected on
the nitrocellulose paper using a primary rabbit antibody (Chemicon, CA) specific for
DNP-protein adducts (1:100), and then a secondary goat anti-rabbit IgG (Sigma, MO)
antibody was applied. The resulting stain was developed by application of Sigma-Fast
(BCIP/NBT) tablets.
4.3.15 Image analysis
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using
Scan jet 3300C (Hewlett Packard, CA). SYPRO ruby-stained gel images were obtained
using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular Dynamics,
Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad) imaging
software was then used to match and analyze visualized protein spots among differential
2D gels and 2D oxyblots, with one blot and one gel for each individual sample.

4.3.16 In-gel trypsin digestion
In those brain proteins less oxidized from EA dogs compared to CC dogs as
judged by PDQuest analysis, protein spots were digested by trypsin using protocols
previously described (Thongboonkerd et al., 2002). Briefly, spots of interest were excised
using a clean blade and placed in Eppendorf tubes, which were then washed with 0.1 M
ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was
then added to the gel pieces and incubated at room temperature for 15 min. This solvent
mixture was then removed and gel pieces dried. The protein spots were then incubated
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with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution
was removed and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The
solution was then incubated at room temperature for 30 min. The iodoacetamide was
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in
50 mM NH4HCO3, with the minimal volume enough to cover the gel pieces. The gel
pieces were incubated overnight at 37 °C in a shaking incubator.
4.3.17 Mass spectrometry
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen,
Germany) and prepared according to AnchorChip recommendations (AnchorChip
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate was
mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol:
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.
The TFA droplet was gently blown off the sample spot with compressed air. The
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser
shots. External calibration of the mass axis was used for acquisition and internal
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calibration using either trypsin autolysis ions or matrix clusters and was applied post
acquisition for accurate mass determination.
4.3.18 Analysis of peptide sequences
Peptide mass fingerprinting was used to identify proteins from tryptic peptide
fragments by utilizing the MASCOT search engine based on the entire NCBI and
SwissProt protein databases. Database searches were conducted allowing for up to one
missed trypsin cleavage and using the assumption that the peptides were monoisotopic,
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass
tolerance of 150 ppm, 0.1 Da peptide tolerances and 0.2 Da fragmentation tolerances was
the window of error allowed for matching the peptide mass values. Probability-based
MOWSE scores were estimated by comparison of search results against estimated
random match population and were reported as -10*log10 (p), where p is the probability
that the identification of the protein is a random event. MOWSE scores greater than 63
were considered to be significant (P < 0.05). All protein identifications were in the
expected size and isoelectric point (pI) range based on the position in the gel.
4.3.19 Immunoprecipitation
Immunoprecipitation of specific proteins was performed as previously described
(Sultana and Butterfield, 2004). Brain samples (200 µg) from control or treated animals
were incubated overnight with anti-GAPDH antibody. This was followed by three
washing steps with buffer B (50Mm Tris HCl (pH-8.0), 150 Mm NaCl, and 1% NP40).
The proteins were resolved by SDS-PAGE followed by immunoblotting on a
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nitrocellulose membrane (BioRad). The proteins were then detected with alkaline
phosphate labeled secondary antibody (Sigma).
4.3.20 Protein Interacteome
The functional protein interacteome was obtained by using Interaction Explorer
TM

Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist

is software for functional interaction analysis. It allows for the identification and
visualization of pathways, gene regulation networks and protein interaction maps. The
proteins are first imported as the gene symbols as a set of data. This data set is then
searched against ResNet, a database containing over 500,000 biological interactions built
by applying the MedScan text-mining algorithms to all PubMed abstracts. These
interactions are then visualized by building interaction networks with shortest-path
algorithms. This process can graphically identify all known interaction among the
proteins. The information of the function of these proteins and their relevance to diseases
are then obtained by using the BIOBASE's Proteome BioKnowledge Library form Incyte
Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002).
4.3.21 Determination of glutathione-S-transferase (GST) activity
Glutathione-S-transferase activity was measured as previously described using 1chloro-2, 4-dinitrobenzene (CDNB) as substrate (Habig and Jakoby, 1981). Briefly, the
standard assay mixture contained CDNB (1 mM), reduced glutathione (1 mM), and
potassium phosphate buffer (100 mM; pH = 6.5) in a volume of 100 µL. The changes in
absorbance were monitored at 340 nm. The thioether formed was determined by reading
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the absorbance at 340 nm, and quantification was performed by using a molar
absorptivity of 9.6 M−1.
4.3.22 Determination of superoxide dismutase (SOD) activity
Superoxide dismutase (SOD) activity was measured as previously described
(Stevens et al., 2000). Briefly, the reaction mixture of total volume 184 µL contained 160
µL of 50 mmol/l glycine buffers, pH 10.4, and 20.0 µL sample. The reaction was initiated
by the addition of 4.0 µL of a 20 mg/ml solution of (–)-epinephrine. Due to its poor
solubility, (–)-epinephrine (40 mg) was suspended in 2 ml water and was solubilized by
adding 2–3 drops of 2N HCl. The auto-oxidation of (–)-epinephrine was monitored at
480nm and the millimolar absorptivity (4.02 mmol · l–1 · cm–1) was used for calculations.
4.3.23 Measurement of HO-1 Protein levels
Mixtures of loading buffer and brain samples (50 µg) were denatured and
electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to
nitrocellulose at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer
and incubated with HO-1 primary antibody for 2 h. The membrane was then washed for
three times in PBS for 5 min and the incubated with a secondary alkaline phosphataseconjugated antibody. Proteins were visualized by developing with Sigma fast tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
using Scion Image (PC version of Macintosh-compatible NIH Image) software.
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4.3.34 Statistics
An analysis of variance was used to compare the 4 treatment groups on measures
of oxidative damage (protein carbonyls, 3-NT, HNE). Post hoc comparisons were made
using both the Bonferroni correction and Dunnett’s post-hoc test. For measures of
antioxidant enzymes and HO-1 protein levels, independent t-tests were used. In all of
these analyses, raw data were used but percent changes are presented in the plots. Pearson
product moment correlations were used to test the linear association between oxidative
damage, antioxidant enzymes and cognition. A linear stepwise multiple regression was
used to determine which of the measures of oxidative damage best predicted cognition.
SPSS for Windows was used and a p value of < 0.05 were used to establish statistical
significance. Statistical analysis of specific protein carbonyl levels matched with antiDNP-positive spots on 2D-oxyblots from brain samples from animals on an enriched
environment and antioxidant fortified diet (EA) and age matched control of dogs that
were on control food- control environment.(CC) was carried out using Student's t-tests. A
value of p < 0.05 was considered statistically significant. Only proteins that are
considered significantly different by Student's t-test were subjected to in-gel trypsin
digestion and subsequent proteomic analyses. This is the normal procedure for
proteomics studies, as sophisticated statistical analysis used for micro array studies are
not applicable for proteomics studies (Maurer et al., 2005).
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4.4 Results
4.4.1 Combined treatment (EA), decreases in the levels of protein oxidation
As shown in Fig.4.1A and 4.1B, total protein oxidation measured by the
accumulation of protein carbonyls (F (3, 22) =4.93 p=0.011) and 3-nitrotyrosine (3NT) (F
(3, 22) =3.82 p=0.027) respectively, were reduced in all treatment conditions. Post hoc
comparisons show that the extent of neuroprotection was greater for the combined
treatment of the enriched environment and antioxidant-fortified food (EA) (p=0.013 and
p=0.031 for protein carbonyls and 3NT, respectively). The levels of lipid peroxidation,
detected as protein-bound 4-hydoxynonenal (HNE), (Fig.4.1C), showed a tendency
towards reduction when the groups were compared, but was not significantly different
than controls (F (3, 22) =1.34 p=0.29).
4.4.2 Combined treatment (EA), results in a decrease in specific protein carbonyl
levels
An estimate of the carbonyl levels of specific proteins were obtained by dividing
the carbonyl level of a protein spot on the nitrocellulose membrane by the protein level of
its corresponding protein spot on the gel. This ratio gives the carbonyl level per unit of
protein. We used a parallel approach to quantify the carbonyl protein levels by SYPRO
Ruby staining and the extent of DNP-bound proteins by immunoblotting (Fig. 4.2 and Fig
4.3). When we analyzed brain samples from canines that were on the control diet and
control environment (CC) and compared them to brain samples from animals that were
on an antioxidant fortified diet and in an enriched environment (EA), six proteins were
identified that were significantly less oxidized. As shown in (Table 4.2), these proteins
were: glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-phosphate dehydrogenase
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(GAPDH), α-enolase, neurofilament triplet L protein, glutathione S-transferase (GST),
and fascin actin bundling protein. The summary of specific carbonyl levels of the six
identified proteins is shown in Table 4.3. The probability of an incorrect identification
was established to be minimal (Table 4.2). Nevertheless, to confirm the proteomics
identification of GAPDH, we used immunoprecipitation of GAPDH with an antiGAPDH antibody and Western blot analysis as shown in Fig. 4.4.
4.4.3 Enzyme activities
We next hypothesized that in addition to reduced protein oxidation that
antioxidant enzyme activity would be increased in response to treatment. We directly
compared the CC animals with the EA animals for these experiments as they showed the
largest difference in protein oxidation treatment effects. Thus, the activity and expression
of key enzyme systems that contribute to tissue defense against oxidative stress and that
are vulnerable to oxidative modification were analyzed following the treatment with an
antioxidant fortified diet and a program of behavioral enrichment in the aging canine
brain.
The activity of GST in aged canine brain isolated from dogs that had been treated
long-term with antioxidants and a program of behavioral enrichment (EA) was found to
be significantly (t (8) =3.3 p=0.011) increased by approximately 25% in aged EA animals
compared to controls (Fig 4.5). The activity of a second antioxidant enzyme, superoxide
dismutase (SOD) was also increased by approximately a 50% (Fig 4.5) in the aging
canines after the combined treatment (EA) compared to controls (CC) (t (8) =2.29
p=0.05). This is consistent with the hypothesis that oxidative modification of an enzyme

122

leads to a loss or decrease in function and the reversal of this oxidative damage can
restore the function of an enzyme (Poon et al., 2005e).
4.4.4 Correlation among Cognition, Oxidative Damage and Antioxidant Status
To determine if error scores on individual cognitive tasks were associated with
reduced oxidative damage or increased antioxidant enzyme/protein levels, a correlational
analysis was used. Table 4.4 shows that generally, higher error scores (i.e. poorer
cognition) on tests of black/white discrimination, black/white reversal and spatial
memory were associated with higher levels of oxidative damage. Correlations were
significant for black/white reversal and 3-NT (Fig 4.7A) and for 3-NT and spatial
memory (Fig. 4.7B). Overall, higher levels of antioxidant enzyme activity (SOD, GST) or
higher protein levels of HO-1 were generally associated with lower error scores on all the
tasks. These were statistically significant for GST and HO-1 (Fig 4.7 C, D) but not SOD,
although all showed the same inverse relationship. Because age at death may also be a
contributor to both increased error scores and increased oxidative damage, correlations
were computed that corrected for age. The correlation between GST activity and
black/white discrimination was significant (r=-0.81 p=0.05) and between black/white
reversal learning and HO-1 protein levels was significant (r=-0.81 p=0.05).
A multiple stepwise regression was used to determine which measures of
oxidative damage or antioxidant status best predicted cognitive dysfunction. Age at
death was also included in the analysis. The best predictor of error scores on black/white
discrimination learning was GST activity (F (1, 6) =14.31 p=0.013 r2=0.74), on
black/white reversal learning was HO-1 (F (1, 6) =11.54 p=0.019 r2=0.70) and on spatial
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memory was age at death (F (1, 6)-7.22 p=0.044 r2=0.59). Thus, at least one significant
explanatory variable for error scores on tasks administered within 1 year of euthanasia
was antioxidant enzyme function.
4.4.5 Protein Interacteome
Fig 4.8 shows the protein interacteome of proteomics-identified proteins with
decreased oxidation in response to the various intervention paradigms are illustrated by
using Interaction Explorer Software Pathway Assist (Stratagene) software. The proteins
identified in this study are related to hormone activities, transcription and regulation of
signal transduction among others. As a result, the present findings continue to confirm
and support previous findings (Poon et al., 2004c; Poon et al., 2005e) that antioxidants
and a programme of behavioral enrichment provide beneficial effect of protection and
improvement in cognitive functions and memory through the deceased oxidation and
increased activity of key proteins
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Figure 4.1 Changes in protein carbonyls (A), 3NT (B) and HNE (C) levels in canine
brain homogenate samples following treatment. There was a decrease in the levels of
protein carbonyls, 3NT and HNE measured from the various treatments i.e. EC, CA and
EA compared to the control group CC. Data are represented as % control ± SEM for
animals in each treatment group. Measured values are normalized to the CC values (n=6)
* p < 0.05 for canines on EA treatment.
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Figure 4.2

Neurofilament L
α-enolase

GAPDH

Neurofilament L

GLUD

α-enolase

GAPDH

FASCIN

FASCIN
GLUD
GST

GST

B

A

Figure 4.2 Two-dimensional SYPRO Ruby-stained gels from the parietal cortex of
canines provided with a combined treatment with an antioxidant fortified diet and
behavioral enrichment EA) (B) and compared to control (CC) (A). Positions of the
proteins identified by mass spectrometry to be less oxidized are shown as the boxed
spots.
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Figure 4.3
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Figure 4.3 Combined treatment of aged dogs with an antioxidant enriched diet and
behavioral enrichment leads to reduced protein oxidation. Carbonyl immunoblots
showing proteins with less oxidation in the parietal cortex of canines given a combined
treatment with an antioxidant fortified diet and an exposure to a behavioral enrichment
programme EA) (B) as compared to control (CC) (A)

128

Figure 4.4
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Figure 4.4 Validation of protein identified by proteomics, (A) shows blots probed with
anti GADPH antibody and, (B) shows position of GAPDH on the gel.
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Figure 4.5

Enzyme activity

% Co ntro l (CC)

250
200

*

*

150
100
50
0
Total SOD

GST

EA

Figure 4.5 SOD and GST activity are significant increased in response to treatment in
aged dogs. Dogs provided with the combination of an antioxidant-fortified diet and
behavioral enrichment show significantly increased GST and total SOD enzyme activity
relative to controls. Activities of GST and SOD are expressed as units per milligram of
protein and data are presented as % control ± SEM for animals in each treatment group,
(n=5) * p <0.05.

132

Figure 4.6
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Figure 4.6 HO-1 protein levels increase in response to treatment in aged canines.
Western immunoblot analysis and quantification of canine brain homogenates samples
containing 50µg of protein loaded onto 10% SDS-PAGE gels were completed using an
anti-HO-1 antibody. A representative immunoblot (A) with Lanes (1-6) representing the
treatment group EA, and 7-12 represent control group CC is shown and GAPDH was
used as a control for equal loading of protein. Densitometric values are plotted as a
function of treatment group (B) showing a significant increase in HO-1 expression
following the combined treatment of enriched environment and antioxidant-fortified food
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(EA) compared to control (CC). GAPDH densitometric data are represented as % control;
± SEM for each group. (n=6), * p <0.05.
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Figure 4.7
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Figure 4.7 Association between cognitive test scores and measures of oxidative damage
in treated animals. Shows error scores on individual cognitive tasks associated with
reduced oxidative damage or increased antioxidant enzyme/protein levels. Higher error
scores on tests of black/white discrimination, black/white reversal and spatial memory
were associated with higher levels of oxidative damage. Higher error scores on a reversal
learning task (A) and on a visuospatial memory task (B) were correlated with 3-NT.
Discrimination learning ability was inversely associated with GST activity (C). Reversal
learning error scores were also negatively associated with HO-1, with higher levels of
HO-1 associated with better cognition (D).
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250

Figure 4.8

Figure 4.8 Schematic diagram of a functional interacteome of all parietal cortex proteins
identified to be significantly less oxidatively modified following the combined treatment
of the enriched environment and antioxidant-fortified food (EA). This diagram was
generated by the interaction explorer ™ Pathway Module (Stratagene), indicating that all
the proteins are directly or indirectly associated with cellular process shown
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4.5 Discussion
Oxidative stress may be involved in the development of pathology leading to
decline in memory and cognitive functions observed in AD and in other age-related
neurodegenerative disorders (Hensley et al., 1995; Butterfield and Kanski, 2001;
Butterfield and Lauderback, 2002). However, interventions with antioxidants delays agerelated cognitive decline and improves performance in animal models of AD and other
age-related neurodegenerative disorders (Joseph et al., 1998b; Bickford et al., 2000; Farr
et al., 2003). The present study investigated the effect of a antioxidant-fortified diet and a
program of behavioral enrichment on the levels of oxidative damage and in restoring
antioxidant reserve systems in the aging canine brain. Four different treatments were
compared (CC, CE, CA and EA) in 23 age-matched beagle dogs for a period of 2.8yrs
and markers of oxidative stress in the parietal cortex were analyzed. There was a
reduction in the levels of brain 3NT and protein carbonyls assayed with all treatments,
but only those in the combined treatment EA showed a significant reduction when
compared to control. The levels of brain lipid peroxidation as measured by HNE were
marginally reduced in all treatments, but none was significantly reduced compared to
control. We also used redox proteomics to show that following the combined treatment
EA; the aging canine shows less oxidation to key brain proteins involved in energy
metabolism, antioxidant systems, and in maintenance and stabilization of cell structure.
In addition, there is a significant increase in the activity of antioxidant enzymes GST and
SOD in the combined treatment EA when compared to control, and a significant increase
in the expression of HO-1 protein, an important defense system in neurons under
oxidative stress (Calabrese et al., 2003a). The significant decrease in oxidation of some of
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these key brain proteins was also shown to correlate with improved cognitive function in
the aged canines undergoing these interventions. These results suggest possible
mechanisms for the improved memory and cognitive function previous reported in the
(Cotman et al., 2002; Milgram et al., 2004) and are discussed herein with relevance to
AD.
In AD, the Aβ peptide plays a central role in the generation of free radicals and
oxidative stress (Hensley et al., 1994; Butterfield et al., 2001). In the aging canine, no
significant correlation between the levels of Aβ deposition in brain and oxidative damage
is observed (Head et al., 2002), however, since the aging canine deposits the more toxic
form of Aβ 1-42 as that seen in human aging (Markesbery, 1997; Butterfield et al.,
2002b) and since Aβ load and decline in cognitive function events develop in parallel, Aβ
could still play a significant role in the mechanism of oxidative stress observed in the
aging canine (Cummings et al., 1993; Cummings et al., 1996b; Head et al., 2000). In the
peptide sequence of Aβ (1-42), there is a methionine-35 residue that our laboratory has
shown to play a critical role in Aβ induced oxidative stress and neurotoxicity observed in
AD (Butterfield et al., 2005). We have proposed that the Aβ1-42 peptide, as a small
oligomer, inserts itself in the lipid bilayer in an alpha helix conformation. A one-electron
oxidation of methionine forms the methionine sulfuranyl radical, which can then abstract
a labile hydrogen atom from neighboring unsaturated lipids forming a carbon-centered
.

lipid radical (L ), which can react with molecular oxygen to from a peroxyl radical
.

(LOO ). This peroxyl radical can abstract hydrogen from a neighboring lipid to form the
.

lipid hydroperoxide LOOH and a carbon centered radical L , which propagates the free
radical chain reaction (Varadarajan et al., 2001; Butterfield et al., 2005). It is with this
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mechanism of free radical generation that we believe is similarly taking place in the aging
canine and is responsible for the increased levels of oxidative stress leading to
neurodegeneration and a decline in memory and cognitive function.
The use of dietary intervention with anti-oxidants or free radical quenchers and a
regular program of behavioral enrichment (social, cognitive, environmental and physical
exercise) is protective against oxidative damage, reduces oxidative stress, protects neurons
and consequently improves cognitive function in human aging and in animal models (Joseph
et al., 1998b; Bickford et al., 2000; Eckles-Smith et al., 2000; Milgram et al., 2002b;
Calabrese et al., 2003a; Adlard et al., 2005b). In the present study, the fortified antioxidant
diet included vitamin E and vitamin C, both well-known free radical quenchers. Vitamin E is
lipid soluble, hence protects cell membranes from oxidative insults while vitamin C protects
the soluble phase of the cell and also regenerates the vitamin E from the vitamin E free
radical (Butterfield et al., 2002c), but recent studies in which vitamin C was not included,
reported vitamin E did not inhibit the conversion of patients with mild cognitive impairment
to AD (Petersen et al., 2005). As a result, the ability of vitamin E in protecting cell
membranes provides one possible mechanism through which the fortified diet given to the
aging canines provides protection from oxidative damage as seen by the decreased levels of
lipid peroxidation assayed by HNE and previously seen to have been elevated as measured
by malondialdehyde (Head et al., 2002). In addition, the inclusion of fruits and vegetables
rich in flavonoids and carotenoids, could help in quenching the possible free radicals
generated by Aβ, which as noted here is deposited in the aging canine brain (Cummings et
al., 1996b; Head and Torp, 2002), leading to the low levels of protein oxidation as measured
by protein carbonyls and 3NT observed in the present study. Further, there was a significant
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correlation between 3NT and spatial memory and black/white reversal learning indicating
that there is a correlation between improved cognition and reduction in oxidative damage in
the aging canine brain following the combined treatment with a diet fortified with
antioxidants and a program of behavioral enrichment.
The behavioral enrichment program used in this study involved a regimen of extra
physical exercise, enhanced environmental and social stimulation and cognitive training
leading to cognitive improvement (Milgram et al., 2005). Exercise is reported to improve
cognitive function, reduce the risk of developing cognitive impairment and reduce
neuropathology in humans or in animal models (Hultsch et al., 1999; van Praag et al.,
1999; Laurin et al., 2001; Adlard et al., 2005b). In aging dogs, behavioral enrichment
leads to significant improvements in visual discrimination learning and frontal-dependent
reversal learning (Milgram et al., 2005). The mechanism by which behavioral enrichment
provides protection against oxidative damage is still unknown, but the current study
provides new insights. Aging usually lowers the expression of antioxidant enzymes and
stress protein expression. This loss can be modulated through interventions with diet or
exercise (Heydari et al., 1993; Wu et al., 1993; Ji, 2002). One effect of the combined
treatment EA was a significant increase in the expression of inducible heme oxygenase
(HO-1) also known as HSP32. The heme oxygenase pathway is an important neuronal
defense system in conditions of oxidative stress (Chen et al., 2000) and has been reported
to be involved in oxidative stress-related neurodegenerative disorders, including AD,
(Takahashi et al., 2000). In AD, for example, the expression of HO-1 is significantly
altered and is up-regulated during oxidative stress, as well as by GSH depletion (Tyrrell,
1999; Calabrese et al., 2004a). The induction of HO-1 catabolizes heme forming carbon
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monoxide (CO) and biliverdin and subsequently bilirubin, a potent antioxidant and antiinflammatory agent (Calabrese et al., 2004a). In the aging canine increased oxidative
stress and depletion of GSH is observed (Head et al., 2002) and with interventions with
an antioxidant diet and a program of behavioral enrichment, a perfect environment is
created for the induction of HO-1. This in effect could provide an additional antioxidant
i.e. bilirubin, contributing to the decreased levels of oxidative damage and improvement
in memory and cognitive function in the aging canine. The higher protein levels of HO-1
were also associated with lower error scores on individual cognitive tasks. This
correlation was statistically significant even after correction for age at death. As a result
HO-1 was one of the best predictors of error scores on black/white reversal learning, i.e.,
higher HO-1 protein levels were associated with improved cognitive function.
A by-product of mitochondrial respiration is the generation of superoxide, which
leaks from the mitochondria inducing more oxidative stress and damage.
Supplementation of the diet in the present study with mitochondrial co-factors, could lead
to more efficiently functioning mitochondria. We have also shown in the present study
that there is increased activity of total SOD, which would then provide protection against
an increase in the production of superoxide, leading to a reduction in oxidative damage.
On looking at the correlation between increased enzymatic activity and cognition, we
found that though high levels of antioxidant activity were associated with lower error
scores, though this correlation was not significant for SOD.
We also hypothesized that of the use of mitochondrial co-factors in the canine
enriched diet would result in improved mitochondrial function and may increase ATP
production, consequently improving cognition (Milgram et al., 2004). Using redox
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proteomics in the current study, we were able to identify key brain proteins not only
related to energy metabolism but also those related to antioxidant systems, and those
involved in the maintenance and stabilization of cell structure to be less oxidized. These
proteins may be playing a role in the improved cognitive function observed in these
animals.
Energy metabolism
Alpha enolase (ENO1) is a glycolytic enzyme that interconverts 2phosphoglycerate to phosphoenolpyruvate and is one of the proteins recently identified to
be significantly oxidatively modified in individuals with mild cognitive impairment
(MCI) (Butterfield et al., 2006d), which to some extent, the aged canine models
(Cummings et al., 1996a; Cotman et al., 2002). We have also shown that α-enolase is
oxidatively modified in AD and in various models of neurodegenerative disorders
(Butterfield et al., 2002a; Perluigi et al., 2005a; Perluigi et al., 2005b; Poon et al., 2005c),
indicating that this key protein is involved in several age-related neurodegenerative
disorders. In addition, we have also shown that following caloric restriction in aging rats
(Poon et al., 2005g) and after treatment with lipoic acid in the SAMP8 mice (Poon et al.,
2005e), the specific carbonyl levels of α-enolase are significantly decreased leading us to
believe that this protein may play a key role in the restoration of cognitive function.
Consistent with this idea, our present findings show that following treatment with
antioxidants and mitochondrial co-factors (including lipoic acid) and a program of
behavioral enrichment in the aging canine, the specific carbonyl levels of α-enolase are
significantly reduced.
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is another glycolytic enzyme that
catalyzes the oxidation of glyceraldehyde-3-phosphate to 1, 3-bisphosphoglycerate and
NADH (Chuang et al., 2005). GAPDH can also act as a sensor for nitrosative stress (Hara
et al., 2006). Our laboratory has shown that GAPDH undergoes significant nitration,
another form of oxidative modification, in the hippocampus of AD patients (Sultana et
al., 2006b) and also in rats after intracerebral injection with Aβ (1-42) (Boyd-Kimball et
al., 2005c). Interestingly, we have also shown that the use of gamma-glutamylcysteine
ethyl ester (GCEE), a compound that leads to increased synthesis of glutathione in
neuronal cell culture treated with Aβ (1-42), protects GAPDH against Aβ (1-42)mediated protein oxidation (Boyd-Kimball et al., 2005b). In the present study we have
also identified GAPDH as one of the proteins that is protected from oxidative damage
following the combined treatment with antioxidants and behavioral enrichment. As a
result, the decreased oxidation of GAPDH and α-enolase could lead to improved
glycolytic function and increased ATP production and possible neuronal recovery and
improved cognitive function as seen in the canine model of human aging.
Maintenance and stabilization of the integrity of the cell structure
Neurofilament triplet L protein also known as NF68/NF-L is a subunit of
neurofilaments (NFs), which give axons their structure and diameter (Hoffman et al.,
1987). In addition NFs are involved in cytoskeleton organization, neurogenesis and
supports the neuronal architecture in the brain (Poon et al., 2006a). The protein levels of
NF-L in brains of AD, Down syndrome, and ALS patients is significantly decreased
(Bergeron et al., 1994; Bajo et al., 2001), suggesting that normal NF-L expression could
be critical to central nervous system (CNS) function. Oxidation or nitration of
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neurofilament (NF) proteins transform the α-helix secondary structure to β-sheet and
random coil conformations, destabilizing the interactions between the NF proteins and
resulting in axonal damage (Crow et al., 1997) and CNS dysfunction. We have previously
shown that NF68 was significantly oxidized in the brain of the gracile axonal dystrophy
(gad) mouse (Castegna et al., 2004). NF-66 (α-internexin) another family of the NF’s is
also significantly oxidized in the brains of old versus young mice (Poon et al., 2005b). In
the SAMP 8 mice, following treatment with alpha lipoic acid, we have observed a
significant increase in the expression of NF-68 and since alpha lipoic acid treated
SAMP8 aged mice have improved learning and memory, this protein could be important
for brain function (Poon et al., 2005e). In the present study we established that the levels
of protein oxidation for neurofilament triplet L protein were decreased following
interventions with antioxidants and a program of behavioral enrichment in aging dogs.
Another cytoskeleton related protein identified to be less oxidized in this study is
Fascin. Fascin, a 55kD globular protein, is an actin bundling protein responsible for
organizing F-actin into well-ordered, tightly packed parallel bundles in vitro and in cells
(Adams, 2004b). It is also known to be one of the core actin bundling protein of dendrites
among other structures (Adams, 2004a). Fascins function in the organization of two
major forms of actin-based structures: dynamic, cortical cell protrusions and cytoplasmic
microfilament bundles (Kureishy et al., 2002). Cell protrusions in the plasma membrane
sense the cellular environment, provide cell adhesion in the extracellular matrix and act in
cellular migration (Adams, 2004b). These cell protrusions usually require a rigid
cytoskeleton to support the localized extension of the plasma membrane. Formation of
these structures is highly regulated by extracellular and intracellular signals, with a key
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point of regulation being the binding of fascin to filamentous actin (F-actin) (Adams,
2004b). Alterations in the expression of fascin are associated with disorders such as
cardiovascular diseases and in various carcinomas among others, (Kureishy et al., 2002;
Adams, 2004b, a). Fascin was one of the brain proteins identified in the aged canine
undergoing treatment with an antioxidant diet and a program of behavioral to be less
oxidized. As a result, the identification of NFL and fascin as less oxidized following the
combined treatment would possibly lead to a decrease in axonal dystrophy (Poon et al.,
2004d), increased cellular migration, cell adhesion and communication, leading to
improved neuronal communication and survival and particularly possibly leading to
improved memory and cognitive function previously seen in the aging canine. However
since the role of fascin in aging or neurodegenerative disorders is not known, the
beneficial role of its reduced oxidation and the role it plays in cognitive function remain
speculative.
Cellular detoxification
Glutathione-S-transferase (GST) catalyzes the conjugation of a number of
exogenous and endogenous compounds such as 4-hydroxynonenal (HNE) or
malondialdehyde (MDA) with glutathione inactivating the toxic products of oxygen
metabolism (Singh et al., 2002). Hence, GST plays a critical role in cellular protection
against oxidative stress. There is a significant decline in the activity of GST in the
amygdala, hippocampus and inferior parietal lobule of patients with AD (Lovell et al.,
1998), contributing to the accumulation of toxic effects of HNE and related compounds.
Our laboratory has previously shown that in the AD brain, GST and multidrug resistant
protein MRP1 are oxidatively modified leading to an impairment of detoxification
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mechanisms causing increased oxidative stress consistent with elevated HNE in AD
(Sultana and Butterfield, 2004). In the aged canine, there is a overall decrease in GSH
content and a significant increase in the lipid peroxidation product, MDA (Head et al.,
2002). In the present study we show that following the combined treatments of an
antioxidant fortified diet and a program of behavioral enrichment, GST was less oxidized.
In addition, we also show that the activity of GST is significantly increased. This would
potentially enhance the clearance of toxic aldehydes leading to improved memory and
cognitive function in aging dogs. The higher activity of GST was also associated with
lower error scores on individual cognitive tasks. This correlation was statistically
significant even after correction for age at death. Further, increased GST activity was the
best predictor of error scores on black/white discrimination learning, thus providing a
possible mechanism underlying improved cognitive function following treatment in the
aging canine with a diet fortified with antioxidants and a program of behavioral
enrichment.
Glutamate dehydrogenase (GDH) is an enzyme located in the mitochondrial
matrix that acts in both catabolic and metabolic pathways. GDH can catalyze the
reductive amination of α-ketoglutarate with NADPH to yield glutamate in the metabolic
pathway and can also catalyze the formation of α-ketoglutarate from glutamate with
NAD+ and ammonium ion in the catabolic pathway (Boyd-Kimball et al., 2005d). The
latter pathway is particularly important in eliminating the excitotoxin glutamate. Excess
glutamate can stimulate NMDA receptors leading to an increase in Ca2+ influx and
altered calcium homeostasis, which would lead to alteration in long-term potentiation
(LTP) and consequently, learning and memory deficits as seen in AD (Boyd-Kimball et

147

al., 2005d). We have shown in the present study that following treatment with
antioxidants and a program of behavioral enrichment in the canine model of human
aging, there is a decrease in the specific carbonyl levels of GDH. This would possibly
lead to an increase in its activity, and more importantly its metabolic activity thereby
helping to clear excess glutamate in the synaptic cleft. Consequently, this may lead to
controlled Ca2+ homeostasis, improved LTP, and eventually improvement in cognitive
function as observed in the canine model of human aging following interventions with
antioxidants and a program of behavioral enrichment.
Using the Interaction Explorer Software PathwayAssist (Stratagene) to analyze
our current results as shown in Fig 5, the proteins identified in this study can be divided
into three functional categories: those related to energy metabolism, antioxidant systems
and maintenance, and stabilization of cell structure. These results therefore continue to
support a role for oxidative damage in the development of age-associated cognitive
dysfunction and indicate that the use of foods enriched with antioxidants and
mitochondrial cofactors can reduce the levels of oxidative damage and result in reducing
the effects of aging on memory and cognitive function. In addition, the increased activity
of GST continues to confirm our previous notion that oxidation of particular proteins lead
to loss of function, and that reduced oxidation of proteins can lead to an improvement in
function (Castegna et al., 2004; Perluigi et al., 2005a; Perluigi et al., 2005b; Poon et al.,
2005f). This study suggests that cognitive decline can be reversed or cognitive function
can be maintained following use of antioxidants and a program of behavioral enrichment
and this approach conceivably can be beneficial to the aging human population and in
age-related neurodegenerative disorders.
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The present study continues to provide additional evidence that oxidative stress
may be a key mechanisms contributing to decline in memory and cognitive function with
age. We have shown that a diet fortified with antioxidants in combination with a program
of behavioral enrichment is capable of reducing the levels of oxidative damage, and
increasing the activity and expression of key endogenous antioxidant enzymes in the
aging canine brain. As a result of the reduction in the levels of oxidative stress/damage
following this intervention, we have also established that key brain proteins associated
with energy metabolism, antioxidant systems, and with the maintenance and stabilization
of cell structure are protected from oxidative damage. This we believe would lead to
improved activity or function consequently leading to the improved memory and
cognitive function observed in the aging canine. Further we have also shown that there is
a strong correlation between the increased in expression/activity of some of the identified
proteins and improved cognitive function. Therefore the present study provides possible
mechanisms through which the aging canine, provided with the combined intervention of
an antioxidant fortified diet and a program of behavioral enrichment, shows
improvements in cognitive function (Milgram et al., 2002b; Milgram et al., 2005) .
Further, the increased expression of HO-1, increased activity of GST and SOD together
could all have synergistic effects in the reduction of oxidative damage and protection of
key proteins from oxidative damage observed in this study. Results from the current
study in aging canines may be translatable to humans, providing a possible intervention
for Aβ induced cognitive decline observed in AD.
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CHAPTER FIVE
Long-Term Treatment with Antioxidants and a Program of Behavioral Enrichment
Leads to Increased Expression of Key Brain Proteins in the Canine Model of
Human Aging
5.1 Overview
Aging and age-related disorders such as Alzheimer’s disease (AD) are usually
accompanied by increased oxidative stress and eventually a decline in memory and
cognitive function. Aging canines develop cognitive dysfunction and neuropathology
similar to those seen in humans, such as, beta-amyloid deposition, oxidative stress and
learning and memory impairments. In the canine model of human aging, interventions
with an antioxidant fortified diet and a program of behavioral enrichment improves
learning ability of the aging dog. To identify the neurobiological mechanisms underlying
these treatment effects, we carried out a comparative proteomics study to identify specific
brain proteins that were differentially expressed from the parietal cortex in treated aged
dogs. Twenty-one beagle dogs (8.1-12.4 years) were treated for 2.8 years after grouping
into 4 treatments: control food with either a control environment (CC) or with behavioral
enrichment (CE); antioxidant fortified food with a control environment (CA); and
behavioral enrichment and antioxidant fortified food (EA). Analysis of the parietal cortex
revealed significant increases in expression of, Cu/Zn superoxide dismutase, fructosebisphosphate aldolase C, creatine kinase, glutamate dehydrogenase and glyceraldehyde3-phosphate dehydrogenase. In addition, we also observed a significant increase in the
enzymatic activity of superoxide dismutase (SOD) following the combined treatment EA.
The increased expression of these proteins in particular Cu/Zn SOD correlated with
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improved cognitive function. These findings provide insights into possible mechanisms
through which long-term treatment with antioxidants and a program of behavioral
enrichment improve and maintain learning ability in aged beagle dogs. In addition it
provides possible mechanisms through which this program can be beneficial when
translated to the aging human population at risk for age-related neurodegenerative
disorders such as AD.
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5.2 Introduction
Elucidating mechanisms and developing therapeutic intervention strategies for
age-related neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and amyotrophic lateral sclerosis (ALS), among others, requires animal
models that can be translated to the human population. We have been using a canine
model of cognitive and brain aging that develops similar features of normal and
pathological aging in humans (Cummings et al., 1996a). Canines show cognitive decline
with increased age, (Milgram et al., 1994; Milgram et al., 2002c) , impairments in
visuospatial learning and memory (Chan et al., 2002), and age-dependent neuropathology
similar to that observed in elderly humans, i.e., accumulation of human-type amyloid βpeptide (Aβ) of the same sequence as humans (Johnstone et al., 1991), which correlates
with age-dependent cognitive dysfunction (Cummings et al., 1996b; Head et al., 1998) .
In addition, the aging canine brain accumulates oxidative damage and a decline in
antioxidant reserves (Kiatipattanasakul et al., 1996; Head et al., 2002) , events similar to
those seen in the AD brain (Markesbery, 1997), providing a possible common
neurobiological mechanism leading to cognitive dysfunction.
The use of antioxidants and regular exercise has beneficial effects in various
models of age-related neurodegenerative disorders, resulting in maintenance,
improvement or restoration of memory and cognitive function (Joseph et al., 1998b;
Laurin et al., 2001). In the canine model of human aging, short term and long term
treatment with a diet rich in a broad spectrum of antioxidants leads to rapid and sustained

153

learning ability and improved spatial attention; these effects were further enhanced with
the addition of behavioral enrichment (Cotman et al., 2002; Milgram et al., 2004).
Improved cognition in response to an antioxidant diet suggests that oxidative
stress plays a significant role in the decline of cognitive function observed in this model.
In addition, there is a significant decline in antioxidant reserves, making the aging canine
more vulnerable to oxidative attack. Consistent with this hypothesis, we previously
reported (Chapter 4) that following a program of behavioral enrichment and an
antioxidant fortified diet in the aging canine, there is a significant reduction in the levels
of protein oxidation as indexed by protein carbonyls and 3-nitrotyrosine (3NT) and also a
significant increase in enzymatic activity of key antioxidant proteins. The reduction in
oxidative stress and increased activity of antioxidant enzymes provides a possible
mechanism for the improvement in memory and cognition following these treatments.
Since the aging canine brain is under significant oxidative stress, we believe that this in
itself could trigger a stress response leading to the altered transcription of key proteins or
enzymes involved in mechanisms for protection against oxidative damage (Calabrese et
al., 2003a). Moreover, the use of an antioxidant fortified diet and a program of behavioral
enrichment could also trigger this response thereby providing an additive effect. To better
understand the mechanisms for protection at the molecular level, we have used
proteomics to identify key brain proteins that have been differentially expressed
following the treatments provided in this program.
Proteomics is the study of the proteome. Proteome analysis is “the analysis of the
entire PROTEin complement expressed by a genOME”. The analysis involves the
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systematic separation, identification, and quantification of many proteins simultaneously
from a single sample (Butterfield and Castegna, 2003b). Proteomic analysis encompasses
the qualitative, quantitative and functional characterization of the entire protein profile of
a given cell, tissue and/or organism. Proteomics has become an important and efficient
tool in the analyses of protein changes in various disease states (Butterfield, 2004). Our
laboratory has been successful in using proteomics to identify key brain proteins that are
oxidatively modified and proteins that have shown differential expression in AD and mild
cognitive impairment (Butterfield et al., 2002a; Castegna et al., 2002b; Castegna et al.,
2003; Butterfield, 2004; Butterfield et al., 2006c; Sultana et al., 2006a), the senescence
accelerated prone mouse strain 8 (SAMP8) (Butterfield and Poon, 2005), and mouse
models of Huntington’s disease (Perluigi et al., 2005b), PD (Poon et al., 2005c) , ALS
(Perluigi et al., 2005a; Poon et al., 2005f), among many others.
In the present study, we identified five proteins from the parietal cortex of the
aging canine showing a significant increase in expression following treatment with
antioxidants, exposure to a program of behavioral enrichment or a combination of both
treatments. The proteins identified were, fructose-bisphosphate aldolase C, creatine
kinase, glutamate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase and Cu/Zn
superoxide dismutase, whose activity was also shown to be significantly increased
following the combined treatment (EA) relative to control. In addition, the increased
expression of Cu/Zn SOD correlates with improvements in cognition as shown by an
improvement in the black/white reversal and spatial learning. These results suggest that a
program of behavioral enrichment and treatment with a diet of antioxidants is capable of
improving age-related cognitive function by increasing the activity of a key antioxidant
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enzyme and by increasing the expression of key proteins involved in energy metabolism
and antioxidant activity.
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5.3 Experimental procedures
5.3.1 Subjects
Subjects same as 4.3.1
5.3.2 Group assignments and study timeline
Group assignment and study timeline same as 4.3.
5.3.3 Behavioral enrichment treatment
Behavioral enrichment treatment same as 4.3.3
5.3.4 Diet treatment
Diet treatment same as 4.3.4
5.3.5 Cognitive Testing
Cognitive testing same as 4.3.5
5.3.6 Animal Euthanasia
Animal euthanasia same as 4.3.6
5.3.7 Two-dimensional electrophoresis
Brain samples (200 µg parietal cortex) were incubated with 4 volumes of 2N HCl
at room for electrophoresis. Proteins were then precipitated by the addition of ice-cold
100% trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples
were then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
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1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue for 1 h.
5.3.8 First dimension electrophoresis
For the first-dimension electrophoresis, 200 µL of sample solution was applied to
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80
°C until the 2nd dimension electrophoresis was to be performed.
5.3.9 Second dimension electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along
with the sample at 200 V for 65 min.
5.3.10 SYPRO ruby staining
After the second dimension electrophoresis, the gels were incubated in fixing
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room
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temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was
then removed and gels stored in DI water.
5.3.11 Image analysis
SYPRO ruby-stained gel images were obtained using a STORM phosphoimager
(Ex. 470 nm, Em. 618 nm, Molecular Dynamics, Sunnyvale, CA, USA) and also saved in
TIFF format. PD-Quest (Bio-Rad) imaging software was then used to match and analyze
visualized protein spots among differential 2D gels with one gel for each individual
sample.
5.3.12 In-gel trypsin digestion
Protein spots statistically different that controls were digested in-gel by trypsin
using protocols previously described and modified by (Thongboonkerd et al., 2002).
Briefly, spots of interest were excised using a clean blade and placed in Eppendorf tubes,
which were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room
temperature for 15 min. Acetonitrile was then added to the gel pieces and incubated at
room temperature for 15 min. This solvent mixture was then removed and gel pieces
dried. The protein spots were then incubated with 20 µL of 20 mM DTT in 0.1 M
NH4HCO3 at 56 °C for 45 min. The DTT solution was removed and replaced with 20 µL
of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was then incubated at room
temperature for 30 min. The iodoacetamide was removed and replaced with 0.2 mL of
50 mM NH4HCO3 and incubated at room temperature for 15 min. Acetonitrile (200 µL)
was added. After 15 min incubation, the solvent was removed, and the gel spots were
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dried in a flow hood for 30 min. The gel pieces were rehydrated with 20 ng/µL-modified
trypsin (Promega, Madison, WI) in 50 mM NH4HCO3 with the minimal volume enough
to cover the gel pieces. The gel pieces were incubated overnight at 37 °C in a shaking
incubator.
5.3.13 Mass spectrometry
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen,
Germany) and prepared according to AnchorChip recommendations (AnchorChip
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol:
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.
The TFA droplet was gently blown off the sample spot with compressed air. The
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100
laser shots. External calibration of the mass axis was used for acquisition and internal
calibration using either trypsin autolysis ions or matrix clusters and was applied post
acquisition for accurate mass determination.
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5.3.14 Analysis of peptide sequences
Peptide mass fingerprinting was used to identify proteins from tryptic peptide
fragments by utilizing the MASCOT search engine based on the entire NCBI and
SwissProt protein databases. Database searches were conducted allowing for up to one
missed trypsin cleavage and using the assumption that the peptides were monoisotopic,
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was
the window of error allowed for matching the peptide mass values (Butterfield and
Castegna, 2003b). Probability-based MOWSE scores were estimated by comparison of
search results against estimated random match population and were reported as 10*log10 (p), where p is the probability that the identification of the protein is a random
event. MOWSE scores greater than 63 were considered to be significant (p < 0.05). All
protein identifications were in the expected size and isoelectric point (pI) range based on
the position in the gel.
5.3.15 Immunoprecipitation
Immunoprecipitation of specific proteins was performed as previously described
(Sultana and Butterfield, 2004). Brain samples (200 µg) from control or treated animals
were incubated overnight with anti-GAPDH antibody. This was followed by three
washing steps with buffer B (50Mm Tris Hcl (pH-8.0), 150 Mm NaCl, and 1% NP40).
The proteins were resolved by SDS-PAGE followed by immunoblotting on a
nitrocellulose membrane (BioRad). The proteins were then detected with alkaline
phosphate labeled secondary antibody (Sigma).
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5.3.16 Protein Interacteome
The functional protein interacteome was obtained by using Interaction Explorer
TM

Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist

is software for functional interaction analysis. It allows for the identification and
visualization of pathways, gene regulation networks and protein interaction maps
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of
data. This data set is then searched against ResNet, a database containing over 500,000
biological interactions built by applying the MedScan text-mining algorithms to all
PubMed abstracts. These interactions are then visualized by building interaction networks
with shortest-path algorithms. This process can graphically identify all known interaction
among the proteins. The information of the function of these proteins and their relevance
to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002).
5.3.17 Statistical analysis
Statistical analysis of differentially expressed protein levels matched with spots
on 2D-gels from parietal cortex brain samples from the various treatment groups control
food- control environment (CC), control food - enriched environment (CE), control foodantioxidant fortified food (CA) and enriched environment - antioxidant fortified food
(EA) were used and carried out using Student's t-tests. Here we report a comparative
proteomics analysis of CC vs. CE, CA, and EA .A value of p < 0.05 was considered
statistically significant. Only proteins that are considered significantly different by
Student's t-test were subjected to in-gel trypsin digestion and subsequent proteomic
analysis. This is the normal procedure for proteomics studies, since sophisticated
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statistical analysis used for micro array studies are not applicable for proteomics studies
(Maurer et al., 2005). To test for associations between cognitive test scores and
differentially expressed proteins identified in the study, we computed correlation coefficients both with and without age at death as a covariate.
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5.4 Results
5.4.1 Antioxidant diet and behavioral enrichment program induces increased
protein expression
Two-dimensional electrophoresis offers an excellent tool for the screening of
abundant protein changes in various disease states (Butterfield et al., 2003; Butterfield,
2004; Perluigi et al., 2005b; Poon et al., 2005a). In the present study, we investigated the
pattern of protein expression in the parietal cortex of aged canines following a 2.8 year
treatment with an antioxidant fortified diet and/or a program of behavioral enrichment
and compared this with age-matched controls in four different groups. We had a four-way
analysis consisting of 23 beagle dogs divided into the following groups: CC, CE, CA and
EA. The final comparison was made as follows 1) CC vs. CE; 2) CC vs. CA, and 3) CC
vs. EA. Fig 5.1 shows SYPRO ruby stained 2D gels of the groups mentioned above with
identified protein boxed and labeled. Compared to control, all treatment groups showed a
significant increase in the expression of specific proteins. Some proteins showed an
increase in expression in all treatment groups while others were specific for a particular
treatment. The proteins identified were: Cu/Zn superoxide dismutase, fructosebisphosphate aldolase C, creatine kinase, glutamate dehydrogenase and glyceraldehyde3-phosphate dehydrogenase, showing that the antioxidant and behavioral enrichment
programme was successful in increasing the expression of proteins associated with
energy metabolism and also a protein associated with antioxidant reserve. These proteins
were identified by mass spectrometry and are shown in Table 5.1. Table 5.2 provides the
changes in protein levels expressed as % control ± S.E.M across the treatment conditions.
As a representative protein to validate these proteomic identifications, we used
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immunoprecipitation of GAPDH with anti-GAPDH as shown (Fig 5.2), confirming our
previous identification by mass spectrometry.
5.4.2 Combined treatment (EA), increases superoxide dismutase (SOD) activity
We have previously shown that the oxidative modification of specific enzymes
generally decreases their activity (Perluigi et al., 2005b; Poon et al., 2006a). Therefore,
in the present study we hypothesized that since increased oxidation leads to loss of
enzymatic activity, then protection from oxidative damage could restore or maintain the
activity of enzymes with up-regulated expression levels. To test this hypothesis, we
measured the activities of total SOD, which was significantly increased following the
combined treatment of an antioxidant fortified diet and exposure to a behavioral
enrichment program in the aging canine. There was a about a 50% increase in the activity
of SOD (Fig 5.3) in canine brain after the combined treatment (EA), and this activity was
found to be significantly increased when compared to control (CC). These results suggest
that oxidative damage plays a key role in the loss of function of key enzymes and that use
of antioxidants not only increases their expression but also likely protects them from
oxidative damage and significantly increases their enzymatic activities.

5.4.3 Correlation between protein expression levels and cognitive function
To determine if error scores on individual cognitive tasks were associated with
increased protein expression of CuZnSOD, FBP, CK, GLUD or GAPDH a correlational
analysis was used. CuZnSOD protein level was negatively correlated with error scores on
a black/white reversal task and on a spatial memory task with higher SOD levels, i.e.
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higher antioxidant protein level, being associated with lower error scores (improved
cognition). Figure 5.4 shows the linear association between CuZnSOD protein and
cognitive ability. Because age at death may also be a contributor to either increased error
scores or increased protein expression, correlations were also computed and corrected for
age. The significant association between CuZnSOD and cognition remained. Other
protein measures (FBP, CK, GLUD, and GAPDH) did not correlate with cognitive
scores.
5.4.4 Protein Interacteome
Fig 5.5 shows the protein interacteome of proteomics-identified proteins of
increase expression following various intervention paradigms. The Interaction Explorer
Software PathwayAssist (Stratagene) software results are shown in (Fig 5). The proteins
identified in this study are related to hormone activities, transcription and regulation of
signal transduction among others. As a result the present findings continue to confirm and
support previous findings (Poon et al., 2004c; Poon et al., 2005e) that antioxidants and a
program of regular exercise provide beneficial effect of protection and improvement in
cognitive functions and memory through the increase in expression and activity of key
proteins.
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Figure 5.1
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Figure 5.1 SYPRO Ruby-stained 2D-gels maps, a) CC vs. EA b) CC vs. CA, and c) CC
vs. CE of canine parietal cortex homogenates samples from the CC, CA, CE and EA
treated animals are presented. Proteins identified by mass spectrometry are presented as
the boxed spots.
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Figure 5.2 Validation of protein identified by proteomics
Same as figure 4.4
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Figure 5.3
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Figure 5.3 Comparison of the specific activity of SOD enzyme measured in canine brains
obtained from animals on a control food- control environment treatment (CC) and canine
on an enriched environment - antioxidant fortified food programme EA. There is a
significant increase in SOD activity in EA compared to CC and is expressed as units per
milligram of protein. Data are represented as % control ± SEM for animals in each
treatment group, (n=6) * p <0.05.
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Figure 5.4
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Figure 5.4 Correlation between measures of protein levels and cognitive function.
Individual error scores are plotted as a function of CuZnSOD protein levels in the parietal
cortex. (A). Black/white reversal learning was poorer in animals with lower levels of
SOD. (B). Spatial learning was also impaired in animals with lower SOD protein levels.
Line represents the results of a linear regression analysis
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Figure 5.5

Figure 5.5 Schematic diagram of a functional interacteome of all parietal cortex proteins
identified whose expression levels are significantly increased following treatment with
and antioxidant-fortified food and a program of behavioral enrichment. This diagram was
generated by the interaction explorer ™ Pathway Module (Stratagene), indicating that all
of the proteins are directly or indirectly associated with cellular process shown.
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5.5 Discussion
Long-term treatment with antioxidants and a program of behavioral enrichment in
the canine model of human aging improves cognition (Milgram et al., 2002c; Milgram et
al., 2004; Milgram et al., 2005). Age-related disorders are often accompanied by an
increase in oxidative stress, reduction in antioxidant reserves and loss in energy
metabolism among other pathological features (Hensley et al., 1996; Markesbery, 1997;
Butterfield and Lauderback, 2002). In many animal models of aging, interventions with
antioxidants are beneficial and result in a reduction of oxidative stress and improvements
in cognitive function, however, the mechanisms that underlie these improvements are still
not well understood (Joseph et al., 1998a; Joseph et al., 1998b; Farr et al., 2003). In the
present study, we used brain tissue from a higher mammalian species provided with a
long treatment protocol (2.8 years), typically not possible in aged rodent models, to
elucidate biochemical pathways and mechanisms for the improvement of cognitive
function observed. Using proteomics, we were able to identify key proteins from the
canine parietal cortex whose expressions were significantly increased following a
program of behavioral enrichment and treatment with a diet fortified with antioxidants.
Four proteins related to energy metabolism, i.e., fructose-bisphosphate, creatine kinase,
glutamate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase were increased
in expression as was the protein level and activity of a key antioxidant protein, Cu/Zn
superoxide dismutase that also showed a significant association with cognition.
Fructose bisphosphate aldolase C (FBP) is a glycolytic enzyme that catalyses the
reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate into dihydroxyacetone-
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phosphate and glyceraldehyde 3-phosphate (Perham, 1990). In vertebrates, three forms of this
enzyme are found: aldolase A is expressed in muscle, aldolase B in liver, kidney, stomach and
intestine, and aldolase C in brain, heart and ovary. The different isozymes have different
catalytic functions: aldolases A and C are mainly involved in glycolysis, while aldolase B is
involved in both glycolysis and gluconeogenesis (Perham, 1990). On the other hand,
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the oxidation of
glyceraldehyde-3-phosphate to 1, 3-bisphosphoglycerate and NADH (Boyd-Kimball et al.,
2005c). In addition to glycolysis GAPDH plays a role in membrane fusion and transport,
accumulation of glutamate into presynaptic vesicles, and acting as a cellular sensor of oxidative
stress (Chuang et al., 2005). Recent studies suggest GAPDH acts as a NO sensor (Hara et al.,
2006). In AD, there is a reduced activity of glyceraldehyde-3-phosphate dehydrogenase
(Mazzola and Sirover, 2001), and our laboratory has shown that GAPDH is significantly
oxidized in AD and in animal models of AD (Boyd-Kimball et al., 2005a; Boyd-Kimball et al.,
2005c; Sultana et al., 2006b). In the present study the expression of these glycolytic proteins
was significantly increased following a program of enriched environment and a diet of
antioxidants. This increased expression of FBP and GAPDH, proteins that are decreased in
patients with AD (Bigl et al., 1999), may lead to increased glycolytic activity and function and
when coupled to other bioenergetics pathways would further lead to an increase and
maintenance of ATP production. Increased ATP production may be important for neuron
survival and thus may serve as one mechanism underlying observed improvements in cognitive
functions in the canine model of human aging.
The creatine kinase (CK) system is the most important immediate energy
buffering and transport system especially in muscle and neuronal tissue (Wallimann et al.,
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1998). CK consists of a cytosolic and a mitochondrial isoform (MtCK) with their substrates
creatine and phosphocreatine. Creatine is typically phosphorylated to phosphocreatine in
the intermembrane space of mitochondria where mitochondrial CK is located and is then
transported into the cytosol (Schlattner et al., 1998). In the cytosol, the energy pool can be
regenerated by transphosphorylation of phosphocreatine to ATP, which is catalyzed by
cytosolic CK in close proximity to cellular ATPases. Moreover, the mitochondrial
synthesis of creatine phosphate is restricted to uMiCK expressing neurons, suggesting
uMiCK protects neurons under situations of compromised cellular energy state, which are
often linked to oxidative stress and calcium overload through compensatory up-regulation
of gene expression (Boero et al., 2003). CKs are prime targets of oxidative damage, MtCK
in particular is a principal target of such damage, not only because if its sensitivity
(Stachowiak et al., 1998; Koufen and Stark, 2000), but also due to its mitochondrial
localization. Our laboratory has shown that though there is increased expression of CK in
AD, it is significantly oxidized and its activity significantly reduced (Aksenov et al., 2000;
Castegna et al., 2002b). In the brain of old brown Norway rats, CK is oxidatively modified
and its activity significantly decreased (Aksenova et al., 1998). Also in aging neuronal
cultures, there is a gradual increase in CK content but decreased activity of the enzyme.
These changes in CK expression have been considered to be an early indicator of oxidative
stress in aging neurons (Aksenova et al., 1999). In the present study, following exposure of
the aging beagle dogs to a program of environmental enrichment and a diet fortified with
anti-oxidants, we observed a significant increase in the expression of CK. This is in
agreement with a previous study from our laboratory that showed a significant increase in
the expression of CK in the senescence accelerated prone mouse strain 8 (SAMP8) mice
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after intervention with alpha-lipoic acid, a mitochondrial co-factor and antioxidant included
in the diet used in the present study (Poon et al., 2005e). This increased expression we posit
is a compensatory mechanism for restoration of ATP production in the aging canine, thus
leading to maintenance of energy reserves and possibly cognitive function
Glutamate dehydrogenase (GDH) is an enzyme located in the mitochondrial
matrix that acts in either a metabolic or a catabolic pathway. In the biosynthetic pathway,
GDH catalyzes the reductive amination of α-ketoglutarate with NADPH to yield glutamate.
Alternatively, GDH can catalyze the formation of α-ketoglutarate from glutamate with
NAD+ and ammonium ion (Boyd-Kimball et al., 2005d). The catabolic activity of GDH is
particularly important for the elimination of excitotoxic glutamate. We have previously
shown using proteomics that when synaptosomes are treated with Aβ (1-42) (BoydKimball et al., 2005d), GDH is oxidized and loses its function, a phenomenon observed in
aging. In the present study, we observed that after treatment with antioxidants and exposure
to a program of behavioral enrichment, the canine brain showed an increased expression of
GDH. Increased expression of GDH could lead to increased elimination of excitotoxic
glutamate by increasing the conversion of glutamate to α-ketoglutarate. The conversion of
excess glutamate to α-ketoglutarate would desensitize NMDA receptors leading to a
reduction in Ca2+ influx. Improved calcium homeostasis would in turn lead to maintenance
of the long-term potentiation (LTP) and consequently, improved learning and memory
(Michaelis, 1997), as observed in the canine study.
Cu/Zn Superoxide dismutase (CuZnSOD, SOD1 protein) is an abundant copperand zinc-containing protein that is present in the cytosol, nucleus, peroxisomes, and
mitochondrial intermembrane space of human cells and acts as an antioxidant enzyme by
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lowering the steady-state concentration of superoxide (Selverstone Valentine et al., 2005).
When mutated, SOD can also cause disease as in the case of the neurodegenerative
disorder, familial amyotrophic lateral sclerosis (fALS) (Selverstone Valentine et al., 2005).
The toxic gain of function of mutant SOD (mSOD) leads to the generation of reactive
oxygen/nitrogen species (Valentine, 2002; Perluigi et al., 2005a; Poon et al., 2005f). Some
researchers believe that the elevated oxidative activity associated with mSOD occurs by
enzymes acting as peroxidases (Valentine, 2002) or as superoxide reductases (Liochev and
Fridovich, 2000) or by producing O2.− to form peroxynitrite (Rakhit et al., 2002). In the
wild type form, SOD dismutates superoxide to oxygen and water, hence reducing the levels
of oxidative stress and protecting proteins, lipid and DNA from the toxic superoxide
molecule (Gutteridge and Halliwell, 2000). In the present study a significant increase in the
expression of SOD1 and significant increase in SOD enzymatic activity in the brain from
canines that had undergone a combination of both treatment with antioxidant diet and a
program of behavioral enrichment compared to age matched controls were found. This
finding shows that a diet of antioxidants and a program of behavioral enrichment provided
to the aging canine are able to increase the expression and activity of a key antioxidant
protein, in turn protecting the cells form oxidative stress and improving memory and
cognitive function. Consistent with this hypothesis is that of the measures of protein
expression that distinguished the treatment groups in the current study. SOD1 protein level
was the best predictor of a frontal-cortex dependent learning task and a measure of spatial
memory. Animals that were showing improved error scores on these two tasks also had
higher SOD1 protein.
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In the current study, we demonstrated that following a long-term treatment with a
diet fortified with antioxidants and a program of behavioral enrichment in the aging
canine, there is a significant increase in the expression of key proteins related to energy
metabolism and antioxidant activity. Increased protein expression does not necessarily
directly translate to increased enzyme activity as reported for creatine kinase in AD
(Aksenov et al., 1998a); however, we have shown here both an increase in expression and
activity of Cu/Zn SOD in response to treatment. In addition, this increase in protein levels
was found to be a good predictor of frontal-cortex dependent learning and a measure of
spatial memory. The present findings therefore provide a neurobiological basis for
improved neuronal function and cognition in canines treated with either or both an
antioxidant enriched diet and behavioral enrichment. The inclusion of vitamin E, alphalipoic acid L-carnitine flavanoids in the diet not only provide improvements in
antioxidant reserves but also plays a role in increasing the expression of key energy
metabolism proteins that help in the maintenance of ATP levels, maintenance of cellular
pathways and functions dependent on ATP eventually leading to an improvement in
cognitive function and memory. Fig 5.6 provides a summary of the functional
consequence of increased expression and reduced oxidation of proteins identified in the
aging canine following treatment with an antioxidants fortified diet and a program of
behavioral enrichment.

180

Figure 5.6 A summary of the functional consequence of increased expression and
reduced oxidation of proteins identified in the aging canine following treatment with an
antioxidants fortified diet and a program of behavioral enrichment.

5.6 Acknowledgement
This work was supported in part by grants from NIH to D.A.B. [AG-05119; AG-10836],
and NIH to C.W.C [AG12694].
Copyright © Wycliffe Omondi Opii 2006

181

CHAPTER SIX
Proteomic Expression Analysis of Brain Proteins from Dementia-free
Nonagenarians: Relevance to Successful Aging and Alzheimer’s disease
6.1 Overview
Aging is a unique phenomenon that affects all animal species. In humans, aging is
usually accompanied by impairments in the functional capacity of the brain leading to its
susceptibility to neurodegenerative disorders such as Alzheimer’s disease (AD) among
others. In spite of functional declines in aging, recently, there has been a rise in the
number of nonagenarian and centenarians who are cognitively intact and who
demonstrate no evidence of neurodegenerative diseases despite their advanced ages; this
phenomenon is usually referred to as successful aging. The mechanisms underlying this
phenomenon of successful aging are still under investigation. Various studies have
identified several genes thought to be responsible for dementia-free aging and extended
longevity, but since no single gene can be found responsible for modulating successful
human aging, it is thought that this process occurs possibly through multiple routes. To
further investigate this phenomenon, we have carried out a proteomic expression profile
analysis on brain proteins in the frontal cortex of 5 nonagenarian (mean age ± SD, 94.8 ±
2.9) with AD and 4 normal non-demented age matched control nonagenarians (mean age
± SD, 94.5 ± 1.3). In addition, we have evaluated biomarkers of oxidative stress as
measured by the levels of protein oxidation and lipid peroxidation, i.e., protein carbonyls
and protein-bound 4-hydroxynonenal (HNE), isoprostanes (F2-IsoP) and neuroprostanes
(F4-NP). There was no significant difference in the levels of protein carbonyls, HNE, F2IsoP and F4-NP when the two groups were compared. However, using proteomics we
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were able to identify six proteins that were differentially expressed. Among these, we
observed a significant decrease in the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), ATP synthase H+ transporting, human peroxiredoxin 5
(PRDX5) and malate dehydrogenase (MDH) in the non-demented nonagenarian
compared to those with AD. However, the levels of protein expression for fructose
bisphosphate aldolase (FBP1) and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1)
were found to be significantly increased when the same groups were compared. In
addition, the severity of cognitive decline (MMSE) and amyloid beta-peptide (Aβ) levels
correlated with these changes in protein expression. These results show that though the
levels of oxidative stress were comparable between age-matched non-demented and
demented nonagenarians, the differential expression of proteins related to energy
metabolism and antioxidant systems could contribute to the mechanisms that result in
extended longevity and maintenance of cognitive reserve and functional capacity in this
rising population of non-demented nonagenarians and centenarians.
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6.2 Introduction
Aging is defined as the gradual alteration in structure and function that occurs
over time, eventually leading to an increased probability of death not associated with
disease or trauma, and it can be considered to be a product of an interaction between
genetic, environmental and lifestyle factors (Ashok and Ali, 1999; Gonos, 2000). Aging
is usually characterized by impairments in physiological functions, such as impairments
in the brain, increased susceptibility to dementia and neurodegenerative disorders, i.e.,
Alzheimer’s disease (AD), Parkinson disease (PD), Huntington’s disease HD, and
amyotrophic lateral sclerosis (ALS), among others (Poon et al., 2004b). Centenarians are
the fastest growing age-group in the USA, and it is projected that there will be more than
400,000 in the next 30 years (Silver et al., 2002). Studies have shown that there is an
increase in the incidence of dementia among people aged 85 years and above (Silver et
al., 2001; Perls, 2004b, a), and most people believe that dementia is inevitable to people
in this age group (Blansjaar et al., 2000; Snowdon, 2003; Perls, 2004a). However, various
studies on nonagenarians and centenarians have shown that approximately 30% of
centenarians are cognitively intact and that among those who are demented, 90% show a
delay in the time they present signs of cognitive impairments well into their 90’s
(Hagberg et al., 2001; Silver et al., 2001; Perls, 2004b, a). As a result, the increasing
number of non-demented nonagenarians and centenarians disputes the notion that
dementia is inevitable as one becomes older (Green et al., 2000; Perls, 2006). This rising
number of the oldest-old provides a unique resource for the study of dementia-free aging
and related disorders.
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The ability to achieve extreme old age while still maintaining intact cognitive
function appears to be the result of a complex combination of factors such as genetics,
environment, and lifestyle, among others, showing the complexity of understanding the
mechanisms for successful aging process in the human population (Perls, 2005; Perls,
2006). Various studies have shown the gene expression profiles in the aging brain
(Galvin and Ginsberg, 2005), but few have been able to show the protein expression
profile in the cognitively intact nonagenarians. Therefore, to better understand the
cellular and biochemical mechanisms involved in the brains of cognitively intact
nonagenarians, a differential expressional proteomic study on brain from nonagenarians
who had undergone successful aging and were non-demented compared to their
demented aged-matched controls was performed in the current study.
Our laboratory has previously used proteomics to identify proteins that have
undergone oxidative modifications or significant differential expression in AD subjects
compared to age-matched controls. These studies among others have continued to
provide evidence that energy metabolism and maintenance of ATP levels plays an
integral role in the pathological and biochemical pathways of age-related
neurodegenerative disorders (Castegna et al., 2002b; Castegna et al., 2002a; Castegna et
al., 2003; Sultana et al., 2006d; Sultana et al., 2006c; Sultana et al., 2006a; Sultana et al.,
2006b). Though we have been successful in these studies, having non-demented
nonagenarians and age-matched subjects with AD is a unique resource that was
previously not available to us. Hence, this current study is the first report using
proteomics to investigate possible mechanisms that are involved in successful aging of
cognitively intact nonagenarians. We identified six brain proteins that were significantly
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differentially expressed. We observed a significant decrease in the expression of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATP synthase, H+ transporting
protein, human peroxiredoxin 5 (PRDX5), and malate dehydrogenase (MDH) in the nondemented nonagenarian compared to those with AD. On the other hand, the levels of
protein expression of fructose bisphosphate aldolase (FBP1) and ubiquitin carboxylterminal hydrolase L1 (UCHL1) were found to be significantly increased when the same
groups were compared. Further, we found that the severity of cognitive decline (MMSE)
correlated with these changes in protein expression and that the extent of Aβ was also
linked to protein expression. These results show that though the levels of oxidative stress
were comparable, the increased expression of proteins related to energy metabolism and
antioxidant systems in the demented brain of nonagenarians compared to their nondemented aged-matched nonagenarians could contribute to the mechanisms that result in
extended longevity and maintenance of cognitive reserve in the successful aging
population.
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6.3 Experimental procedures
6.3.1 Subjects
Subjects in the study were participants in the 90+ study, a population based investigation
of aging and dementia in the oldest old. In the early 1980s, residents of Leisure World, a
retirement community in southern California, were mailed a health questionnaire. Those
who completed and returned the questionnaire became members of the Leisure World
Cohort Study. Of the members of the Leisure World Cohort, those who were alive and
aged 90 years or older on January 1, 2003 were eligible to participate in The 90+ Study.
Participants in the 90+ study were given neuropsychological testing every 6 months until
their death. A subset of these participants agreed to brain autopsy and tissue donation.
The subjects in this study were selected from the first 19 cases to come to autopsy.
Subjects were selected based on their clinical and neuropathological diagnoses. The
subject demographics are summarized in Table 6.1. The neuropsychological testing and
neuropathology diagnosis were performed by Dr Daniel J. Berlau at the Institute for
Brain Aging and Dementia, Department of Neurology, University of California, Irvine,
California.
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6.3.2 Neuropsychological testing
The Mini-Mental State Exam (MMSE) was administered to the participants in the
90+ study every 6 months as a measure of overall cognitive status. Only the data from
their final examination was used for statistical analysis in this study. The MMSE score is
out of 30 possible points and includes the following sections: temporal orientation, spatial
orientation, attention, mental reversal, recall, naming, repetition, writing, reading and
obeying a command, constructional praxis, and visual construction (Folstein, 1975).
6.3.3 Neuropathology diagnosis
Each brain was weighed at autopsy and one cerebral hemisphere (together with
the brainstem and cerebellum) was fixed in 4% paraformaldehyde for 2 weeks, and the
contralateral hemisphere was coronally sectioned and frozen at -80°C. Cortical and
subcortical regions were dissected and paraffin embedded for histological and
immunohistochemical examination. Modified Bielschowsky, hematoxylin-eosin and
immunostains for tau, α-synuclein, ubiquitin, glial fibrillary acidic protein (GFAPastrocytosis) and CD68 (activated microglial cells) were applied. Microscopically,
neuritic plaque formation and neurofibrillary degeneration was categorized according to
Braak & Braak staging (Braak and Braak, 1991; Braak and Braak, 1995). The final
neuropathology diagnosis was established using NIA/Reagan criteria (disease, 1997).
6.3.4 Sample preparation
Brain samples were minced and suspended in 10 mM HEPES buffer (pH 7.4)
containing 137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.1 mM EDTA, and 0.6 mM
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MgSO4 as well as proteinase inhibitors: leupeptin (0.5 mg/mL), pepstatin (0.7 µg/mL),
type II S soybean trypsin inhibitor (0.5 µg/mL), and PMSF (40 µg/mL). Homogenates
were centrifuged at 14,000 × g for 10 min to remove debris. Protein concentration in the
supernatant was determined by the BCA method (Pierce, Rockford, IL, USA).
6.3.5 Measurement of protein carbonyls
Protein carbonyls are an index of protein oxidation and were determined as
described previously (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein)
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples
were then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30%
glycerol). Derivatized protein samples were then blotted onto a nitrocellulose membrane
with a slot-blot apparatus (250 ng per lane). The membrane was then washed with wash
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by
incubation in the presence of 5% bovine serum albumin, followed by incubation with
rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h.
The membranes were washed with wash buffer and further incubated with alkaline
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion
Image (PC version of Macintosh-compatible NIH Image) software.
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6.3.6 Lipid peroxidation
6.3.6.1 Measurement of protein-bound 4-hydoxynonenal (HNE)
HNE is a marker of lipid oxidation and the assay was performed as previously
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v)
glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus
containing a nitrocellulose membrane under vacuum pressure. The membrane was
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in
PBST for 90 min. Following completion of the primary antibody incubation, the
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The
membrane was washed in PBST three times and developed using Sigmafast Tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
by Scion Image.
6.3.6.2 Measurement of Neuroprostanes and Isoprostanes
Dr. J.D Morrow at the Vanderbilt University School of Medicine quantified the
levels of Isoprostanes (F2-IsoPs) and Neuroprostanes (F4-NPs) in brain specimens of the
oldest old. This was done using highly precise and accurate mass spectrometric assays
applying stable isotope dilution techniques, as described previously (Morrow and
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Roberts, 1999; Musiek et al., 2004). Briefly, specimens were dissected from frozen
middle frontal gyrus of individual cases and lipids were extracted from specimens by the
method of Folch and colleagues (Folch et al., 1957). F2-IsoP and F4-NPs were esterified
in tissue and hydrolyzed by chemical saponification, extracted using C18 and silica SepPak cartridges (Waters Corporation, Milford, MA), purified by thin-layer
chromatography, converted to pentafluorobenzyl ester trimethylsilyl ether derivatives,
and quantified using gas chromatography/negative ion chemical ionization/mass
spectrometry. The stable isotope dilution techniques used [2H4]-8-iso-PGF2a as an
internal standard for F2-IsoPs and [18O2]17-F4c-NP as an internal standard for F4-NPs.
6.3.7 Two-dimensional electrophoresis
Brain samples (200 µg) were incubated with 4 volumes of 2N HCL at room for
electrophoresis. Proteins were then precipitated by the addition of ice-cold 100%
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3 min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
1:1 ratio (v/v) of the zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v)
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h.
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6.3.8 First dimension electrophoresis
For the first-dimension electrophoresis, 200 µL of sample solution was applied to
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80
°C until the 2nd dimension electrophoresis was to be performed.
6.3.9 Second dimension electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along
with the sample at 200 V for 65 min.
6.3.10 SYPRO ruby staining
After the second dimension electrophoresis, the gels were incubated in fixing
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room
temperature with 50 ml SYPRO Ruby gel stains (Bio-Rad). The SYPRO ruby gel stain
was then removed and gels stored in deionized water.
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6.3.11 Image analysis
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using
Scan jet 3300C scanner (Hewlett Packard, CA). SYPRO ruby-stained gel images were
obtained using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular
Dynamics, Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad)
imaging software was then used to match and analyze visualized protein spots among
differential 2D gels for each group of subjects.
6.3.12 In-gel trypsin digestion
Samples were digested by trypsin using protocols previously described
(Thongboonkerd et al., 2002). Briefly, spots of interest were excised using a clean blade
and placed in Eppendorf tubes, which were then washed with 0.1 M ammonium
bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was then added to
the gel pieces and incubated at room temperature for 15 min. This solvent mixture was
then removed and gel pieces dried. The protein spots were then incubated with 20 µL of
20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution was removed
and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was
then incubated at room temperature for 30 min. The iodoacetamide was removed and
replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room temperature for
15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the solvent was
removed, and the gel spots were dried in a flow hood for 30 min. The gel pieces were
rehydrated with 20 ng/µL modified trypsin (Promega, Madison, WI) in 50 mM
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NH4HCO3, with the minimal volume enough to cover the gel pieces. The gel pieces were
incubated overnight at 37 °C in a shaking incubator.
6.3.13 Mass spectrometry
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen,
Germany) and prepared according to AnchorChip recommendations (AnchorChip
Technology, Rev. 2, and Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol:
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.
The TFA droplet was gently blown off the sample spot with compressed air. The
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser
shots. External calibration of the mass axis was used for acquisition and internal
calibration using either trypsin autolysis ions or matrix clusters and was applied post
acquisition for accurate mass determination.
6.3.14 Analysis of peptide sequences
Peptide mass fingerprinting was used to identify proteins from tryptic peptide
fragments by utilizing the MASCOT search engine based on the entire NCBI and
SwissProt protein databases. Database searches were conducted allowing for up to one
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missed trypsin cleavage and using the assumption that the peptides were monoisotopic,
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass
tolerance of 150 ppm, 0.1 Da peptide tolerances and 0.2 Da fragmentation tolerances was
the window of error allowed for matching the peptide mass values. Probability-based
MOWSE scores were estimated by comparison of search results against estimated
random match population and were reported as -10*log10 (p), where p is the probability
that the identification of the protein is a random event. MOWSE scores greater than 63
were considered to be significant (P < 0.05). All protein identifications were in the
expected size and isoelectric point (pI) range based on the position in the gel.
6.3.15 Aβ ELISA
Dr. Elizabeth Head of the University of California Irvine performed the Aβ
ELISA assay described here. Aβ was sequentially extracted from approximately 200 mg
of frozen midfrontal cortex taken adjacent to cortex for proteomics experiments in 0.1M
Tris pH = 6.8 with 1% SDS and a Protease inhibitor Cocktail Kit (MP Biochemicals Inc.)
containing 0.4 mg/ml AEBSF, 1mg/ml EDTA-Na2, 1µg/ml Leupeptin and Pepstatin A)
at 1 mL buffer/150mg wet weight tissue using Potter Elevehjem 10 ml Wheaton glass
tube and centrifuged at 4° C at 100 000 x g for 1 hour. The pellet was resuspended in
70% formic acid and sonicated on ice. After centrifugation at 4° C at 100 000 x g for 1
hour, the supernatant was collected and stored at –80°C until assayed. Brain samples
were run in triplicate on ELISA plates coated with a monoclonal anti-Aβ1-16 antibody
(kindly provided by Dr. William Van Nostrand, Stony Brook University, Stony Brook,
NY) and detection was by monoclonal HRP conjugated anti-Aβ1-40 (MM32-13.1.1) and
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anti-Aβ1-42 (MM40-21.3.1) antibodies (kindly provided by Dr. Christopher Eckman,
Mayo Clinic Jacksonville, Jacksonville, CA) (Das et al., 2003; Kukar et al., 2005;
McGowan et al., 2005). For standards, Aβ1-40 and Aβ1-42 (Bachem California, Inc.,
Torrance, CA) were used after a pretreatment with HFIP to prevent fibril formation.
6.3.16 Statistical analysis
Statistical analysis of differentially expressed protein levels matched with spots
on 2D-gels from brain samples from cognitive intact nonagenarians and demented agematched subjects were used and carried out using Student's t-tests. A value of p < 0.05
was considered statistically significant. Only proteins that are considered significantly
different by Student's t-test in the brains of the old normal versus the old with AD were
subjected to in-gel trypsin digestion and subsequent proteomic analysis. This is the
normal procedure for proteomics studies, since sophisticated statistical analysis used for
microarray studies are not applicable for proteomics studies (Maurer et al., 2005). To
analyze the association between proteomic outcome measures and clinical and
neuropathological characteristics of autopsy cases used in the current study, we
calculated Spearman Rho’s correlation co-efficients.
6.3.17 Protein Interacteome
The functional protein interacteome was obtained by using the Interaction
Explorer TM Software Pathway Assist software package (Stratagene, La Jolla, CA).
Pathway Assist is software for functional interaction analysis. It allows for the
identification and visualization of pathways, gene regulation networks and protein
interaction maps (Donninger et al., 2004). The proteins are first imported as the gene
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symbols as a set of data. This data set is then searched against ResNet, a database
containing over 500,000 biological interactions built by applying the MedScan textmining algorithms to all PubMed abstracts. These interactions are then visualized by
building interaction networks with shortest-path algorithms. This process can graphically
identify all known interaction among the proteins. The information of the function of
these proteins and their relevance to diseases are then obtained by using the BIOBASE's
Proteome BioKnowledge Library form Incyte Corporation (Incyte, Wilmington, DE)
(Hodges et al., 2002).
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6.4 Results
6.4.1 Pathology of brain from oldest-old cognitively normal and AD subjects
As shown in Table 6.2, nondemented and demented individuals were not different
in education level (t (7) =1.38 p=0.21), age (t (7) =0.28 p=0.79), post mortem interval
(t(7)=0.33 p=0.75) or interval between last clinic assessment and death (t(7)=1.25
p=0.25). Nondemented subjects selected for this study had Braak & Braak tangle stages
between III and IV whereas those with dementia had Braak & Braak tangle stages V and
VI. Individuals with AD had significantly lower MMSE scores (t (7)=6.19 p<. 0005) but
not brain weights (t (7)=1.89 p=0.10). The short post-mortem intervals employed
suggests little oxidative damage or degradation occurred following death prior to
harvesting the brain (Butterfield et al., 2003; Butterfield, 2004; Poon et al., 2005a; Poon
et al., 2005b).
6.4.2 Protein oxidation levels in the demented and nonagenarians
Oxidative stress and the resulting damage has been shown to be one of the main
mechanisms contributing to neurodegeneration and cognitive decline in a number of agerelated neurodegenerative disorders such as AD (Aksenov et al., 1998b; Aksenov et al.,
2000; Aksenov et al., 2001; Butterfield et al., 2001; Butterfield and Lauderback, 2002).
Protein carbonylation is one of the markers of protein oxidation (Butterfield and
Stadtman, 1997). There was no significant difference in both the levels of protein
carbonyls among the subjects investigated (Fig.6.1).
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6.4.3 Levels of lipid peroxidation in the demented and nonagenarians
4-hydroxynonenal HNE is a marker of lipid oxidation (Lauderback et al., 2001).
HNE binds to proteins by Michael addition (Butterfield and Stadtman, 1997), altering
their conformation, and thereby reducing there activity (Subramaniam et al., 1997;
Lauderback et al., 2001). In the current study there was no significant differences
observed in the levels of lipid peroxidation markers as measured by HNE, isoprostanes
and neuroprostanes between the non-demented nonagenarians and the demented agedmatched nonagenarians (Fig.6.2) This is consistent with a previous study that showed no
significant increase in the levels of malondialdehyde (MDA), another measure of lipid
peroxidation in nondemented nonagenarians compared to septo/octogenarians (Rea et al.,
2004).
6.4.4 Differential expression of protein levels in the demented and non-demented
nonagenarians
Two-dimensional electrophoresis offers an excellent tool for the screening of
abundant protein changes in various disease states (Butterfield et al., 2003; Butterfield,
2004; Poon et al., 2006b; Poon et al., 2006a). To assess whether there were any changes
in the proteomic profile in the brains of cognitively intact nonagenarians in the present
study, we investigated the pattern of protein expression in the frontal cortex from the
demented nonagenarians compared to the age-matched cognitively intact nonagenarians.
Comparing the densitometric intensities of individual spots on the gels, four proteins
were expressed at significantly lower levels, and two proteins were expressed at
significantly higher levels in the brains of the nonagenarians with AD compared to the
non-demented nonagenarians. Fig 6.3 shows SYPRO ruby stained 2D gels of the old
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normal (A) vs. old AD (B) groups mentioned above, with identified protein boxed and
labeled. The brain proteins identified with decreased expression in the non-demented
nonagenarians compared to aged-matched AD were: peroxiredoxin 5 (PRDX5), malate
dehydrogenase (MDH), ATP Synthase H+ transporting protein, and glyceraldehyde-3phosphate dehydrogenase (GAPDH). In contrast, two proteins, ubiquitin carboxylterminal hydrolase L1 (UCHL1) and fructose bisphosphate aldolase (FBP1) were
identified by proteomics to have increased expression in the non-demented nonagenarians
compared to the demented nonagenarians. These proteins identified by mass
spectrometry are shown in Table 6.3. Table 6.4 provides the changes in protein levels
expressed as percent control ± S.E.M.
6.4.5 Correlations between changes in protein expression, Aβ and cognitive status.
Table 6.5 shows that several significant correlations were observed between Aβ,
MMSE scores and protein expression levels. Overall, Aβ 40 either in the soluble or
insoluble fractions was associated with protein expression of GAPDH, MDH and FBP.
In contrast, the amount of soluble or insoluble Aβ 42 did not correlate with any of the
observed changes in protein expression. Further, MMSE scores were significantly
associated with MDH such that higher MMSE scores (better cognition) was linked to
lower MDH, which is consistent with overall lower levels of MDH in nondemented
nonagenarians. Despite the small sample size used for these correlation analyses, the
general trends appear to be promising.
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6.4.6 Protein interacteome
Fig 6.4 shows the protein interacteome of proteomics-identified proteins
differentially expressed in the brains of cognitively intact and demented nonagenarians.
The Interaction Explorer PathwayAssist (Stratagene) software shows that the proteins
identified in this study are related to regulation of signal transduction, energy
metabolism, and chaperone activity among others. As a result, the present findings
suggest that in brains of non-demented nonagenarians, cognitive functions and memory
are preserved in part via pathways associated with these functions.
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Figure 6.1
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Figure 6.1 Shows protein carbonyl levels. There was no significant difference in the
levels of protein carbonyls measured in both the old nonagenarians with AD compared to
their age-matched normal nonagenarians.
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Figure 6.2
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Figure 6.2 Shows lipid peroxidation levels as measured by 4-hydroxynonenal
(HNE), isoprostanes (IP) and neuroprostanes (NP). There were no significant differences
in the levels of all lipid peroxidation biomarkers in the old nonagenarians with AD
compared to their age-matched normal old nonagenarians.
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Figure 6.3
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Figure 6.3 Shows SYPRO Ruby-stained 2D-gels maps of brain samples from normal old
(A) nonagenarians vs. old nonagenarians with AD (B). Proteins identified by mass
spectrometry showing differential expression are presented as the boxed spots.
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Figure 6.4

Figure 6.4 Schematic diagram of a functional interacteome of all proteins identified to be
differentially expressed in the brains of cognitively intact nonagenarians compared to
their demented age-matched controls. This diagram was generated by the interaction
explorer ™ Pathway Module (Stratagene), indicating that all the proteins are directly or
indirectly associated with cellular process shown.

210

6.5 Discussion
Some centenarians and nonagenarians escape or delay the onset of age-related
disorders such as stroke, diabetes, cancer and AD (Perls et al., 2002a). The mechanism
for the delay or escape of cognitive impairments in this group of individuals is still not
well understood. Genetic predisposition seems to play a significant role in the
mechanisms of dementia-free longevity, but the identification of a single gene
responsible for this is still far from being archived (Gonos, 2000; Perls et al., 2000; Perls,
2001). As a result, the mechanism for cognitive preservation in the oldest-old is thought
to follow multiple routes (Perls, 2004a; Galvin and Ginsberg, 2005). To better understand
the mechanisms through which the oldest-old remain cognitively intact and maintain
functional reserve, we analyzed the levels of oxidative damage by measuring the levels of
protein carbonyls and protein-bound 4-hydroxynonenal (HNE), F2-IsoP and F4-NPs, all
being biomarkers of oxidative stress. We also carried out a proteomic study to investigate
differentially expressed proteins in the brains of age-matched non-demented and
demented nonagenarians. There were no significant changes in the levels of protein
oxidation as measured by the levels of protein carbonyls. In addition, there also were no
significant changes observed in the levels of lipid peroxidation as measured by the levels
of HNE, F2-IsoP and F4-NPs between these two groups. These results are consistent with
a previous study that showed no changes in the levels of malondialdehyde (MDA) in
nonagenarians (Rea et al., 2004). We speculate that elevated oxidative stress in brains of
subjects with cognitive normality is the same as that from subjects with elevated
oxidative stress in AD brains (Butterfield and Lauderback, 2002). However, using
proteomics, we were able to identify four proteins whose expressions were significantly
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decreased in the non-demented nonagenarians compared to nonagenarians with AD; these
included: PRDX5, MDH, ATP synthase, and GAPDH. We also identified two proteins
UCHL1 and FBP1 whose expressions were significantly increased in the cognitively
intact nonagenarians compared to frontal cortex in age-matched AD individuals. The
proteins identified were related to the antioxidant system, proteosome function and
energy metabolism. The consequences of their differential expressions are discussed here
with relevance to successful aging.
Peroxiredoxins (Prdxs) are a family of peroxidases that act as antioxidants by
reducing hydrogen peroxide (H2O2), and alkyl hydroperoxides (Kim et al., 2000a). This is
achieved with the use of reducing equivalents derived from thiol-containing donor
molecules, such as thioredoxin. Prdxs have been identified in a variety of organisms
ranging from prokaryotes to mammals (Chae et al., 1994), and to date, six distinct groups
of mammalian prdxs (I–VI) have been identified. Prdxs I, II and VI are localized
predominantly to the cytosol, while Prdxs III and V are largely detected in the organelles
(Kang et al., 1998; Seo et al., 2000). Prdx2 expression has been shown to be significantly
increased in AD, ALS, Down’s syndrome and Parkinson’s disease (PD) most probably as
a compensatory mechanism (Kim et al., 2001; Allen et al., 2003; Krapfenbauer et al.,
2003). Our laboratory has previously shown that prdx2 is significantly oxidized in the
brain of the gracile axonal dystrophy (gad) mouse and is implicated as a possible
mechanism of oxidative stress-induced neurodegeneration (Castegna et al., 2004). In the
brain of senescence-accelerated mice prone 8 (SAMP8) mice, we have shown that
following administration of antisense oligonucleotide directed at the Aβ region of
amyloid precursor protein (APP), there is a significant decrease in the protein carbonyl
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levels of prxd2, which could elevate antioxidant levels, thereby contributing to the
observed improvements in learning and memory in the mice (Poon et al., 2005d). From
the present study, we have observed a significant decrease in the expression levels of
prdx5 in the brains of non-demented nonagenarians compared to the aged-matched
demented nonagenarians. This results continues to support our previous study that
showed an increase in expression in AD patients as a possible compensatory mechanism
(Krapfenbauer et al., 2003), this in effect would provide protection against apoptosis by
blocking of TNF-induced AP-1 activation (Shau et al., 1998) and in essence lead to
improved cellular and biological functions contributing to maintenance of cognitive
function observed in the normal nonagenarians.
Malate dehydrogenase (MDH) is a mitochondrial metabolic enzyme involved in
the malate-aspartate shuttle that links glycolysis to the mitochondria electron transport
chain (ETC), by transferring NADH to the electron transport complex 1, resulting into
increased ATP synthesis (Poon et al., 2005a). The activity of MDH has previously been
shown to be decreased during aging, probably through oxidative modification
(Hrachovina and Mourek, 1990). Our laboratory has previously shown that MDH
expression is significantly increased in the olfactory bulb of old mice possibly to
compensate for reduced activity of ATP synthase seen in this model (Poon et al., 2006a).
We have also shown that there is reduced nitration of MDH in the hippocampus of aged
rats on caloric restriction (Poon et al., 2006b). In the present study, we observed a
significant decrease in the levels of MDH in the brains of successfully aged
nonagenarians. This decrease in expression conceivably would mean that normal
nonagenarians compared to their demented controls have sufficient levels of MDH
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resulting in an increased supply of NADH to the ETC leading to more production of
ATP, maintaining energy metabolism, improved neuronal function and maintenance of
cognitive function and reserve in these successfully aged individuals. This is consistent
with our additional observations that higher MMSE scores were associated with lower
MDH and similarly, higher amounts of Aβ 40 are linked to lower MDH protein
expression.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a glycolytic enzyme
located in the cytosol that catalyzes the conversion of glyceraldehyde-3-phosphate to 1,
3-phosphoglycerate, the first oxidation-reduction reaction in the glycolytic pathway. The
activity of GAPDH has been found to be reduced in AD (Mazzola and Sirover, 2001)
and its accumulation together with other glycolytic enzymes such as α-enolase and γenolase has been shown in AD brain (Schonberger et al., 2001), possibly as compensation
for altered energy metabolism seen in AD (Vanhanen and Soininen, 1998; Messier and
Gagnon, 2000; Scheltens and Korf, 2000). GAPDH has been identified as one of the
nitrated proteins in AD (Sultana et al., 2005b). GAPDH was also identified to be oxidized
by intracerebral injection of amyloid beta-peptide Aβ (1-42) into rat brain, likely
explaining the possible loss or reduced activity of the enzyme in AD (Boyd-Kimball et
al., 2005c). In the present study, we report GAPDH as one of the proteins whose
expression is significantly decreased in the brain of cognitively intact nonagenarians and
further, we observed a significant positive correlation between GAPDH and the amount
of soluble Aβ1-40 extracted from the brain. As a result, normal nonagenarians possibly
have enough levels and activity of GAPDH thus not necessitating increased expression
which would lead to increased ATP production consequently leading to improved
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function of ATP dependent cellular pathways related to maintenance of memory and
cognitive function for the demented nonagenarians.
ATP synthase F1 subunit (ATP5A1) is a component of the mitochondrial ATP
synthase complex. ATP synthase uses the electrochemical proton gradient established
across the mitochondria membrane for synthesis of ATP from ADP and inorganic
phosphate Pi (Leyva et al., 2003). Our laboratory has previously shown that ATP
synthase is significantly oxidized in the gracile axonal dystrophy (gad) mouse brain
(Castegna et al., 2004), a condition resulting from defective ubiquitin carboxyl hydrolase
(UCHL-1) enzyme and proteosomal dysfunction. ATP synthase deficiency has been
associated with an increase in oxidative stress, as observed in PD (Basso et al., 2004). In
the aging human brains, the protein levels of ATP5A1 have been shown to be downregulated (Lu et al., 2004) and its expression has been shown to be decreased in the
olfactory bulb of the aging mice (Poon et al., 2006a). In the present study, we identified
ATP5A1 as one of the proteins whose expression was significantly decreased in the
brains of non-demented nonagenarians. We believe that this decrease in protein
expression of ATP5A1 just like the rest of the proteins discussed above shows that due to
successful aging cognitively intact nonagenarians don’t require compensation for ATP
synthesis like the aged-matched demented nonagenarians thus, the decrease in the
expression of the above proteins in the cognitively intact nonagenarians compared to the
age-matched demented nonagenarians should not seem unusual. The presence of Aβ in
AD potentially necessitates for a compensatory mechanism to counter the effects of Aβ
induced oxidative stress and possible cognitive decline. On the other hand, in the normal
nonagenarians though there could be Aβ, its levels might not be sufficient to warrant for
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this compensation mechanism hence the observed decrease in their expression during
successful aging.
In the present study, we also identified UCHL1 and FBP1 as two proteins that
were significantly increased in the brains of cognitively intact nonagenarians compared to
aged-matched AD. UCH L-1 is an enzyme involved in the process of proteolytic
degradation of misfolded or damaged proteins by the enzymatic complex, the proteosome
(Kornitzer and Ciechanover, 2000). Proteolytic degradation is usually signaled by the
covalent conjugation of ubiquitin to damaged proteins and is catalyzed by specific
ubiquitin-transferring enzymes (Hershko and Ciechanover, 1998). As aging occurs, there
is accumulation of misfolded, damaged or oxidized proteins and hence there is a need for
their degradation since their accumulation could contribute to the increase in the number
of oxidized proteins observed in AD among other deleterious effects (Keller et al., 2000;
Castegna et al., 2004). UCHL1 has previously been shown to be oxidatively modified in
AD (Castegna et al., 2002b), and point mutations in its gene cause familial PD (Leroy et
al., 1998; Zhang et al., 2000). In addition, mutations in a gene encoding UCHL1 in the
gracile axonal dystrophy (gad) mutant mouse results in brain axonal degeneration, severe
motor neuronal impairment and Aβ deposition in the brain (Saigoh et al., 1999; Kurihara
et al., 2001). The increased expression of UCHL-1 in successful aging observed here may
reflect the observation that proteosomal activity is elevated in normal controls compared
to AD brains (Keller et al., 2000; Castegna et al., 2004), and we speculate that though
there could be possibly less oligomeric Aβ (1-42) in the normal nonagenarians relative to
AD brain where copious amounts of oligomeric Aβ (1-42) occur (Butterfield and
Lauderback, 2002), there could still be a relatively large amount of oxidized or damaged
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proteins in the normal non-demented nonagenarians brain thereby necessitating for more
expression of UCHL1 thus contributing to successful aging.
Fructose bisphosphate aldolase C (FBP) on the other hand is a glycolytic enzyme
that catalyses the reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate
into dihydroxyacetone-phosphate and glyceraldehyde 3-phosphate (Perham, 1990). The
role of FBP in aging and age-related disorders is still not well established, though we
speculate that an increased expression would result into possibly increased activity and an
increase in energy metabolism. FBP protein expression may be at least partially linked to
the extent of Aβ as we observed a significant correlation between higher levels of
insoluble Aβ 40 and lower FBP. The identification of these differentially expressed
proteins in the brains of cognitively intact nonagenarians seems unusual. However, with
advanced age and the presence of neurodegenerative disorders such as AD, there is a
decrease in energy metabolism and accumulation of damaged proteins as previously
mentioned (Vanhanen and Soininen, 1998; Messier and Gagnon, 2000) and as a
compensatory response, we expect to observe a global increase expressions of proteins
related to these functions. However, as observed in the present study this is not
necessarily the case adding to the complexities in the mechanisms involved in successful
aging.
In an extreme case from the Nuns study in which despite genetic predisposition
to AD and presence of AD pathology in the neocortex, this part of the brain remained
perfectly preserved, suggesting that her neocortex was resistant to Alzheimer-related
neurodegeneration (Snowdon et al., 1997; Snowdon, 2003). In addition, a study on
neuropathology on cognitively normal older adults has shown that brains of many
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nondemented elderly individuals contain variable numbers of senile plaques. This has
been known as pathologic aging, referring to a form of senile cerebral amyloid not
associated with clinical manifestations of AD (Crystal et al., 1988; Dickson et al., 1992;
Crystal et al., 1993). Therefore, the presence of neurofibrillary tangles NFT and senile
plaques and other AD-related pathology and the lack of a correlation between dementia
and neuropathology in the brain of non-demented centenarians and nonagenarians, could
possibly suggest impairment in the proteosome functions in the brain. Hence, we expect
an increase in the expression of proteins related to proteosomal function such as UCHL1.
Thus, despite an increase in damaged proteins as observed in the pathology, cognition is
still maintained. In addition, it has been established that the role of AD pathology on
cognition is a discontinuous process and until a certain threshold is reached, this
pathology has no significant effect on cognition (Knopman et al., 2003) thus, this
findings could not be so unusual. Most recently, it has been established that UCHL1 is
required for normal synaptic and cognitive function (Gong et al., 2006). As a result, the
increased expression of UCHL-1 in successful aging observed here may reflect that one,
the proteosomal activity is elevated in normal controls compared to AD brains (Keller et
al., 2000; Castegna et al., 2004), and two that synaptic function is well maintained
leading to improvements and maintenance of cognitive function. On the other hand, the
increase in expression of FBP might have a significant but subtle effect in the increment
of energy levels, especially since we have also seen a significant decrease in the
expression of more proteins related to energy metabolism in the present study.
This study therefore, has provided us with possible additional mechanisms and
insights on how the oldest-old are able to remain cognitive intact. It has previously been
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established that there is a significant increase in the levels of oxidative stress associated
with advanced age; we have also shown that key proteins undergo significant oxidative
modification leading to a loss in function in most neurodegenerative disorders(Butterfield
and Castegna, 2003a; Boyd-Kimball et al., 2005c; Poon et al., 2005d; Butterfield et al.,
2006d; Poon et al., 2006b; Poon et al., 2006a; Sultana et al., 2006a). In the present study
there was no significant difference observed in the levels of oxidative stress biomarkers,
protein carbonyl, HNE, F2-IsoP and F4-NPs in the brains of age-matched cognitively
intact and demented nonagenarians. This finding was consistent with a previous study
that showed no significant increase in the levels of MDA, another measure of lipid
peroxidation in cognitively intact nonagenarians compared to septo/octogenarians (Rea et
al., 2004). As a result, we can conclude that oxidative stress did not play a significant role
in the maintenance of cognitive function in the non-demented nonagenarians. In addition,
it has been reported that there is altered energy metabolism in AD (Vanhanen and
Soininen, 1998; Messier and Gagnon, 2000; Scheltens and Korf, 2000). The reduction in
the levels of ATP could potentially lead to dysfunction in electrochemical gradients, ion
pumps, and ion channels among others. This would eventually lead to loss in synaptic
plasticity, neuronal dysfunction and loss in long-term potentiation and eventual loss in
memory and cognition (Michaelis, 1997; Boyd-Kimball et al., 2005c). In the present
study, we have shown that there is a significant increase in the expression of proteins
related to energy metabolism and antioxidant system in the demented nonagenarians
compared to the age-matched normal nonagenarians and we believe that one mechanism
for the maintenance of neuronal function hence cognitive and memory function is
through, but not exclusively, maintenance of ATP levels. Also using correlation analyses,
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we have shown that there is a general trend of association between protein expression
levels and intact cognition. In particular, MMSE scores were significantly associated with
MDH, i.e., higher MMSE scores (better cognition) was linked to lower MDH, which is
consistent with overall lower levels of MDH in nondemented nonagenarians. On
analyzing our current results using the Interaction Explorer Software PathwayAssist
(Stratagene), as shown in (Fig 6.4), the proteins identified in this study are related to
regulation of signal transduction, energy metabolism, and chaperone activity among other
cellular process relevant to the maintenance or improvement of cognitive function. Since
we have previously seen that there is altered ATP production in the aging brain, the
increased expression of energy metabolism related proteins can improve ATP production
leading to neuronal recovery and improved cognitive function as seen in the cognitive
intact nonagenarians and centenarians. Therefore, in addition to genetic, environmental
and other factors in playing a role in achieving dementia-free aging, we believe that by
maintaining sufficient ATP levels through efficient energy metabolism and improving
antioxidant reserves, one is capable of maintaining synaptic plasticity, neuronal function
through long-term potentiation and eventually improving memory and cognitive function
(Michaelis, 1997). Thus, centenarians/nonagenarians have the potential to represent a
model of resistance to age-related diseases and successful aging.
A possible caveat in this study could be the number of subjects used. We had four
non-demented and five aged-matched demented nonagenarians; this may be a small data
set to provide global interpretations. Also the short post mortem intervals (PMI) used in
obtaining tissues and the low standard deviations obtained within each group provide
additional confidence that the number of subject used is sufficient enough to provide a
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model to study and understand events taking place in disease-free aging. In our previous
proteomics studies, the use of five subjects per group was acceptable for statistical
analysis, considering also that in most proteomic studies, the use of sophisticated
statistical analysis like those used for micro array studies are not applicable. Therefore,
we have confidence in the observations we have made and we believe that our present
findings are able to provide a good representation of events and mechanisms taking place
in successful aging.
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Figure 6.5 Summary of the functional consequence for the differential expression of
proteins in the cognitively intact nonagenarians.
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CHAPTER SEVEN
Proteomic Identification of Oxidized Mitochondrial-related Proteins Following
Experimental Traumatic Brain Injury (TBI)
7.1 Overview
Experimental traumatic brain injury (TBI) has been know to result into a
significant loss of cortical tissue at the site of injury and in the ensuing hours and days a
secondary injury exacerbates this primary injury resulting into a massive loss of tissue
leading into significant neurological dysfunction. The mechanism of the secondary injury
is not well understood, but is thought to be mediated by the mitochondria. This
mitochondrial dysfunction is believed to involve excitatory amino acids, disruption of
Ca2+ homeostasis, production of reactive oxygen species (ROS), ATP depletion, oxidative
damage of mitochondrial proteins and an overall breakdown of mitochondrial energetics
and eventual cell death. The identity of proteins that undergo oxidative modification after
TBI has not been known. As a result, in the present study we utilized a 3h post-injury
controlled cortical impact (CCI) model of TBI, coupled with proteomics to identify these
specific mitochondrial fraction proteins from the cortex and hippocampus that were
oxidatively modified after injury. We were able to identify from the Cortex; Pyruvate
dehydrogenase (lipoamide), Voltage dependent anion channel (VDAC), Fumarate
hydratase 1, ATP synthase H+ transporting and prohibitin. From the hippocampus we
identified; Cytochrome C Oxidase Va, Isovaleryl Coenzyme A Dehydrogenase, alpha
enolase and Glyceraldehyde-3-phosphate dehydrogenase as proteins that had undergone
oxidative modification following experimental TBI. In addition, we have also shown that
following TBI, there is a reduction in the consumption of oxygen. Also, the activities of
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complex I, complex IV, and pyruvate dehydrogenase (PDH), have been shown to be
decreased. The present findings show that following TBI, the proteins of the electron
transport chain and related ATP production mechanisms are highly oxidatively modified,
leading to a massive breakdown of mitochondrial energetics and eventual cell death. The
identification of these proteins provides new insights into the mechanisms that ensue
following TBI and also provide avenues of possible therapeutic interventions after TBI.
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7.2 Introduction
Traumatic brain injury (TBI) is a serious health care problem in the United States,
with more than 400,000 individuals hospitalized each year with an estimated annual cost
of greater than 25 billion dollars. (Tibbs et al., 1998; McNair, 1999). As a result, there is
an urgent need of therapeutic interventions to curb this growing epidemic. The discovery
and development of possible therapeutics will only be achieved the mechanism involving
the pathogenesis of TBI are completely or well understood.
Traumatic brain injury has been known to result in a rapid a significant loss
cortical tissue through necrosis. In the ensuing hours and days, a secondary injury
exacerbates this primary injury resulting in a significant neurological
dysfunction.(Sullivan et al., 1998b; Sullivan et al., 1999) The neuropathology of TBI is
believed to involve excitatory amino acids, a disruption in Ca2+ homeostasis, production
of reactive oxygen species (ROS), depletion of ATP and an overall breakdown in
mitochondria bioenergetics (Sullivan et al., 1998b; Scheff and Sullivan, 1999)
Mitochondria are known to serve a number of functions. Its principle role is that
is acts as the powerhouse of the cell, generating the much need ATP that is necessary for
normal physiological functions to occur.(Wallace, 1999; Szewczyk and Wojtczak, 2002).
Other than its role in energy metabolism, the mitochondria also play a role in cell survival
or cell death (apoptosis) process. The mitochondria act as Ca2+ sinks, maintaining Ca2+
homeostasis for normal cell functions. In the event of an excessive uptake of Ca2+and
eventual overload, the mitochondria has been shown to increase the production of
reactive oxygen species (ROS), that induces the opening of the mitochondrial
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permeability pore (mPTP), release of cytochrome C, inhibition of ATP production and
cell death.(Sullivan et al., 2005)
Reactive oxygen species (ROS) are always produced as byproducts of ATP
synthesis. It has been shown that following TBI there is an increase in the production of
(ROS). (Zhang et al., 2005) The generation of these ROS and eventual oxidative stress
has been reported in many animal models and human disorders to have effects in
inactivation of various enzymes. This is believed to occur through oxidative
modifications of DNA, RNA, Lipids, proteins, among others (Butterfield and
Lauderback, 2002). Mitochondrial enzymes in particular have been found to be targets of
oxidative stress in most neurodegenerative diseases(Gibson and Huang, 2004). A recent
study of brain ischemia showed that Pyruvate dehydrogenase (PDH) is inactivated by an
increase ROS (Martin et al., 2005), α-ketoglutarate dehydrogenase complex (KGDHC)
activity has also been shown to be inhibited under conditions of oxidative stress in AD
(Gibson et al., 1998). In TBI, complex I respiration has been shown to be dramatically
decreased, with a possible involvement of inhibition of PDH being evoked leading to
reduction in ATP production (Sullivan et al., 2005).
All these studies have shown the inhibition or inactivation of these enzymes, but
the mechanisms that ensue leading to inactivation are still speculative. Proteomics has
recently been used with a lot of success in identifying various proteins that have been
oxidatively modified hence inactivated in various neurodegenerative diseases and
disorders such as, ALS, AD, Parkinson’s, among others. (Castegna et al., 2002a;
Castegna et al., 2003; Boyd-Kimball et al., 2005b; Poon et al., 2005f). Gene expression
analysis studies in the rat hippocampus following TBI have shown that there is
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differential expression at both mRNA and protein levels of genes associated with energy
metabolism (Li et al., 2004). Using proteomics, we report for the first time the significant
oxidation of Pyruvate dehydrogenase (lipoamide), Voltage dependent anion channel
(VDAC), Fumarate hydratase 1,ATP synthase H+ transporting, Prohibitin, Cytochrome C
Oxidase Va, Isovaleryl Coenzyme A Dehydrogenase, alpha enolase and Glyceraldehyde3-phosphate dehydrogenase following experimental TBI. In addition, we also report the
decreased activity of PDH, complex I and IV. These findings are discussed here to
provide new insights into the mechanisms of TBI and also provide possible new targets
for therapeutic interventions.

227

7.3 Experimental Procedures
7.3.1 Animal and surgical procedures
All procedures using animals were approved by the University of Kentucky
Animal Use and Care Committee. Approximately 20 young adult (250–300 g), male
Sprague–Dawley rats (Harlan Laboratories, IN) were pooled giving n=5 with each animal
acting as its own control. All animals were housed in group cages on a 12-h light/dark
cycle with free access to water and food. Animals were subjected to a moderate unilateral
cortical contusion as previously described (Sullivan et al., 1999; Sullivan et al., 2000).
This cortical contusion results in severe behavioral deficits, significant loss of cortical
tissue, blood–brain barrier disruption and a loss of hippocampal neurons (Sullivan et al.,
2002), mimicking some of the events that take place in human closed-head injury.
Briefly, the subjects were anesthetized using isoflurane (2%) and placed in a stereotaxic
frame (Kopf Instruments, Tujunga, CA). The head was positioned in the horizontal plane
with the nose bar set at negative 5. Using sterile procedures, the skin was retracted and a
craniotomy made with a hand-held trephine lateral to the sagittal suture and centered
between Bregma and lambda. The skullcap was carefully removed without disrupting the
underlying dura. The exposed brain was injured using a pneumatically controlled
impacting device with a 5-mm beveled tip, which compressed the cortex at 3.5 m/s to a
depth of 1.5 mm (Baldwin and Scheff, 1996; Sullivan et al., 1999). After injury, Surgicel
(Johnson and Johnson, Arlington, TX) was laid on the dura and the skullcap replaced. A
thin coat of dental acrylic was then spread over the craniotomy site and allowed to dry
before the wound was stapled closed. After 3 h animals were then anesthetized and
samples harvested.
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7.3.2 Mitochondria isolation.
Isolation of total mitochondria was carried out as previously described (Sullivan
et al., 2003; Sullivan et al., 2004b; Sullivan et al., 2004a). At 3 h post injury, the injured
cortex and hippocampi from the ipsilateral and corresponding contralateral regions were
dissected using a cork punch (d=8 mm) that was centered over the impact area, the tissue
minced, and then homogenized separately in a glass dounce homogenizer containing
approximately five times the volume of isolation buffer with 1 mM EGTA (215 mM
mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, pH 7.2). The
homogenate was spun twice at 1300 × g for 3 min in an eppendorf microcentrifuge at
4◦C. The supernatant were then transferred to new tubes, topped off with isolation buffer
with EGTA and spun at 13,000 × g for 10 min. The resulting supernatant was discarded
and the pellet resuspended in 500 µL of isolation buffer with EGTA. The resulting pellet
was then resuspended in 0.5 ml of mitochondrial isolation buffer (215 mM mannitol, 75
mM sucrose, 0.1% bovine serum albumin, 1 mM EGTA, 20 mM HEPES, pH 7.2), and
the plasma membranes were ruptured by nitrogen decompression (Parr Cell Disruption
Bomb) at 1000 p.s.i. for 5 min (Brown et al., 2004). The homogenized tissue and an equal
volume of 30 % Percoll in isolation buffer was added (~4 ml). The resultant homogenate
was layered on a discontinuous Percoll gradient with the bottom layer containing 40 %
Percoll solution in isolation buffer, followed by a 24 % Percoll solution, and finally the
sample in a 15 % Percoll solution. The density gradients were spun in a Sorvall RC-5C
plus super speed refrigerated centrifuge (Asheville, NC) in a fixed angle SE-12 rotor at
30,400 x g for 10 minutes. Following centrifugation, band 3 (Sims, 1990) were
separately removed from the density gradient. The samples were washed by
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centrifugation at 16,700 x g for 15 minutes. The supernatant was discarded and the loose
pellet was resuspended in the 1 ml of isolation buffer. The mitochondrial fractions were
then placed in separate 15 ml conical tubes and an equal volume of 30 % Percoll was
added to each sample and discontinuous Percoll density gradient centrifugation was
performed again as described above. Band 3 was obtained from the gradients and 10 ml
of isolation buffer without EGTA (215 mM mannitol, 75 mM sucrose, 0.1 % BSA, 20 mM
HEPES, pH is adjusted to 7.2 with KOH) was added. The fractions were centrifuged at
16,700 x g for 15 minutes and subsequently at 11,000 x g for 10 minutes. The resultant
pellet was resuspended in 1 ml of isolation buffer without EGTA and centrifuged at
10,000 x g for 10 minutes. The final mitochondrial pellet was resuspended in isolation
buffer without EGTA to yield a protein concentration of ~10mg/ml and stored on ice for
respiration assays or resuspended in lysis buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM
KCl, 1.1 mM KH2PO4, 0.6 mM MgSO4 and 0.5 mg/mL leupeptin, 0.7 µg/mL pepstatin,
0.5 µg/mL trypsin inhibitor, and 40 µg/mL PMSF) for subsequent assays. Protein
concentration was assayed using the Pierce BCA method.
7.3.3 Mitochondria respiration assay
Mitochondrial oxygen consumption was measured by using a Clark-type
electrode in a continuously stirred, thermostated sealed chamber (Oxytherm System;
Hansatech Instruments Ltd.) at 37°C as previously described (Brown et al., 2004; Jin et
al., 2004; Sullivan et al., 2004b). Isolated mitochondrial protein (~30 µg) was suspended
in respiration buffer (215 mM mannitol, 75 mM sucrose, 20 mM HEPES, 2 mM MgCl2,
2.5 mM inorganic phosphate, 0.1% BSA, pH 7.2) in a final volume of 0.25 ml. The
respiratory control ratio (RCR) was calculated as the ratio of oxygen consumption in the
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presence of 10 mM pyruvate and 5 mM malate or 10 mM succinate in the presence of
ADP (state III) and in the absence of ADP (State IV).
7.3.4 Measurement of protein carbonyls
Protein carbonyls are an index of protein oxidation and were determined as
described previously (Butterfield and Stadtman, 1997). Briefly, the mitochondrial
samples n=5 (5 µg of protein) were derivatized with 10 mM 2, 4-dinitrophenylhydrazine
(DNPH) in the presence of 5 µL of 12% sodium dodecyl sulfate for 20 min at room
temperature (23°C). The samples were then neutralized with 7.5 µL of the neutralization
solution (2 M Tris in 30% glycerol). Derivatized protein samples were then blotted onto a
nitrocellulose membrane with a slot-blot apparatus (250 ng per lane). The membrane was
then washed with wash buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween
20) and blocked by incubation in the presence of 5% bovine serum albumin, followed by
incubation with rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary
antibody for 1 h. The membranes were washed with wash buffer and further incubated
with alkaline phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody
for 1 h. Blots were developed using Sigma-fast tablet (BCIP/NBT; Sigma-Aldrich) and
quantified using Scion Image (PC version of Macintosh-compatible NIH Image)
software.
7.3.5 Measurement of 3-nitrotyrosine (3-NT)
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003).
The nitrotyrosine content was determined immunochemically as previously described
(Drake et al., 2003b). Briefly, samples were incubated with Laemmli sample buffer in a
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1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) for
20 min. Protein (250 ng) was then blotted onto the nitrocellulose paper using the slot-blot
apparatus and immunochemical methods as described above for protein carbonyls. The
mouse anti-nitrotyrosine antibody (5: 1000 dilutions) was used as the primary antibody
and alkaline phosphatase-conjugated anti-mouse secondary antibody was used for
detection. Blots were then scanned using scion imaging and densitometric analysis of
bands in images of the blots was used to calculate levels of 3-NT.
7.3.6 Measurement of 4-hydoxynonenal (HNE)
HNE is a marker of lipid oxidation and the assay was performed as previously
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v)
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus
containing a nitrocellulose membrane under vacuum pressure. The membrane was
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in
PBST for 90 min. Following completion of the primary antibody incubation, the
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The
membrane was washed in PBST three times and developed using Sigmafast Tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and
quantitated with Scion Image.
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7.3.7 Two-dimensional electrophoresis
Mitochondrial proteins (200 µg) were incubated with 4 volumes of 2N HCL at
room for electrophoresis or 20mM DNPH for western blotting at room temperature for 20
min. Proteins were concentrated through precipitation by the addition of ice-cold 100%
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v)
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h.
7.3.7.1 First dimension electrophoresis
For the first-dimension electrophoresis, 200 µl of sample solution was applied to a
110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were then
actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The isoelectric
focusing was performed in increasing voltages as follows; 300 V for 1 h, then linear
gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 °C until
the 2nd dimension electrophoresis was to be preformed.
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7.3.7.2 Second dimension electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%), 13.3 x 8.7 cm (W x L) (Bio-Rad) were used to
perform second dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA)
were run along with the sample at 200 V for 65 min.
7.3.8 SYPRO ruby staining
After the second dimension electrophoresis, the gels were incubated in fixing
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was
then removed and gels stored in DI water.
7.3.9 Western Blotting
Mitochondrial proteins (200 µg) incubated with 20mM DNPH were used for
western blotting. The strips and gels were run as described (Sections 7.3.7.1 and 7.3.7.2)
above. After the second dimension, the proteins from the gels were transferred onto
nitrocellulose papers (Bio-Rad) using the Transblot-Blot® SD semi-Dry Transfer Cell
(Bio-Rad), at 15 V for 4 h. The 2,4-dinitrophenyl hydrazone (DNP) adduct of the
carbonyls of the proteins was detected on the nitrocellulose paper using a primary rabbit
antibody (Chemicon, CA) specific for DNP-protein adducts (1:100), and then a
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secondary goat anti-rabbit IgG (Sigma, MO) antibody was applied. The resulting stain
was developed by application of Sigma-Fast (BCIP/NBT) tablets.
7.3.10 Image analysis
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using
Scanjet 3300C (Hewlett Packard, CA). SYPRO ruby-stained gel images were obtained
using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular Dynamics,
Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad) imaging
software was then used to normalize the gels and blots using the total spot density option,
match and analyze visualized protein spots among differential 2D gels and 2D oxyblots,
with one blot and one gel for each individual sample. The spot intensity of the gel
corresponded to the protein levels, while the spot intensity if the blot corresponded to the
carbonyl levels.
7.3.11 In-gel trypsin digestion
Samples were digested by trypsin using protocols previously described and
modified by (Thongboonkerd et al., 2002). Briefly, spots of interest were excised using a
clean blade and placed in Eppendorf tubes, which were then washed with 0.1 M
ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was
then added to the gel pieces and incubated at room temperature for 15 min. This solvent
mixture was then removed and gel pieces dried. The protein spots were then incubated
with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution
was removed and replaced with 20 µl of 55 mM iodoacetamide in 0.1 M NH4HCO3. The
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solution was then incubated at room temperature for 30 min. The iodoacetamide was
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in
50 mM NH4HCO3 with the minimal volume enough to cover the gel pieces. The gel
pieces were incubated overnight at 37 °C in a shaking incubator.
7.3.12 Mass spectrometry
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen,
Germany) and prepared according to AnchorChip recommendations (AnchorChip
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol:
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.
The TFA droplet was gently blown off the sample spot with compressed air. The
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100
laser shots. External calibration of the mass axis was used for acquisition and internal
calibration using either trypsin autolysis ions or matrix clusters and was applied post
acquisition for accurate mass determination.
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7.3.13 Analysis of peptide sequences
Peptide mass fingerprinting was used to identify proteins from tryptic peptide
fragments by utilizing the MASCOT search engine based on the entire NCBI and
SwissProt protein databases. Database searches were conducted allowing for up to one
missed trypsin cleavage and using the assumption that the peptides were monoisotopic,
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was
the window of error allowed for matching the peptide mass values. Probability-based
MOWSE scores were estimated by comparison of search results against estimated
random match population and were reported as -10*log10 (p), where p is the probability
that the identification of the protein is a random event. MOWSE scores greater than 63
were considered to be significant (P < 0.05). All protein identifications were in the
expected size and isoelectric point (pI) range based on the position in the gel.
7.3.14 Immunoprecipitation
Immunoprecipitation of specific proteins was performed as previously described
(Sultana and Butterfield, 2004). Mitochondria samples (200 µg) from control or injured
animals were incubated overnight at 4 oC with respective antibodies of identified
proteins. The antibody–antigen complexes were collected with protein A/G–Sepharoseconjugated beads. This was followed by three washing steps with buffer B (50Mm Tris
Hcl (pH-8.0), 150 Mm NaCl, and 1% NP40). The proteins were resolved by SDS-PAGE
followed by immunoblotting on a nitrocellulose membrane (BioRad). The proteins were
then detected with alkaline phosphate labeled secondary antibody (Sigma).

237

7.3.15 Statistical analysis
Statistical analysis of specific protein carbonyl levels matched with anti-DNPpositive spots on 2D-oxyblots from mitochondria from the ipsilateral cortex (IC) and
hippocampus (IH) with contralateral cortex (CC) and hippocampus (CH), was carried out
using Student's t-tests. That is, each animal served as its own control, the contralateral
side being the control for the ipsilateral side. A value of p < 0.05 was considered
statistically significant. Only proteins that are considered significantly different by
Student's t-test were subjected to in-gel trypsin digestion and subsequent proteomic
analysis. This is the normal procedure for proteomics studies, sophisticated statistical
analysis used for micro array studies are not applicable for proteomics studies.(Maurer et
al., 2005)

7.3.16 Protein Interacteome
The functional protein interacteome was obtained by using Interaction Explorer
TM

Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist

is software for functional interaction analysis. It allows for the identification and
visualization of pathways, gene regulation networks and protein interaction maps
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of
data. This data set is then searched against ResNet, a database containing over 500,000
biological interactions built by applying the MedScan text-mining algorithms to all
PubMed abstracts. These interactions are then visualized by building interaction networks
with shortest-path algorithms. This process can graphically identify all known interaction
among the proteins. The information of the function of these proteins and their relevance
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to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002).

7.3.17 Complex I assay:
Complex I activity was measured in isolated mitochondria as the rotenonesensitive decrease in NADH absorption at 340 nm with ubiquinone-1 as the final
acceptor, as previously described (Sriram et al., 1998) with some slight modifications
(Sullivan et al., 2004b). Briefly, mitochondria were freeze-thawed and sonicated three
times and diluted 1 µg/µl in 10 mM KPO4 buffer. The assay was performed in 25 mM
KPO4 buffer (pH 7.2) containing mitochondrial protein (6 µg), 5 mM MgCl2, 1 mM
KCN, 1 mg/ml BSA, and 150 µM NADH. The reaction was preincubated for 2 minutes
at 30°C, the baseline established, and the reaction initiated by addition of coenzyme Q-1
(50 µM). The activity was measured by monitoring NADH fluorescence (340 nm
excitation, > 450 nm emission) over time under the same conditions as described above.
The assay was also performed in the presence of rotenone (10 µM) to determine the
rotenone-insensitive activity and the rotenone-sensitive complex I enzyme activity
calculated by subtracting the rotenone-insensitive activity from the total activity. All the
assay protocol for a 96-well plate performed with BioTek Synergy HT plate reader
(Winooski, VT, USA).
7.3.18 Pyruvate Dehydrogenase complex (PDHC) assay:
PDHC activity was measured with previously protocol previously described
(Starkov et al., 2004) with slight modification using increment in fluorescence
measurement of NADH with BioTek Synergy HT plate reader (Winooski, VT, USA).
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Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg of
double ficoll gradient purified mitochondrial protein were added into the buffer
containing final concentration of 50mM KCl, 10mM HEPES pH 7.4, 0.3mM thiamine
pyrophosphate (TPP), 10µM CaCl2, 0.2mM MgCl2, 5mM pyruvate, 1 µM rotenone and
0.2mM NAD+. Reaction started by addition of 0.14mM CoASH and assay was performed
at Exλ 340 nm/ Emλ 460nm and increase in fluorescence was observed at 1 min interval at
300C. The PDHC activity calculated and expressed as nmol/mg protein.

7.3.19 Complex IV assay:
Cytochrome C Oxidase (Complex IV) of mitochondrial electron transport chain
component activity was as previously described (Wharton and Tzagoloff, 1967) with
slight modification using

BioTek Synergy HT plate reader (Winooski, VT, USA).

Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg of
double ficoll gradient purified mitochondrial protein were added into the 10mM KPO4
buffer pH 8.0, 50µM reduced cytochrome c and the decrease in absorbance was observed
with difference with and without addition of Cytochrome C at 1 min interval at 370C at
550nm. First the rate constant k was calculated for oxidation reaction of ferricytochrome
c calculated and the specific activity were expressed as (k/mg protein) for cytochrome c
oxidase.
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7.4 Results
7.4.1 Reduction in mitochondrial bioenergetics following TBI.
Mitochondrial bioenergetics was measured following TBI. As illustrated in Figure
7.1, mitochondria isolated 3h post injury from the ipsilateral cortex of TBI animals show
a reduction in the rate of respiration in the presence of ADP (state III) or FCCP (state V)
compared to mitochondria isolated from contralateral cortex or sham-operated animals.
Mitochondria from TBI animals demonstrated a significant reduction in state III
respiration and a significant loss in the electron transport chain (ETC) capacity, as
measured by the rate of respiration in the presence of the uncoupler FCCP (state V; in
excess) when driven by the complex-I substrates pyruvate/malate or the complex-II
substrate succinate (Figure 7.1B). As demonstrated in Figure 7.1 C, there was also a
significant decline in the respiratory control ratio (RCR) in the mitochondria isolated
from the ipsilateral cortex compared to those from the contralateral and sham operated
animals. No difference in respiration rates were observed between contralateral
mitochondria or mitochondria isolated from sham-operated animals (Figure 7.1B). It is
also apparent that the loss bioenergetics was not due to a disruption in the inner
membrane since states II and IV (absence of ADP) are not significantly altered,
indicating that a loss of ADP phosphorylation and ETS activity was the underlying cause.
7.4.2 Increase in oxidative stress levels from mitochondria isolated after TBI
To determine if the cause of this loss of ETS activity and bioenergetics could be
related to oxidative damage to the mitochondrial proteins, the level of protein carbonyls,
3NT and HNE as indicators of oxidative stress were measured in mitochondrial proteins
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isolated from the cortex and hippocampus of TBI animals. Fig.7.2 shows that, following
TBI, there is a significant increase in the levels of 3NT, HNE and protein carbonyls
measured from mitochondria isolated from the ipsilateral hippocampus (IH) compared to
the contralateral (CH) hippocampus. Fig.7.3 shows that the levels of 3NT, HNE and
protein carbonyl from the cortical IC vs. CC were increased, but these changes were not
significant. Together, these results extend previous findings of an increase protein and
lipid oxidation following TBI (Braughler and Hall, 1992; Sullivan et al., 1998a; Sullivan
et al., 1999; Sullivan et al., 2000; Lifshitz et al., 2004b).
7.4.3 Mass spectrometry analysis of mitochondrial proteins from the hippocampus
and cortex.
Mass spectrometry analysis and data base searches allowed for the identification
of these protein spots from the cortex (Table 7.1) and hippocampus (Table 7.2). From the
cortex, the following mitochondrial proteins were identified as being oxidatively
modified in TBI: pyruvate dehydrogenase, voltage dependent anion channel-2 (VDAC2), fumarate hydratase 1, ATP synthase H+ transporting F1 alpha subunit, all of which are
proteins involved in ATP production, transport or the activity of the ETS, and prohibitin.
From the hippocampus, cytochrome C oxidase Va, Isovaleryl coenzyme A
dehydrogenase, enolase-1 and glyceraldehyde-3-phosphate dehydrogenase were
identified as being oxidatively modified in TBI. As can be seen in tables 7.1 and 7.2, the
probability of a random identification is exceedingly low.
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7.4.4 Redox proteomics identification of mitochondrial proteins from the
hippocampus and cortex following TBI
Proteomics has previously been used to identify brain proteins that have
undergone oxidative modifications in different human diseases and models thereof
(Butterfield et al., 2003; Butterfield and Castegna, 2003a; Butterfield, 2004; Butterfield
and Boyd-Kimball, 2004b). Here, we used a similar approach, with slight modifications,
to identify oxidized mitochondrial proteins following TBI. Protein oxidation levels in the
mitochondria isolated from the cortex and hippocampus were measured by identifying
carbonylated proteins using anti-DNPH immunochemical detection of 2D-oxyblots from
the cortex (Fig 7.4) and hippocampus (Fig 7.5). Using PD-Quest (Bio-Rad) imaging
software, protein spots were matched between 2D-PAGE maps and the 2D-oxyblots. The
immunoreactivity of each spot was normalized using total spot density option to the
protein content in the 2D-PAGE. Only protein spots that showed a significant increase in
protein carbonylation in the ipsilateral side compared to the contralateral side were
excised from the gels and subjected to in-gel trypsin digestion. Tables 7.3 and 7.4 provide
a summary of the levels of oxidation for individual proteins.
7.4.5 Validation of identified protein spots
Prior experience from our laboratory has demonstrated validation of each
proteomic-identified protein by immunochemical means with no exceptions. In this
study, VDAC-2 was probed with anti-VDAC antibody. Figure 7.6 shows validation of
VDAC-2 through western blot analysis Figure 7.6 (b) and immunoprecipitation Figure
7.6(c). Thus, we are confident that the protein identifications reported are correct.
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7.4.6 Decreased Complex I, Complex IV and PDH activities following TBI
The activities of complex I, complex IV and pyruvate dehydrogenase (PDH) were
measured following 3 h post TBI. As shown in Figure 7.7 (a) and 7.7 (b), there is a
significant decline in the activities of complex I and complex IV respectively, from the
mitochondria isolated from ipsilateral cortex compared to those isolated from
contralateral cortex. Figure 7.7 (c) on the other hand, illustrates the enzymatic activity of
PDH. As shown, there was a decline in the activities of PDH following TBI from
mitochondria isolated from the ipsilateral cortex compared to mitochondria isolated from
the contralateral cortex; however this decline in activity was not significant. These results
confirm our previous findings showing that the loss in mitochondrial bioenergetics
observed is most likely due to a decline in the activities of the ETC complexes.
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Figure 7.1

Figure 7.1 Traumatic brain injury (TBI) significantly impairs mitochondrial
bioenergetics. As illustrated in panel A, TBI results in a loss of mitochondrial function
demonstrated by reduction in oxygen consumption. Animals were injured (1.5 mm) and
mitochondria isolated 3 hrs post-injury from the ipsilateral or contralateral cortex as well
as sham-operated animals. Respiration rates were quantified and expressed as nmols
O2/min/mg consumed under various experimental conditions (panel B). TBI significantly
reduced mitochondrial oxygen consumption in the presence of ADP (state III), indicating
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a reduction in the ability to phosphorylate ADP. Significant differences were also
apparent when the mitochondrial electron transport system (ETS) was uncoupled (excess
FCCP) from the ATP synthase, a measure of maximum ETS capacity. This loss in ETS
capacity was demonstrated when the ETS was driven via NADH-linked, complex-I
substrates (pyruvate/malate; P/M) or the FADH-linked, complex-II, substrate (succinate;
Succ). Panel C demonstrate the reduction in RCR ratio in mitochondria isolated from the
ispi lateral relative to those isolated from sham and contralateral. Bars are group means,
SEM. *p < 0.05 using a Neuman-Keuls post hoc.
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Figure 7.2

Figure 7.2 Protein carbonyls, 3NT and HNE levels of hippocampal mitochondria. There
was a significant increase in the levels of all parameters measured from the contralateral
and ipsilateral regions (CH vs. IH) of rats that had undergone TBI. Data are represented
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as % control; error bars indicate the SEM for animals in each group. Measured values are
normalized to the CC values (n=5) * p <0.05.
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Figure 7.3

Figure 7.3 Protein carbonyls, 3NT and HNE levels of cortical mitochondria. There was
an increase in the levels of all parameters measured from the contralateral and ipsilateral
regions (CC vs. IC) of rats that had undergone TBI, but these levels were not significant.
Data are represented as % control; error bars indicate the SEM for animals in each group.
Measured values are normalized to the CC values.
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Figure 7.4
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Figure 7.4 2D-oxyblots of cortical mitochondrial samples CC vs. IC. Proteins identified
by mass spectrometry are presented as the boxed spots.
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Figure 7.5
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Figure 7.5 2D-oxyblots of hippocampal mitochondrial samples CH vs. IH. Proteins
identified by mass spectrometry are presented as the boxed spots
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Figure 7.6

(a)
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(c)

Figure 7.6 Validation of protein identified by MS. (a) Cortex mitochondria gel showing
position of VDAC (b) blots probed with anti VDAC antibody (c) shows gel of cortex
mitochondria immunoprecipitated with anti-VDAC antibody.
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Figure 7.7

*

(a)

(b)

(c)
Figure 7.7 Shows the activity of Complex I (a), Complex IV (b) and Pyruvate
dehydrogenase (PDH) (c) as a percentage of sham. There was a significant
decline in the activities of Complex IV following TBI in the IC compared to
the CC. There was also a reduction in the activities of complex I and the
activity of PDH though not significant.
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7.5 Discussion
The present study demonstrates that following TBI, critical mitochondrial fraction
proteins from the cortex and hippocampus involved in energy metabolism are susceptible
to oxidative damage, and hence inactivation. We demonstrate that these proteins are
significantly and rapidly oxidized, presenting a possible mechanism for the decreased
mitochondrial bioenergetics as seen particularly in the cortical mitochondria following
TBI. Following TBI, there is an increase in the production of ROS (Braughler and Hall,
1992; Sullivan et al., 1998a; Sullivan et al., 1999; Sullivan et al., 2000; Lewen et al.,
2001; Lifshitz et al., 2004b), which has been established to contribute to
neuropathological events observed following TBI and other brain injury models (Sullivan
et al., 1998b; Sullivan et al., 2002; Fiskum et al., 2003; Martin et al., 2005; Sullivan et al.,
2005). In addition to increase in ROS, there is reduced mitochondrial bioenergetics
following experimental TBI. This loss in the capacity of the ETC to consume oxygen has
been shown to be an etiology observed in most CNS injuries (Lifshitz et al., 2004b;
Sullivan et al., 2005). The present study extends these findings to show elevated
oxidative stress levels following TBI and is the first to report the identification of specific
mitochondrial-related proteins that are significantly oxidized following TBI and
following this modification there is decreased activity of key enzymes and ETC
complexes. The implications for the identification of these proteins are discussed below.
Pyruvate dehydrogenase (PDH) is a mitochondrial multienzyme complex composed of
pyruvate dehydrogenase (E1), a dihydrolipoamide S-acetyltransferase (E2) and
dihydrolipoamide dehydrogenase (E3). It catalyses the irreversible conversion of
pyruvate, NAD+ and CoA to acetyl CoA, NADH and CO2 making it the central link
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between glycolysis and TCA cycle (Zaidan et al., 1998; Martin et al., 2005). The activity
of PDH is usually regulated through events of continuous phosphorylation (inactivation)
and dephosphorylation (activation) by the enzymes pyruvate dehydrogenase kinases and
phosphatases respectively (Holness and Sugden, 2003). Inactivation of PDH or its
deficiency has been reported in several studies of models of ischemia-reperfusion and
human diseases (De Meirleir et al., 1993; Zaidan et al., 1998; Hard et al., 2001). Leading
to metabolic failure, secondary lactic acidosis (Hard et al., 2001), increase in ROS
production (oxidative stress) leading to cellular damage and death (Bogaert et al., 2000).
Following canine cardiac arrest and resuscitation, it has been reported that there is a
selective loss of PDH activity in different neuronal subclasses (Bogaert et al., 2000),
short-term forebrain ischemia in rats, causes a partial inactivation of PDH activity
(Zaidan et al., 1998) and low levels of PDH have been associated with various
neurodegenerative disorders such as Alzheimer’s disease (Sheu et al., 1985),
Huntington’s disease (Sorbi et al., 1983), Wernicke-korsakoffsyndrome (Lavoie and
Butterworth, 1995) and other hereditary ataxias (Sheu et al., 1989).
One mechanism for inactivation of PDH has been hypothesized to be the
oxidative modification of the enzyme, involving possible site-specific protein oxidation
of critical sulfhydryl groups (Tabatabaie et al., 1996). Or possibly due to metal-catalyzed
oxidation of susceptible amino acids (Bogaert et al., 1994). The activity of PDH in
different models of TBI has been extensively studied. In a recent micro array study of
gene expression in the hippocampus following experimental TBI, PDH E1 α-subunit
gene was found to be down regulated after moderate injury but unregulated in severe
injury (Li et al., 2004). A study of rat hippocampus after chronic antidepressant
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treatment, showed that PDH EI complex had undergone modulation (Khawaja et al.,
2004). While in another proteomic study of an animal model for schizophrenia, protein
levels of PDH complex E2 were found to be decreased (Paulson et al., 2003; Paulson et
al., 2004). These studies provide evidence that different subunits of the PDH complex are
susceptible to modulation during conditions of oxidative stress, and as had been
established, inactivation of one subunit of the complex renders the whole enzyme
complex inactive (Zaidan et al., 1998).
In the present proteomic study we found PDH lipoamide beta complex to be
significantly oxidized following TBI. In addition, we have also shown that following
experimental TBI the activity of PDH is also decreased though not significantly. As a
consequence of these events, the activity of complex I was also found to be decreased,
this would therefore disrupt the supply of NADH, a required substrate for complex I,
contributing to the NADH-linked impairment of mitochondrial bioenergetics as seen in
Fig. 7.1.
Voltage dependent anion channel-2 (VDAC) are pore-forming proteins (porins)
found in the outer mitochondrial membrane of all eukayotes (Yoo et al., 2001). VDAC in
conjunction with adenine nucleotide translocator (ANT), mediate the exchange of
adenine nucleotides between the cytosol and the matrix (Vander Heiden et al., 2000).
VDAC has also been known to form part of a mega pore known as the mitochondrial
permeability transition pore mPTP, which mediates the release of cytochrome c from the
mitochondria to the cytosol in early events of apoptosis leading to activation of the
caspase cascade (Sullivan et al., 2002). VDAC has also been found to interact with Bcl-2
family of proteins regulating mitochondrial potential and release of cytochrome c
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(Vander Heiden et al., 2001). Pro-apoptotic proteins Bax and Bid have been shown to
accelerate the opening of the pore while anti-apoptotic protein BcL-2 binds directly to
VDAC hence closing it (Yoo et al., 2001).
Impairment in ATP-ADP exchange by the closure of VDAC inhibits the activity
of F1F0-ATPase. This leads to the inhibition of proton H+ re-entry, hyperpolarization of
the inner mitochondrial membrane, which promotes osmotic matrix swelling, rupturing
the outer membrane releasing cytochrome c and activation of the caspase cascade. In a
recent report (Liberatori et al., 2004), VDAC proteins were found to be involved in the
loss of mitochondrial potential and neurodegeneration during ischemia reperfusion. In
patients with AD and Downs syndrome, the expression of VDAC proteins has been found
to be significantly reduced (Yoo et al., 2001). Other than its role in being part of mega
pore mPTP, the activity of VDAC in brain injury models has not been extensively
studied, the only reports provided confirm the presence of VDAC as part of the that is
involved in release of cytochrome c.
In the present study, we show for the first time that VDAC-2 is significantly
oxidized following TBI. The oxidation of VDAC posses a number of possible
consequences. The conformational changes of the porin after oxidation could leave the
channel in an open state; this could lead to entry of solutes into the mitochondria leading
to swelling and eventual rupture of the outer mitochondrial membrane and release of
cytochrome c. The conformational change might also leave VDAC in a closed state,
preventing the exchange of ATP-ADP leading to hyperpolarization and activation of
caspase cascade and eventual cell death. As a result oxidation of VDAC after TBI can be
one of the causes for injury induced cell death following TBI.
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ATP synthase (Complex V) is a multicatalytic subunit enzyme made up of two
portions, the F0, an integral membrane complex responsible for translocation of protons
and the larger extra membrane complex, FI, which is composed of five subunits (α3β3γδε)
(Kanski et al., 2005). ATP synthase uses the electrochemical proton gradient established
across the mitochondria membrane during respiration for the synthesis of ATP from ADP
and inorganic phosphate Pi (Leyva et al., 2003). The mechanism of ATP synthesis
involves sequences of coordinated conformational changes of the α and β subunits.
Human diseases associated with a deficiency in ATP synthase show that there is
no complete loss but a partial loss of the ATP synthase enzyme activity. This deficiency
results from mutations in MTATP6, a mitochondrial encoded component (De Meirleir et
al., 2004). ATP synthase deficiency has been associated with and increase in oxidative
stress as seen in Parkinson’ disease (Basso et al., 2004). Our laboratory has shown that
ATP synthase is significantly oxidized in gracile axonal dystrophy (gad) mouse
(Castegna et al., 2004). ATP synthase has also been found to be a target for cysteine
oxidation of proteins during renal oxidative stress (Eaton et al., 2003). A study of rat
cardiac proteins, recently identified ATP synthase as one of the proteins significantly
nitrated as a function of age (Kanski et al., 2005). In a proteomic study after an
inflammatory challenge, ATP synthase was again identified as one of the proteins that’s
was significantly nitrated (Aulak et al., 2001). A proteomic study of Muscles of A
Diabetes Model Otsuka Long-Evans Tokushima Fatty (OLETF) rat (Oh-Ishi et al., 2003)
found ATP synthase to be significantly oxidized. These studies have shown that ATP
synthase is susceptible to oxidation and hence inactivation under conditions of oxidative
stress.
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In the present study, we identified ATP synthase as one of the mitochondrial
proteins that were significantly oxidized following TBI. The oxidation of this subunit will
as a result inhibit the activity of this enzyme compromising a crucial cellular process of
ATP generation after brain injury eventually leading to neuronal cell death.
Cytochrome C Oxidase Va (COX) is also known as Complex IV. This is the
terminal enzyme complex of the electron transport chain (ETC). It transfers reducing
equivalents from cytochrome c to oxygen that is then reduced to water (Harris et al.,
2001). COX is composed of 13 subunits. Three subunits form the catalytic core of the
enzyme and are encoded by the mtDNA, while the rest are nuclear encoded and are
involved in the assembly and regulation of the enzyme (Mootha et al., 2003). Human
COX deficiency results into a condition known as Leigh syndrome, French-Canadian
type (LSFC). It is characterized by a subacute neurodegeneration of the brainstem and
basal ganglia and recurrent episodes of acute and often fatal metabolic acidosis and coma
(Mootha et al., 2003).
The activity of COX has been shown to be reduced in drosophila, as an effect of
oxidative stress and age (Schwarze et al., 1998). A recent review found a possible role for
COX in stress induced apoptosis and degenerative diseases (Kadenbach et al., 2004). In
Alzheimer’s disease, various studies have shown an impairment of cytochrome c oxidase
activity and depletion of ATP (Kim et al., 2000c). The activity of COX in various models
of brain injury has also been extensively established. In one study, it was shown that
following TBI there is a reduction of gene expression and activity of COX (Harris et al.,
2001). Earlier fluid percussion injury studies of concussive brain injury in rats, found that
after concussion, the cerebral cortex ipsilateral to the site of injury showed a decrease in
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the activity of COX, this began as soon as one day and lasting for up to 10 days after the
injury. The ipsilateral dorsal hippocampus also showed a decrease in COX activity, but
not as severe as in the cortex (Hovda et al., 1991). COX activity in injured animals 24 h
following an ablation of rat sensorimotor cortex was found to be significantly reduced
throughout the cerebral cortex and particularly at the hemisphere ipsilateral to the
ablation (Sutton et al., 2000). The above studies among others have provided evidence for
the reduction in activity of COX after brain injury. These studies have though come short
at presenting mechanisms that ensue in the inactivation of this enzyme. In the present
study, we identify a subunit of COX as one of the proteins that was significantly oxidized
following TBI, and as was discussed, oxidation of a single subunit could render the whole
enzyme inactive. COX is the terminal complex of the ETC and as we have seen, it is a
key site in the regulation of energy metabolism. Its oxidation would therefore lead to a
reduction in the membrane potential; a compromise in ATP production and the
generation of more ROS. This could in part be of the possible mechanisms of
neurodegeneration observed after TBI.
Prohibitin is an evolutionarily conserved protein with homologues from yeast to
man. Its exact physiological function has been difficult to define. Despite this, it has been
demonstrated that prohibitin is involved in many cellular processes, such as cell cycle
regulation, senescence, transcription regulation and tumor suppression (Coates et al.,
2001). Recently, it has been established that PHB is located in the inner mitochondria
membrane and that it acts as a chaperone in the assembly of subunits of mitochondrial
respiratory chain complexes and stabilization of membrane proteins (Nijtmans et al.,
2000; Nijtmans et al., 2002). Impaired assembly of ATP synthase is associated with
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neurological muscle weakness, ataxia and retinitis pigmentosa (NARP) syndrome, a
possible role of disruption of PHB (Nijtmans et al., 2001). A disruption on the PHB genes
has been shown to have a decreased replicative lifespan in yeast, due to a gradual decline
in cellular metabolic capacity (Coates et al., 1997) and a larval arrest in fruit fly (Eveleth
and Marsh, 1986). In higher organism therefore, disruption of PHB could possibly have
greater metabolic effect. It should be noted however that its involvement in TBI is still
speculative.
It has recently been demonstrated that prohibitin can be induced by metabolic
stress (Liu et al., 2004), its expression is increased in apoptotic cells and that it might
play a role in regulation of the mitochondrial respiratory activity (Liu et al., 2004). These
roles suggest that PHB is a critical mitochondrial protein required to maintain normal
mitochondrial homeostasis. In the present study, we identified prohibitin as one of the
proteins that were significantly oxidized following TBI. Oxidation of prohibitin may
disrupt its functions of the assembly of ETC, leading to a breakdown in energy
metabolism.
Isovaleryl Coenzyme A dehydrogenase (IVD). This is a nucleus-encoded,
homotetrameric mitochondrial flavoprotein, which is found in the third step of the leucine
catabolism pathway. It is a member of the acyl-CoA dehydrogenase (ACD) family of
enzymes, all of which employ a similar enzyme mechanism for the α, β-dehydrogenation
of acyl-CoA substrates (Mohsen et al., 2001). IVD catalyzes the conversion isovalerylCoA to 3-methylcrotonyl-CoA and transfers electrons to the electron-transferring
flavoprotein (ETF). A specific ETF dehydrogenase then shifts the electrons to coenzyme
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Q in the electron-transport chain for ATP synthesis (Mohsen et al., 1998; Volchenboum
and Vockley, 2000).
A common disorder associated with a deficiency of this enzyme is Isovaleric
academia (Mohsen et al., 1998). Isovaleric acidemia is a rare inborn error of metabolism
caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD). The activity of IVD has
been extensively studied in both humans and plant physiology (Daschner et al., 1999;
Daschner et al., 2001) but no study has reported its role in TBI or any other brain injury
models.
IVD was one of the mitochondrial proteins that were found to be significantly
oxidized following TBI. We report here for the first time its involvement in brain injury.
It is possible that following TBI there is a reduced amount of ATP being generated from
the ETC, leading to the dependence on other pathways for the supply of substrates for
energy production. Here we see the possible involvement of the leucine catabolism
pathway, which also gets inhibited due to the oxidation of IVD a key enzyme in this
pathway. The oxidation of IVD following brain injury could as a result lead to a critical
compromise of the total bioenergetics homeostasis and eventual cell death following TBI.
Fumarate hydratase (FH) also known as fumarase is an enzyme of the
Tricarboxylic Acid Cycle (TCA), which catalyzes the conversion of Fumarate to Lmalate. FH is also found in the glyoxylate and urea cycles (Pollard et al., 2003). The
intracellular localization of this enzyme is not limited to the mitochondria, it can also be
found in the cytosol as was found in rat liver, its function here is still unknown (Tuboi et
al., 1990). A deficiency of this enzyme or mutations in the genes encoding this enzyme
have been known to be the cause of Multiple cutaneous and uterine leiomyomata
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MCUL1 (uterine fibroids), skin leiomyoma, and papillary type II renal cell cancer
(Tomlinson et al., 2002). Recent proteomic study on mitochondrial proteins in
cardiomyocytes from chronic stressed rat, showed a decrease in expression of Fumarate
hydratase-1 after chronic restrain stress and a decrease in energy metabolism (Liu et al.,
2004).
In the present study, we found Fumarate hydratase-1 as one of the key
mitochondrial proteins that were significantly oxidized after TBI. The resulting
consequence of this would be a breakdown of the TCA cycle and its inability to supply
necessary substrates required for energy metabolism leading into an overall breakdown of
bioenergetics and eventual cell death as observed in TBI.
Enolase-1 and Glyceraldehyde-3-phosphate dehydrogenase GAPDH
Enolase and GAPDH are glycolytic enzymes known to be located in the cytosol.
Enolase interconverts 2-phosphoglycerate and phosphoenolpyruvate while GAPDH
catalyzes the NAD+ dependent oxidation of glyceraldehyde-3-phosphate to 1,3bisphosphoglycerate and NADH in the second phase of glucose catabolism. GADPH has
been typically known for its role in glycolysis but recent studies are now supporting the
idea that it has diverse activities. Possible roles include regulation of the cytosol,
membrane fusion and transport, accumulation of glutamate into presynaptic vesicles a,
binding to low molecular weight G-protein and acting as a cellular sensor of oxidative
stress. It is also thought that GADPH forms an integral part of apoptosis and may
participate in neuronal death in some age related neurodegenerative diseases (Chuang et
al., 2004). These emerging roles of GADPH raise questions on its cellular localization.
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Enolase and GADPH are not typical mitochondrial proteins, but evidence has it
that some glycolytic proteins can be localized in the mitochondria (Liaud et al., 2000;
Taylor et al., 2003). A well-known glycolytic enzyme found in the mitochondria is
hexokinase. Hexokinase has been found to be associated with the outer mitochondrial
membrane where its activity has been implicated in regulation of ATP synthesis. It has
also been found to promote closure of VDAC and prevent apoptosis (Azoulay-Zohar et
al., 2004). In a recent proteomic study of the human heart mitochondrial proteome,
(Taylor et al., 2003) 4% of total proteins identified were found to be associated with
glycolysis. In another study (Liaud et al., 2000), GADPH and TPI were shown to be
imported to the mitochondria of diatom Phaeodactylum tricornutum as a GADPH-TPI
fusion. Another plant mitochondrial proteomic study GADPH and enolase were among
the glycolytic proteins identified from the mitochondria, this study was even able to show
that these protein were attached to the outer membrane of the mitochondria (Giege et al.,
2003).
Taken together, the above studies continue to provide increasing evidence for the
mitochondrial localization of glycolytic proteins. The purpose for this localization is not
well known, but studies speculate that the whole glycolytic pathway could be associated
with the OMM or IMS. This could be possible because most glycolytic enzymes have
hydrophobic regions that could form membrane-spanning domains (Giege et al., 2003).
This localization would be to provide pyruvate directly and at high concentrations where
it can be taken up as substrate for respiration and ATP generation. When levels of ATP
are reduced the mitochondria might initiate the interaction of glycolysis and the OMM to
compensate for the reduction in energy production.

268

There is increasing evidence that GADPH and enolase –dependent pathways are
being associated with different pathologies that involve oxidative stress. Our lab has
previously identified α-enolase, as one of the enzymes one that was significantly oxidized
in AD (Castegna et al., 2002a) and SAMP8 mice (Poon et al., 2004d). Our lab has also
identified GAPDH as one of the proteins found to be significantly oxidized by Aβ(1–
42)(Boyd-Kimball et al., 2005b). In recent proteomics study of Staphylococcus aureus
(Weber et al., 2004), it was shown that oxidative stress triggers thiol oxidation of
GADPH consistent with previous reports of the oxidation of glycolytic enzymes .
Recently enolase was also found to be oxidatively modified in rat skeletal muscle
(Kanski et al., 2005), this same study also identified GADPH as a target for protein
nitration another example of protein oxidation.
In the present study we identified two glycolytic proteins enolase and GADPH
from a mitochondrial preparation, as “mitochondrial” proteins that had been significantly
oxidized following TBI. Oxidation of these proteins will most probably inactivate these
enzymes hence inhibiting their glycolytic functions, reducing the amount of pyruvate
supplied to the TCA leading to a reduction in ATP production and eventual cell death.
Following TBI, alterations in excitatory amino acids, increased ROS and
disruption of Ca2+ homeostasis have been found to contribute to the cellular damage and
eventual neurological dysfunction. The sequel of events that ensue following TBI have
though not been well understood though the mechanism of this neurodegeneration is
believed to be mediated in part by the mitochondria via an oxidative stress pathway.
Mitochondrial bioenergetics plays a critical role in the normal physiology of cells. With a
loss in the respiration capacity of the ETC and production of ROS after TBI (Sullivan et
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al., 2005), it has been hypothesized that various mitochondrial proteins could be
oxidatively modified and inactivated (Bogaert et al., 2000; Fiskum et al., 2004; Martin et
al., 2005). This proteomics study is the first to provided new insights into the
mechanisms of oxidative cellular damage after TBI.
We have demonstrated that following TBI and isolation of total mitochondria,
key components of the ETC are oxidatively modified. Specifically, we have shown that
the activities of PDH, complex I, and complex IV are reduced following TBI. This
continues to support the notion that oxidative modification of proteins tends to lead to
their inactivation. Additionally, we also have identified other proteins associated with
energy metabolism that are significantly oxidized following TBI, which interact directly
or indirectly with cellular bioenergetics pathways. The Stratagene software to determine
the “interacteome” of the proteomics identified oxidatively modified proteins following
TBI was determined. The oxidation of these identified proteins are of significant
importance, due to their involvement with the ETS and/or apoptotic pathways, as well as
their roles in the maturation and assembly process of key mitochondrial proteins. The
identification of these oxidatively modified proteins present the first causal evidence for
the significant loss of mitochondrial function that has been demonstrated to occur after
TBI (Figure 7.1). They may also provide new insights into the mechanism of cellular
damage after TBI and also provide novel targets for potential therapeutic interventions in
this significant health problem. A summary of our working hypothesis involving
oxidative damage to mitochondrial-related proteins is provided in Fig 7.8 below.
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Figure 7.8 Summary of mechanisms that ensue following experimental TBI
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CHAPTER EIGHT
Conclusions and Future Studies
8.1 Conclusions
The work presented in this dissertation examined the mechanisms of improved
cognitive function following intervention with a diet rich in antioxidants and a program
of behavioral enrichment in a canine model of human aging. Additionally, the
mechanisms of successful aging were also investigated. Through a proteomic analysis,
we also examined the role of oxidative stress in traumatic brain injury specifically
looking at oxidatively modified mitochondrial proteins.
Investigation on the role of an antioxidant fortified diet and a program of behavioral
enrichment in the improvement of memory and cognitive function in the aging canine was
examined. It was demonstrated that there was a significant decrease in the levels of oxidative
stress as measured by protein carbonyls and 3NT in the parietal cortex of aged dogs that had a
combination of these interventions (EA) compared to the other paradigms used, i.e., CC, EC and
CA. Additionally, a proteomic analysis showed that there was a significant increase in the
expression of Cu/Zn superoxide dismutase, fructose-bisphosphate aldolase C, creatine kinase,
glutamate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase, proteins related to
energy metabolism, antioxidant system and detoxification mechanisms. Further redox proteomic
analysis identified glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, glutathione S-transferase
(GST) and fascin actin bundling protein, as proteins that were significantly less oxidized
following an examination of the EA and CC treated canine. An examination of the enzymatic
activity of some of these identified proteins determined that there was a significant increase in
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the activities of glutathione-S-transferase (GST) and total superoxide dismutase (SOD following
the EA treatment compared to control. A significant correlation was also obtained between the
levels of protein expression, oxidative damage, antioxidant activity and the improvement in
cognitive function. We conclude that the combination of an antioxidant fortified diet and a
program of behavioral enrichment in the aging canines may be translated to humans, providing a
possible intervention for those at risk for developing age-related neurodegenerative disorders,
including Alzheimer’s disease.
The possible mechanisms involved in successful aging were explored. Frontal
cortex samples from cognitively intact nonagenarian and those of demented
nonagenarians were examined. Analysis of the level of oxidative stress in these groups of
individual determined that there were no significant differences in protein oxidation as
measured by the levels of protein carbonyls and lipid peroxidation as indexed by the
levels of isoprostanes, neuroprostanes and HNE. However, proteomic analysis showed
that there was a significant increase in the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), ATP synthase H+ transporting, human peroxiredoxin 5
(PRDX5) and malate dehydrogenase (MDH) in the brains of demented nonagenarians
compared to the cognitively intact nonagenarians. On the other hand the protein levels of
fructose bisphosphate aldolase (FBP1) and ubiquitin carboxyl-terminal hydrolase L1
(UCHL1) were found to be increased in the cognitively intact nonagenarians compared to
the demented age matched control. The consequence of this is still unknown; however, a
recent study supports the role of UCHL-1 in normal synaptic and cognitive function. As a
result, the increased differential expression of these proteins and in particular UCHL-1
observed here may reflect the following, one, the proteosomal activity is elevated in
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normal controls compared to AD brains, and two that synaptic function is well
maintained leading to improvements and maintenance of cognitive function in the normal
nonagenarians. In addition, using correlation analyses, we have shown that there is a
general trend of association between protein expression levels and intact cognition. In
particular, MMSE scores were significantly associated with MDH, i.e., higher MMSE
scores (better cognition) was linked to lower MDH, which is consistent with overall
lower levels of MDH in nondemented nonagenarians. We conclude that this increase in
the expression of key proteins may play a key role in the mechanisms leading to
successful aging.
Lastly, the role of oxidative stress in experimental traumatic brain injury (TBI)
was examined. Analysis of the oxygen consumption capacity of these mitochondria
revealed that there was a significant decline in the respiratory capacity of brain
mitochondria isolated from the ipsilateral cortex (IP) compared to those isolated from the
contralateral cortex (CC) 3 h following experimental TBI. There were no differences in
the respiratory capacities between mitochondria isolated from sham-operated animals
compared to those from the CC animals. This investigation demonstrated that there was a
significant increase in the levels of oxidative stress in the brain mitochondria isolated
from the IP compared to those isolated from the contralateral cortex CC of rat after 3h
following controlled cortical impact injury. We further explored the identity of key
mitochondrial proteins that would have undergone possible oxidative modification
following TBI from the cortex and hippocampus. We identified Cytochrome C Oxidase
Va, Isovaleryl Coenzyme A Dehydrogenase, alpha enolase and Glyceraldehyde-3phosphate dehydrogenase from the hippocampus and Pyruvate dehydrogenase
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(lipoamide), Voltage dependent anion channel (VDAC), Fumarate hydratase 1, ATP
synthase H+ transporting and prohibitin from the cortex. Further examination of
enzymatic activities demonstrated that there was a decline in the activities of pyruvate
dehydrogenase and a significant decline in the activities of complex I and IV of the
electron transport chain. We conclude that oxidative stress plays a significant role in the
pathogenesis of TBI and it contributes to the oxidative modification of key
mitochondrial-related proteins leading to a loss in mitochondrial bioenergetics and
possible cell death.
Taken together, these studies continue to support the role of oxidative stress in
neurodegenerative disorders and that intervention with antioxidant contribute to the
maintenance of memory and cognitive function providing a possible avenue for the
development of therapeutic interventions for oxidative stress mediated disorders and in
particular to the aging population at risk for developing AD and those prone to CNS
injury.

8.2 Future Studies
Based on the findings in this dissertation, the following experiments may warrant further
exploration:
1.

Based on the findings of increased oxidative stress following TBI and also the
significant oxidative modification of key mitochondrial-related proteins, an
expressional proteomic analysis of brain proteins and/or plasma following TBI
would provide further insight into on the disorder and possible development of
potential biomarkers.
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2.

Also since oxidative stress plays a key role in TBI, intervention with possible
antioxidants or antioxidant related compounds such as brain soluble D609 and the
identity of mitochondrial proteins protected should be further examined.

3.

The findings of differentially expressed proteins in the cognitively intact
nonagenarians though promising were not complete due to the limited number of
subjects. With the increase in the number of subjects, this would provide further
insight into the biochemical mechanisms that lead to successful aging.

4.

Though there were no differences in the levels of oxidative stress between the
cognitively intact nonagenarians and the demented controls, a redox proteomics
analysis would be able to identify the redox status of key proteins hence providing
additional insight into the successful aging process.

5.

The availability of plasma extracted from the aging canines undergoing the
combined therapy of antioxidant diet and a behavioral enrichment program is a
unique resource that warrants further examination with a possibility of developing
potential biomarkers for age-related disorders AND in particular AD.

Copyright © Wycliffe Omondi Opii 2006
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Appendix A
Nucleoside Reverse Transcriptase Inhibitor (NRTI) - 2', 3’-dideoxycytidine (ddC)
Induce Oxidative Stress: Relevance to HIV Dementia

A1. Overview
Human immunodeficiency virus dementia (HIVD) is the most common
form of dementia occurring among young adults. In HIVD, neuronal cell loss occurs in
the absence of neuronal infection. With the advent of highly active anti-retroviral therapy
(HAART), the incidence of HIVD has drastically reduced, though prevalence of milder
forms of HIVD continues to rise. Though these agents have been used successfully in
suppressing viral production, they have also been associated with a number of side
effects. Here, we examine the possible role of NRTI’s, in particular 2', 3’dideoxycytidine (ddC), in the neuropathology of HIVD. Synaptosomes and isolated
mitochondria treated and incubated for 6 h with CSF-achievable concentrations of ddC,
i.e., 6-11ng/ml, were found to show a significant increase in oxidative stress with 40 nM
ddC as measured by protein carbonyls and 3-nitrotyrosine (3NT). Protection against
protein oxidation induced by ddC was observed when mitochondria isolated from gerbil
brain 1 h after injection i.p with the brain accessible antioxidant and glutathione mimetic
tricyclodecan-9-yl-xanthogenate (D609). In addition, there is a significant reduction in
the levels of anti-apoptotic protein Bcl-2 and a significant increase in cytochrome-c
release and also a significant increase in the expression of pro-apoptotic protein caspase-3
were observed after mitochondria were treated with 40 nM ddC. The results reported
show that ddC at 40 nM can induce oxidative stress, cause the release of cytochrome c,
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and in addition, reduce the levels of anti-apoptotic proteins leading to a induction of
apoptosis. These findings provide evidence for a possible role of the NRTI’s, and in
particular, ddC, in the mechanisms involved in HIVD.
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A2. Introduction
Infection of the brain with HIV often results in a dementing disorder known as HIVdementia (HIVD), the most common form of dementia occurring in human populations
of less than 60 years of age. This dementia is marked by loss in memory and impaired
cognitive function, among other indices of dementia (Navia and Price, 1987).
Pathologically, reactive astrocytosis, myelin pallor, infiltration by macrophages and
multinucleated giant cells, among others, characterize HIVD (Nath et al., 998). Since the
neuronal loss and dysfunction observed in HIVD occurs, though the virus rarely infects
neurons (Mattson et al., 2005), the mechanism of this neurodegeneration is still not
known. Several studies have implicated the involvement of HIV viral proteins such as
Tat, gp120 and gp 41, as well as neurotoxins that are produced from activated astrocytes
and microglia, in the pathways leading to neurodegeneration (Adamson et al., 1996;
Cheng et al., 1998; Nath et al., 2000; Pocernich et al., 2005).
In recent years, the use of highly active antiretroviral therapies (HAART) has
revolutionized the treatment of AIDS, with a suppression of viral load and consequent
reduction in complications observed in the late-stages of the disease (Gray et al., 2003).
HAART can suppress the replication of the virus in the long term, but this is often
accompanied by significant toxicities that can compromise treatment (Egger et al., 1997;
Brinkman and Kakuda, 2000). Among the toxicities reported with the NRTI’s include:
hepatic steatosis, lactic acidosis, encephalopathy, lipodystrophy, peripheral neuropathy,
and myopathy (Scalfaro et al., 1998; Blanche et al., 1999). Anti-retrovirals such as the
nucleoside reverse transcriptase inhibitors (NRTIs), which include, 2', 3’-dideoxycytidine
(ddC), are of great significance and are an important component of HAART (White,
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2001).The mechanisms of these toxicities has been found to involve inhibition of neurite
regeneration and inhibition of DNA polymerase gamma, leading to inhibition of
mitochondria DNA synthesis, resulting in oxidative stress and eventual mitochondrial
dysfunction (Cui et al., 1997). But recently, Mallon et al. (2005) have shown that NRTIs
could cause mitochondrial dysfunction through other mechanisms other than inhibition of
DNA polymerase gamma (Mallon et al., 2005).
With the advent of HAART, the incidence of HIVD has fallen, while the
cumulative prevalence of HIVD has risen (Neuenburg et al., 2002). Despite the decline of
HIVD incidence, neurological complications still remain an important cause of disability
and death associated with AIDS (Kandanearatchi et al., 2003; McArthur et al., 2003). The
rise in the prevalence of HIVD despite the use of HAART is consistent with the poor
penetration of some of these anti-retrovirals into the CNS, hence increasing the longevity
of the virus in the CNS (Deutsch et al., 2001). However, it has recently been reported that
these drugs can effectively cross into the CNS, therefore, raising the question of their
efficacy in the CNS and their possible role in HIVD (Enting et al., 1998; Sawchuk and
Yang, 1999; Gibbs et al., 2003a; Gibbs et al., 2003b). For example, one treatment study
showed variable results on the efficacy of NRTIs in the brain: one group of patients on
HAART and having HIVD remained stable from cognitive impairment, while the other
group showed signs of progressive neurological impairment even with treatment
(Kandanearatchi et al., 2003). This disparity could possibly be due to the increased
survival of the virus in the brain or could possibly be due to the NRTIs on their own
being neurotoxic as has recently been shown with the increase in damage to brain
mitochondria in HIV positive patients using NRTI’s (Schweinsburg et al., 2005). The
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latter may be of particular concern, since several experimental strategies are currently
being considered to increase the transport of NRTIs across the blood brain barrier.
Therefore, in the current study, we have investigated these NRTIs, and specifically
ddC, with the hypothesis that NRTIs could in themselves be neurotoxic and thus play a
role in the progression of HIVD through an oxidative stress mechanism, possibly
involving mitochondria. We report here that ddC, at concentrations achievable in the
CSF, induces oxidative stress when treated to synaptosomes and isolated mitochondria.
The levels of oxidative stress as measured by protein carbonyls on synaptosomes were
significantly reduced upon the use of a known brain accessible antioxidant and
glutathione mimetic [D609] (Zhou et al., 2001; Lauderback et al., 2003; Sultana et al.,
2004). In addition, we observed a significant reduction in the levels of the anti-apoptotic
protein Bcl-2, a significant release of cytochrome c and an equally significant increase in
caspase-3 protein levels upon treatment of mitochondria with ddC. These results provide
a possible mechanistic pathway for cell death through oxidative stress-induced apoptosis
and are consistent with the notion of the possible contribution of ddC to HIVD.
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A3. Experimental procedures
Material and Methods
Unless stated otherwise, all chemicals and antibodies were purchased from
Sigma-Aldrich (St. Loius, MO). The oxidized protein detection kit was purchased from
Intergen (Purchase, NY). The nucleoside reverse transcriptase inhibitor (NRTI), 2', 3’dideoxycytidine (ddC), was obtained from NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH (NSC 606170). Assays for protein oxidation,
lipid peroxidation, cytochrome c release and Bcl-2 levels were performed 6 h after NRTI
treatment with some modifications as previously described (Butterfield et al., 1999a;
Yatin et al., 1999; Butterfield and Lauderback, 2002).

Animals
The animal protocols were approved by the University of Kentucky Animal Care
and Use Committee. For all studies in this paper, male Mongolian gerbils 3 months of
age and approximately 100 g in weight were used. The rodents were housed in the
University of Kentucky Central Animal Facility under 12-h light/dark conditions and fed
standard Purina rodent laboratory chow.

Isolation of synaptosomes
Synaptosomes were isolated from three-month old male Mongolian gerbils as
previously described (Whittaker, 1993). Briefly, the gerbils (n=5) were sacrificed by
decapitation and the brain immediately isolated and dissected. The cortex was placed in
0.32 M sucrose isolation buffer containing 4 µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml
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aprotinin, 2 mM ethylene di-amine tetra-acetic acid (EDTA), 2 mM ethylene glycol-bistetraacetic acid (EGTA), 20 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES), 20 µg/ml trypsin inhibitor, and 0.2 mM phenylmethanesulfonyl fluoride
(PMSF), pH 7.4. The tissue was homogenized by 20 passes with a Wheaton tissue
homogenizer. The homogenate was centrifuged at 1500 g for 10 minutes. The
supernatant was retained and centrifuged at 20,000 g for 10 minutes. The resulting pellet
was resuspended in ~1 ml of 0.32 M sucrose isolation buffer and layered over
discontinuous sucrose gradients (0.85 M pH 8.0, 1.0 M pH 8.0, 1.18 M pH 8.5 sucrose
solutions each containing 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES) and spun at
82,500 g for 1 hr at 4oC. Synaptosomes were collected from the 1.0/1.18M sucrose
interfaces, and washed in Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2,
1.0 mM MgCl2, 3.6 mM NaHCO3, 5 mM glucose, 5 mM HEPES) twice for 10 minutes at
32,000 g. The resulting synaptosomal membranes were assayed for protein concentration
by the Pierce BCA method. The synaptosomal preparation was relatively free of nonsynaptic moieties (Whittaker, 1993).

Isolation of Mitochondria
Mitochondria were isolated from gerbil brain following i.p. injection with saline
(control) or with D609 (50 mg/ kg body wt), 1 h after injection as previously described
(Sultana et al., 2004). The brain mitochondria were isolated as previously described with
minor modifications (Sims, 1990). Briefly gerbils, (n=6) were decapitated and the whole
brain was isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250
mM sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 µg/ml leupeptin, 4
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µg/ml pepstatin, 5 µg/ml aprotinin 20 µg/ml trypsin inhibitor) with 6 passes of a Wheaton
tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation
buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was
washed in PBS at 6,900× g for 10 min at 4°C.
Incubation of synaptosomes and mitochondria with ddC
Stock solutions of ddC were diluted in phosphate buffered saline (PBS).
Synaptosomal and mitochondrial concentrations of 4mg/ml were then treated with the
ddC to a final concentration based on the CSF-achievable concentration range of 611ng/ml (Sawchuk and Yang, 1999). These samples were then incubated for 6 h at 37oC
with frequent vortexing. Controls were incubated with PBS. These samples were then
frozen for subsequent assays.

Oxidation of synaptosomes with Fe2+/H2O2
Protein oxidation was initiated by addition of hydroxyl radical generating mixture
(30 µM FeSO4/3 mM H2O2) as previously described (Pocernich et al., 2000). Briefly,
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synaptosomes (4 mg proteins/ml) were suspended in 0.987 ml of lysing buffer and treated
with 30 µM Fe2+ (FeSO4.7H2O) and 3 mM H2O2 (diluted from 30% H2O2), bringing the
total volume to 1 ml, for 30 min at room temperature. Fe2+ reacting with H2O2 produce
hydroxyl free radicals (Butterfield and Stadtman, 1997). The protein suspension was then
washed four times with lysing buffer at 14,000 rpm for 4 min. This sample was used as a
positive control for protein oxidation.

Measurement of protein carbonyls
Protein carbonyls are an index of protein oxidation and were determined as
described previously (Butterfield and Stadtman, 1997). Briefly, 5µl of sample were
derivatized with 10mM 2, 4-dinitrophenylhydrazine in the presence of 5µl of 12% SDS
for 20 min at room temperature. The samples were neutralized with 7.5 µL of the
neutralization solution (2 M Tris in 30% glycerol). Derivatized protein samples were
blotted onto nitrocellulose membrane with a slot-blot apparatus (250 ng/lane). The
membrane then was washed with wash buffer (10mM Tris-HCl (pH 7.5), 150mM NaCl,
0.05% Tween 20), blocked by incubation of 5% BSA, followed by incubation with rabbit
polyclonal anti-DNPH antibody as primary antibody for 1 h. The membranes were
washed with wash buffer and further incubated with alkaline phosphatase (ALP)conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots were
developed using Sigma fast tablets (BCIP/NBT) and were quantified using Scion Image
(PC version of Macintosh compatible NIH Image) software.

285

Measurement of lipid peroxidation
4-Hydroxynonenal (HNE) levels
HNE is a marker of lipid peroxidation, and this assay was performed as
previously described (Lauderback et al., 2001). Briefly, 10 µl of sample both from cell
culture or synaptosomes were incubated with 10 µl of Laemmli buffer containing 0.125
M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) Glycerol. The resulting sample (250
ng) was loaded per well in the slot blot apparatus. Samples were loaded onto a
nitrocellulose membrane under vacuum pressure. The membrane was blocked with 3%
(w/v) BSA in phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 (PBST) for 1 hr and incubated with a 1:5000 dilution of anti-4hydroxynonenal (HNE) polyclonal antibody in PBST for 90 min. Following completion
of the primary antibody incubation, the membranes were washed three times in PBST.
An anti-rabbit IgG alkaline phosphatase secondary antibody was diluted 1:8000 in PBST
and added to the membrane. The membrane was washed in PBST three times and
developed using Sigma fast Tablets (BCIP/NBT substrate). Blots were dried, scanned
with Adobe Photoshop, and quantified with Scion Image.

Measurement of cytochrome c release
Cytochrome c release was detected as previously described with slight
modifications (Yang et al., 1997). Briefly, after incubation and centrifugation of
mitochondrial samples, the supernatant was used for Western blot analysis for
cytochrome c release. The membrane was blocked in blocking buffer (3% bovine serum
albumin) in PBS/Tween for 2 h and incubated with a 1:2000 dilution of anti-cytochrome
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c polyclonal antibody (C-5723; anti-sheep; Sigma) in PBS/Tween for 2 h. The membrane
then was washed in PBS/Tween for 5 min three times after incubation. The membrane
was incubated for 1 h, after washing, with an anti-sheep IgG alkaline phosphatase
secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The membrane then was
washed three times in PBS/Tween for 5 min and developed in Sigma Fast tablets. Blots
were dried, scanned with Adobe PhotoShop, and quantified using Scion Image software.

Measurement of Bcl-2 levels
The levels of anti-apoptotic protein Bcl-2 were detected as previously described
(Yang et al., 1997) with slight modification as described above, except a 1:2000 dilution
of anti-Bcl-2 monoclonal antibody (AAM-072; anti- mouse; stressgen) in PBS/Tween for
2 h was used.

Statistical analysis
Student’s t-test was used to assess statistical significance; p values < 0.05 were
considered significant.
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A4 Results
Increased oxidative stress in synaptosomes following treatment with ddC
Synaptosomes are a good model for studying neuronal synaptic function at nerve
terminals and display markers of neurodegeneration upon treatment with various oxidants
such as amyloid β-peptide (Aβ) (Butterfield and Boyd-Kimball, 2005). Hence,
synaptosomes were used for the present study to determine if ddC caused oxidative
damage. Oxidative stress can lead to a variety of detrimental effects on neurons including
protein cross linking, decreased protein turnover, loss of protein function, altered redox
potential, disruption of Ca2+ homeostasis, and ultimately cell death (Butterfield and
Stadtman, 1997). As shown in Fig A1a, synaptosomes were exposed to a known hydroxyl
radical generating mixture (30 µM FeSO4/1 mM H2O2) as a positive control and a range
of ddC concentrations (29 nM- 52 nM). There was a significant increase in protein
carbonyls levels on synaptosomes treated with 40 nM ddC p < 0.05. These levels were
comparable to those of the synaptosomes treated with Fe2+/H2O2. Fig A1b shows levels
3-nitrotyrosine (3NT), another marker of protein oxidation, in ddC treated synaptosomes.
A significant increase in the levels of 3NT with 40nM ddC was observed; however, there
was no significant change in the levels of lipid peroxidation as indexed by HNE when
synaptosomes were treated with ddC in all the concentration ranges Fig A1c.
Increased oxidative stress in mitochondria following treatment with ddC
Fig A2 shows the levels of protein carbonyls and HNE in mitochondria treated
with ddC. Fig A2a shows a significant increase in the levels of protein oxidation as
indexed by protein carbonyls. These results were significant at 40 nM ddC, seen
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previously with synaptosomes. Fig A2b shows the levels of lipid peroxidation as indexed
by HNE was unaffected when mitochondria were treated with a varying range of
concentrations of ddC, consistent with the results with synaptosomes.
D609 protects mitochondria from oxidative stress mediated by ddC
The use of antioxidants has been shown to provide protection against oxidative
insult in a number of models of neurodegenerative disorders (DeAtley et al., 1999;
Calabrese et al., 2003a; Farr et al., 2003; Lauderback et al., 2003; Sultana et al.,
2005a).The levels of protein oxidation as indexed by protein carbonyls in mitochondria
isolated from brain of gerbils injected 1 h before sacrifice with saline or D609 are shown
in Fig. A3. These brain mitochondrial samples were subsequently treated with 40 nM
ddC, the concentration that showed the most effect. The levels of protein carbonyls were
significantly increased in mitochondria isolated from brain of saline-injected gerbils and
treated with ddC compared to control. Mitochondria isolated from brain of D609-injected
gerbils and subsequently treated with 40 nM ddC showed a significant decrease in the
levels of protein carbonyl levels compared to mitochondria isolated from brain of salineinjected gerbils and subsequently treated with 40 nM ddC.
Increased cytochrome c release from mitochondria following treatment with ddC
Mitochondria are the main source for the generation of reactive oxygen species
(ROS), which has been known to contribute to the release of cytochrome c and
subsequent induction of apoptosis (Sullivan et al., 1999). Fig. A4 shows the level of
cytochrome c released from mitochondria isolated from gerbil brain and treated with
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various CSF concentrations of ddC. There was a significant increase in the amount of
cytochrome c released by mitochondria treated with 40nM ddC compared to control.
Decreased levels of anti-apoptotic protein Bcl-2 following treatment with ddC
Bcl-2 is a human proto-oncogene that modulates cell death or apoptotic pathways
by regulating the release of pro-apoptotic molecules from the mitochondria. Fig A5
shows the level of Bcl-2 protein in mitochondria isolated from gerbil brain and treated
with various CSF concentrations of ddC. Though there was a decrease in the levels of
Bcl-2 with all concentrations of ddC used, there was a significant decrease in the levels of
Bcl-2 with 52nM ddC treatment compared to control.
Increased expression of pro-apoptotic protein caspase-3 after treatment with ddC
As an additional evidence of apoptotic events talking place after the treatment of
mitochondria with ddC, we measured the levels of caspase-3 protein levels as shown in
figure A6. There was an observable increase in the levels of caspase- 3 in all treatment
but there was a higher increase in the 40nm ddC treated mitochondria. It should be noted
that since this was just additional proof of apoptotic events taking place, and n = 4 was
used. The changes observed are about 40% of control with statistical significance p<
0.05.
No effect on protein carbonyl levels following treatment with 3TC
As additional evidence for the oxidative stress-induced toxicities of NRTI’s we
have shown that 3TC the most tolerable NRTI in HIV therapy did not induce oxidative
stress in synaptosomes treated using concentrations achievable in the CSF compared to
DDC Figure A7. As a result the oxidative stress-related effects we are observing in the
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present study are specific to only ddC and not any other NRTI. It should be noted that
n=4

291

Figure A1
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Figure A1 Protein oxidation and lipid peroxidation as indexed by protein carbonyls, 3NT
and HNE in ddC treated synaptosomes. There is an increase in the levels of protein
carbonyls (Fig A1a) and 3NT (Fig A1b) on synaptosomes treated with 40nM ddC. The
levels of protein carbonyls were comparable to those of synaptosomes treated with the
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positive control of the hydroxyl radical generating mixture of Fe2+/H2O2. Fig A1C shows
the levels of lipid peroxidation as indexed by HNE; there was no significant difference
among the treatments. Results here are given as the mean ± S.E.M. expressed as
percentage of control values. (*) p < 0.05 n=5.

293

Figure A2
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Figure A2 Protein oxidation and lipid peroxidation as indexed by protein carbonyls and
HNE respectively on ddC treatment of isolated mitochondria. There is an increase in the
levels of protein carbonyls (Fig A2a) on mitochondria treated with 40nM ddC. Fig A2b
shows the levels of lipid peroxidation as indexed by HNE; there was no significant
difference among the treatments. Results here are given as the mean ± S.E.M. expressed
as percentage of control values. (*) p < 0.05 n=6.
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Figure A3
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Figure A3. The levels of protein oxidation as indexed by protein carbonyl in
mitochondria isolated from brain of gerbils injected with saline or D609. The levels of
protein carbonyls were found to be significantly increased in mitochondria isolated from
brain of saline- injected gerbils and treated with ddC compared to control. Mitochondria
isolated from brain of D609-injected gerbils and treated with 52nM of ddC showed a
significant decrease in the levels of protein carbonyl levels as compared to mitochondria
isolated from brain of saline-injected gerbils brain and subsequently treated with 52nM
ddC. Results here are presented as the mean ± S.E.M. expressed as percentage of control
values. (*) p < 0.05 n=6. D609 concentration used was 50 µM, chosen based on prior
studies of this agent
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Figure A4
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Figure A4. The level of cytochrome-c release from mitochondria isolated from gerbil
brain and treated with different concentrations of ddC. There was a significant release in
cytochrome-c when 40 nM ddC was added to isolated mitochondria. Data here are
presented as the mean ± S.E.M. expressed as percentage of control values. (*) p < 0.05
n=4.
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Figure A5
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Figure A5. The protein levels of anti-apoptotic protein Bcl-2 in brain mitochondria
isolated from gerbil brain and treated with ddC. There was a reduction in the levels of
Bcl-2 in with all ddC concentrations used, but a significant reduction was observed with
52 nM ddC. Data here are presented as the mean ± S.E.M. expressed as percentage of
control values. (*) p < 0.05 n=4.
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Figure A6
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Figure A6 The protein levels of pro-apoptotic protein Caspase-3 in brain mitochondria
isolated f from gerbil brain and treated with ddC. There was an increase in the levels of
caspase 3 in with all ddC concentrations used, with 40 nM ddC showing the highest level.
Data here are presented as the expressed as percentage of control values. n =4 p< 0.05
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Figure A7
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Figure A7 Protein oxidation as indexed by protein carbonyls in ddC and 3TC treated
synaptosomes. There is an increase in the levels of protein carbonyls (Fig A7a) on
synaptosomes treated with 40nM ddC but no significant changes are observed in 3TC
treated synaptosomes (Fig A7b). Results here are given as the mean ± S.E.M. expressed
as percentage of control values. n = 4(*) p< 0.05
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A5 Discussion
The findings reported here show that ddC, at physiologically relevant
concentrations achievable in the CSF and especially at 40nM, is able to induce oxidative
stress in both synaptosomes and isolated mitochondria, as measured by the elevated
levels of protein oxidation. DDC also reduced the levels of the anti-apoptotic protein Bcl2, slightly increased the levels of Bax, induced the release of cytochrome c, and increased
caspase-3 protein levels. These results implicate oxidative stress and the mitochondria as
possible pathways involved in NRTI-induced neuronal death.
Infection of the brain with HIV often results in a decline of neuropsychological
performance, neurological impairments (McArthur et al., 1989; Karlsen et al., 1993,
1995; Baldewicz et al., 2004), and a dementing disorder known as HIV-dementia
(HIVD). HIVD is the most common form of dementia in young adults, and it is estimated
that 30% of adults infected with HIV usually develop HIVD (Janssen et al., 1992; Nath
and Geiger, 1998). The mechanism of this neurodegeneration remains unknown, since
HIV rarely infects neurons (Nath and Geiger, 1998). Recent studies have proposed
various mechanisms for HIVD, for example, HIV over-activates immune cells within the
brain to produce cytokines or chemokines, which can inhibit the growth and survival of
brain cells or trigger cell death and low levels of transforming growth factor β 1(TGF β
1) may enhance brain cell damage in people with HIV infection (Ensoli et al., 1999;
Letendre et al., 1999). HIV proteins such as Tat, nef, gp120, and gp 41, have also been
implicated in the pathways leading to this neurological dysfunction (Adamson et al.,
1996; Cheng et al., 1998; Nath et al., 2000; Pocernich et al., 2004; Pocernich et al.,
2005). Oxidative stress has been found to play a major role in most neurodegenerative
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disorders (Farr et al., 2003; Butterfield and Boyd-Kimball, 2005; Keller et al., 2005;
Pocernich et al., 2005). This could be another possible mechanism involved in HIVD
induced neurodegeneration, since recent studies have shown that there is increased
oxidative stress in the brain and CSF of HIVD patients (Chauhan et al., 2003; Turchan et
al., 2003).
The NRTIs, including ddC, form the basis of the HAART therapy (White, 2001).
These molecules are derivatives of nucleoside bases with varying modifications that give
alternative substrates for the DNA polymerases. The most common chemical
modification is the lack of 3’OH group of the sugar bases (Kakuda, 2000). The
mechanism for action of ddC is through inhibiting the attachment of nucleic acids and at
the same time terminating DNA chain elongation once incorporated (Balzarini, 1994).
Just like endogenous nucleic acids, NRTIs have to undergo phosphorylation by a number
of kinases to give the active triphosphorylated form (Kakuda, 2000). It is known that the
concentrations of NRTIs decrease progressively as they move from the plasma to the
CSF (Sawchuk and Yang, 1999; Kandanearatchi et al., 2003). The penetration of NRTIs
into the CNS has been an issue to date (Enting et al., 1998; Sawchuk and Yang, 1999).
An increase in the incidence of HIV dementia has been thought to be due to the
prolonged survival of the HIV virus in the brain resulting from the poor penetration of the
antiretroviral used in the therapy (Deutsch et al., 2001), but studies now suggest that
some of these drugs do effectively penetrate the CNS (Enting et al., 1998; Arendt et al.,
2001; Gibbs et al., 2003a). DDC is transported to the CNS through organic anion
transporters (Hedaya and Sawchuk, 1989). This could be a possible explanation for the
lack of any significant difference observed in the levels of lipid peroxidation product
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HNE measured in both synaptosomes and isolated mitochondria treated with ddC in the
current study. For HNE to be generated, the oxidant must be capable of inserting itself
into the lipid bilayer to trigger the cascade for lipid peroxidation (Butterfield and BoydKimball, 2005). Since the transport of ddC into the CNS is through organic anion
transporters ddC may not get into the bilayer and thus not induce lipid peroxidation,
though this is speculative at present.
Though NRTIs are capable of controlling the replication of the HIV virus, they also
have adverse effects during therapy (Scalfaro et al., 1998; Blanche et al., 1999).
Mitochondrial dysfunction has been previously observed with NRTIs, and extensive
studies on the mechanism of NRTI toxicity has been linked to mitochondrial dysfunction,
mutations in mtDNA and oxidative stress through inhibition of DNA polymerase gamma,
which encodes 13 oxidative phosphorylation (OXPHOS) genes (Lewis et al., 2001;
Lewis et al., 2003). It has recently been suggested that NRTIs could cause mitochondrial
dysfunction through mechanisms other than inhibition of DNA polymerase gamma
(Mallon et al., 2005). Of the above mechanisms of toxicity, oxidative stress seems to play
a major role. Oxidative stress is an imbalance between reactive oxygen species and
cellular antioxidant defenses (Butterfield and Stadtman, 1997). The role of HIV infection
and NRTI on induction of oxidative stress has been known for a while, but has not been
well explored (Droge, 2002). We have shown in the present study that, on treatment of
synaptosomes and isolated mitochondria with CSF-achievable concentrations of ddC,
there is a significant increase in the oxidative stress as indexed by the levels of protein
oxidation biomarkers, i.e., protein carbonyls and 3NT. These results support the role
NRTI induction of oxidative stress. DDC at lower concentrations had very little effect of
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the induction of protein oxidation; however at 40nM of ddC there was a significant
increase in the levels of protein oxidation, which on further increase in the concentration
of ddC had no effect. This observed concentration-effect relationship could be possibly
due the saturation of ddC transporters at 40 nM ddC.
The use of antioxidants has been found to be protective in various models
neurodegenerative disorders (DeAtley et al., 1999; Calabrese et al., 2003a; Farr et al.,
2003; Lauderback et al., 2003). Tricyclodecan-9-yl-xanthogenate (D609) is an inhibitor
of phosphatidylcholine-specific phospholipase C, an antioxidant, anti-tumor and a
glutathione (GSH) mimetic (Zhou et al., 2001; Lauderback et al., 2003; Sultana et al.,
2004). Mitochondria isolated from brain of D609-injected gerbils and treated with 52 nM
ddC showed decreased oxidative stress as measured by the levels of protein carbonyls,
demonstrating that though ddC can induce oxidative stress, these effects can be
modulated when a brain accessible glutathione mimetic antioxidant is used. We
previously suggested that D609 possibly could have therapeutic relevance in treating
HIVD (Pocernich et al., 2005).
Mitochondria are not only an essential component of the cell for energy
generating capacity but are targets of oxidative stress because of their ability to generate
ROS. In addition mitochondria also are prodigious regulators of cell death (Melov, 2000).
Several molecules contained within the mitochondria, such as cytochrome c, have a proapoptotic influence. In contrast, Bcl-2 members regulate the pores in the inner membrane
of the mitochondria, which when opened lead to release of pro-apoptotic molecules and
induction of apoptosis (Stefanis, 2005). The inhibition of mtDNA replication can result in
acquired defects that leads to most mitochondrial genetic diseases (Lewis et al., 2003). As
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a result, NRTIs could thus generate phenotypic OXPHOS defects that would eventually
compromise the electron transport chain (ETC), resulting in energy depletion and
eventually cellular dysfunction. It is from this consideration that the phrase
“mitochondrial dysfunction hypothesis” was introduced (Lewis et al., 2003), linking
NRTI toxicity to their effects on the mitochondria (Moyle, 2000; Dalakas et al., 2001). In
the present study, we have observed a significant decrease in the levels of anti-apoptotic
protein Bcl-2 and consequently a significant increase in the release of cytochrome c, upon
treatment of mitochondria with ddC. We also observed an increase in the protein levels of
caspase-3. These results present a possible mechanism through which NRTIs could
induce cell death and neuronal loss in HIV-related dementia. The decrease of Bcl-2
protein, increase in cytochrome c and increase in caspase-3 provides a synergistic
environment for the induction of apoptosis. The down regulation of Bcl-2 levels, leads to
the release of cytochrome c, which binds to Apaf-1and pro-caspase 9 forming the
apoptosome. Also the slight observation of the increase in Bax levels would lead to an
increase in the permeability of the mitochondrial membrane possibly leading to the
release of cytochrome c (Susin et al., 2000). These mediators then activate caspase 9,
which triggers the cascade of “effectors” caspases and eventual cell death (Stefanis,
2005). Our findings are consistent with a recent report that showed that other than ddC,
2’, 3’-didehydro-3'-deoxythymidine (d4T), also caused apoptosis in rat dorsal root
ganglion neuronal cell cultures in HIV free environments (Bodner et al., 2004).
Despite the use of HAART, neurological complications still remain an important
cause of disability and death associated with AIDS (Kandanearatchi et al., 2003;
McArthur et al., 2003). The efficacy of these drugs in the brain is still controversial and
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research into the effect of HAART on the signs and symptoms of HIVD has resulted into
a number of conflicting findings. For example, there are reports showing that HAART is
capable of reducing HIV encephalitis and leukoencephalopathy, improving
neurocognitive function, mental concentration, speed of mental processing, memory, and
visuo-spatial and constructional abilities (Gendelman et al., 1998; Dougherty et al., 2002;
Vago et al., 2002). Another study reports a partial improvement of clinical abnormalities
after patients were on HAART (Stankoff et al., 2001). A study by (Bouwman et al.,
1998)) has reported that after HAART treatment some patients remained free of cognitive
impairment with prolonged life span, while others become neurologically impaired.
Dougherty et al. (2002) treated 96 HIV- demented patients with HAART, and of the 30
patients that had adequate follow-up data, 60% showed neurological improvement
(Dougherty et al., 2002). These studies among others continue to raise the question on the
effect of the antiretroviral therapy on the incidence and prevalence of HIVD and the
efficacy of the NRTIs in the brain, therefore supporting the possibility that these drugs
could themselves contribute to the neurological impairments. In a recent study, it has
been shown that there is brain mitochondrial injury in HIV positive patients who are on
NRTI therapy (Schweinsburg et al., 2005), this provides additional support for the
present study of the possible involvement of NRTI’s in HIV-dementia.
As a result, the current study was an effort at studying a possible toxic effect of
NRTI’s and in particular ddC, with oxidative stress and mitochondrial dysfunction as the
key mechanism of toxicity. Synaptosomes provide a good model of the synapse and
display markers of neurodegeneration upon treatment with various oxidants. Equally,
isolated mitochondria provide a good model to study mechanisms of neurodegeneration
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since they are a source of ROS and control cell death through regulation of apoptosis
(Butterfield et al., 1999a; Lauderback et al., 2001; Lauderback et al., 2003; Brito et al.,
2004; Pocernich et al., 2004; Butterfield and Boyd-Kimball, 2005). As noted above,
despite the reduction of late stage HIV complications with the use of antiretroviral
treatment, neurological complications are still being reported, questioning the efficacy of
these drugs in the brain (Bouwman et al., 1998). It is therefore our view that in addition
to the prolonged survival of the HIV virus in the brain (Deutsch et al., 2001) and
increased penetration of the antiretrovirals to the CNS (Enting et al., 1998; Sawchuk and
Yang, 1999), these NRTIs could by themselves contribute to this neurological
complication through increased oxidative stress as shown by the increase in oxidative
stress biomarkers measured here. It is also possible that ddC could potentiate and act
synergistically with other compounds such as Tat, gp120 and gp41 in inducing
mechanisms implicated in HIVD (Pocernich et al., 2005). This is particularly possible
since Bonder et al (2004) have recently reported that there exists a possible synergy in
toxicity to DRG neuronal cell cultures by gp120 and another NRTI, d4T. In addition, a
recent study has also provided evidence for the injury to brain mitochondria from patients
taking NRTI’s (Schweinsburg et al., 2005) and that NRTI-oxidative stress-induced DNA
damage through inhibition of repair mechanism could lead to oxidative stress-induces
apoptosis in neurons (Hashiguchi et al., 2004; Harrison et al., 2005). Therefore, evidence
provided in the present study suggests that ddC could possibly contribute to the
mechanisms involved in HIVD through induction of oxidative stress, reduction in antiapoptotic protein Bcl-2, release of cytochrome c and increase in caspase 3 and bax
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proteins making this study the first to establish the possible involvement of NRTIs in
HIV related dementia.
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Appendix B
Analysis of Protein Expression Levels in Brain of NF-Kβ P50 Heterozygous
Knockout Mice

B1 Overview
Nuclear factor kappa B (NF-κB) is an important transcriptional factor. Its role in
oxidative stress, and most recently in pro- and anti-apoptotic related mechanistic
pathways, have well been established, however, there still lacks a complete understanding
of the roles its various subunits play in normal human physiology or disease. Because of
the dual nature of NF-κB, the wide range of genes it regulates and the plethora of
stimulus that activates it, various studies addressing the functional role of NF-κB proteins
have resulted in a number of differing findings. As a result, in this dissertation, we
undertook to examine the effect of a stimulus-free environment on the frontal cortex of
mice brain with the p50 subunit of NF-κB partially knocked p50 (-/+). Heterozygous p50
mice knockout (KO) and wild type (WT) were used, and at 7-9 weeks they were
sacrificed and various brain regions dissected. We analyzed the levels of oxidative
damage in the frontal cortex of both the p50 (-/+) and WT mice; measuring the levels of
4-hydroxynonenal (HNE), 3-nitrotyrosine (3NT) and protein carbonyls. There was a
significant reduction in the levels of all oxidative stress parameters analyzed in the p50 (/+) mice when compared to the WT. We further carried out a proteomic profile analysis
to identify proteins that were differentially expressed in these two groups of animals. We
identified proteins whose expressions were significantly increased in the p50 (-/+) mice
compared to the WT. These identified proteins were: ATP synthase gamma chain,
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Ubiquinol-cyt-C reductase, Heat shock protein 10 (Hsp10), Fructose Bisphosphate
aldolase C, and NADH-ubiquinone oxidoreductase. We have therefore established that
partial knock out of the p50 subunit of NF-κB results in a reduction in the levels of
oxidative stress. In addition, there is a significant increase in the expression of key
proteins in the p50 (-/+) brain compared to that of the WT. These findings suggest that
the p50 subunit is an essential component of NF-κB transcription factor that potentially
can be targeted for the development of therapeutic interventions in disorders where
oxidative stress plays a key role.
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B2 Introduction
Nuclear factor kappa B (NF-κB) is a key transcription factor that was earlier
known to regulate the immune and inflammatory processes and viral replication
(Baeuerle and Henkel, 1994; Baldwin, 1996). The NF-κB family of transcription factors
plays key roles in the regulation of cell growth, activation, differentiation, and survival
(Santoro et al., 2003). In addition, an increasing amount of evidence suggests that NF-κB
plays an important role in synaptic plasticity and long-term memory formation (Albensi
and Mattson, 2000; Mattson et al., 2000). The activation of NF-κB is responsible for
transcription of various genes like: TNFα, interleukins, such as IL1, IL2, and IL6;
chemokines, adhesion molecules, such as ICAM-1 VCAM, and E-selectin; enzymes such
as iNOS, COX-2 and proliferation-related proteins such as Cyclin D1 among many others
(Karin et al., 2002; Ferrucci et al., 2004; Chung et al., 2005). The dysregulation of NF-κB
activity has been shown to play a critical role in many inflammatory diseases and in
various neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease (Hunot
et al., 1997; Kaltschmidt et al., 1997; Yoshidome et al., 1999).
NF-κB transcription factor represents a group of both homodimeric and
heterodimeric complexes. In mammals, this family of NF-κB consists of several proteins,
which include NF-κB1 (p50), NF-κB2 (p52), RelA (p65), c-Rel (Rel), and RelB (Hayden
and Ghosh, 2004). A hallmark of this family of proteins is that they contain a highly
conserved domain of ~300 amino acids, termed the Rel homology domain, which
contains sequences important for dimerization, DNA binding, and nuclear localization
(Grilli et al., 1993; Hayden and Ghosh, 2004). The classical and well studied NF-κB
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heterodimer, which is also a potent activator of gene expression, is composed of p50 and
p65 subunits. Unlike p65, p50 and p52 subunits lack transactivation domains and are
produced either by the proteolytic processing of the precursor molecules p105 and p100
in the presence of ATP (Ghosh et al., 1998; Sun and Andersson, 2002) or as has been
suggested, cotranslationally from incompletely synthesized molecules by the proteosome
(Moorthy et al., 2006).
NF-κB is expressed in many cell types in the nervous system and is constitutively
active in subsets of cells in the cortex and hippocampus of the rodent brain at comparably
low levels (Kaltschmidt et al., 1994; O'Neill and Kaltschmidt, 1997). In resting cells, the
classical NF-κB heterodimer p65/p50 is complexed with the inhibitor protein IκB and
sequestered as an inactive complex in the cytoplasm. Activation or stimulation of NF-κB
in the cells leads to the phosphorylation and immediate proteosomal-mediated
degradation of IκB. This leads to the nuclear translocation of NF-κB which then binds to
the regulatory region and transcription of various responsive genes (May and Ghosh,
1998; Santoro et al., 2003; O'Donnell et al., 2005). NF-κB can be activated in both
transcriptional activating and repressing forms. In systems in which NF-κB is activated
during apoptosis, NF-κB can either prevent or potentiate cell death signaling (Beg and
Baltimore, 1996; May and Ghosh, 1998). For example, a pro-apoptotic role for NF- B in
ischemia or glutamate-related damage has been reported (Grilli et al., 1996), while on the
other hand, there is evidence from cell culture models that NF-κB may counteract cell
death in neurons induced by β-amyloid (Mattson et al., 1997; Lezoualc'h et al., 1998).
Hence, depending on the experimental settings NF-κB and can either be pro- or antiapoptotic. This dual role of NF-κB has indeed presented considerable complexities and
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difficulties in studies that try to examine the mechanisms of the action of this
transcription factor. In addition, the wide range of stimuli capable of activating NF-κB,
and also the large number of genes it regulates, differing results have been reported on
the roles of specific subunits of NF-κB. As a result the precise role of NF-κB and its
related mechanistic pathways have been difficult to study and have not been completely
established.
Although classical NF-κB is a heterodimer composed of the p50 and p65
subunits, little is known about gene regulation involving other hetero- and homodimeric
forms of NF-κB which contain trans-activation domains and can act as activators or
inhibitors of transcription (Gadjeva et al., 2004). In an effort to determine the various
roles of the subunits that mediate the observed regulation of NF-κB activity, various mice
with certain subunits knocked out have been used. In particular, since the p65/p50
heterodimeric form is the most predominant and the indispensable component of NF-κB,
knockouts of these two subunits have been developed (Flohe et al., 1997). However, p65
knockouts have been found to have defects during development and they die prematurely
of liver apoptosis (Beg et al., 1995; Hayden and Ghosh, 2004), hence not many studies of
p65 knockouts have been carried out. On the other hand, although p50 deficient mice
have been shown to display functional defects in immune response, they develop
normally (Beg et al., 1995), and also, since neurons from animals genetically ablated for
p50 survive well in culture and are no more sensitive or resistant to neuronal death than
wild type neurons (Aleyasin et al., 2004), they provide the best avenue to study various
mechanisms of NF-κB-related activity. Of the two subunits, less is known regarding the
precise role of p50 in NF-κB-mediated inhibition of apoptosis, and at present, the
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importance of the NF-κB signaling pathway is still in question especially since various
studies of p50 knockout mice carried out so far have presented contradictory findings.
For example, in one study, the absence of the p50 subunit of NF- B resulted in a
significant reduction in infarct size in parts of the vascular territory of the middle cerebral
artery (Kawano et al., 2006). Also, in an initial report of mice with targeted disruption of
the NF-κB1 subunit, p50 (p50 −/− mice), it was discovered that while these mice are
more susceptible to certain bacterial pathogens, they are resistant to murine
encephalomyocarditis virus (EMCV) infections causing myocarditis and dilated
cardiomyopathy that kills normal healthy mice (Schwarz et al., 1998). On the other hand,
it has been shown that mice depleted of the p50 subunit have been more susceptible to
neuronal injury when exposed to a wide range of toxins and stimulants (Yu et al., 1999;
Pennypacker et al., 2001; Kassed et al., 2002).
Considering the above, the present study involved further analysis of the p50
subunit of NF-κB. Since most studies on p50 knockout mice have so far been carried out
using a wide range of stimuli (Weih et al., 1997; Iimuro et al., 1998; Pennypacker et al.,
2001; Mabley et al., 2002; Gadjeva et al., 2004; Kassed and Herkenham, 2004), the
present study provided a unique opportunity for investigating the role of p50 subunit in a
stimulus-free experimental environment hopefully providiing us with additional evidence
on the mechanism of NF-κB activation. We hypothesized that the partial knock out of the
p50 (-/+) subunit could potentially be protective in a stimulus-free environment through
an oxidative stress mechanism. To test our hypothesis, we measured the levels of
oxidative stress biomarkers in the brain of WT and p50 (-/+) mice and observed a
significant reduction in the levels of lipid peroxidation as measured by HNE and the
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levels of protein oxidation as measured by the levels of 3NT and protein carbonyls in the
p50 (-/+) mice compared to the WT. We further carried out a differential expression
proteomic analysis on the p50 (-/+) mice. Proteomics has recently been successfully used
in our laboratory to identify various proteins that have undergone modifications in
various disease states and models thereof (Butterfield, 2004; Butterfield et al., 2006a;
Butterfield et al., 2006c; Sultana et al., 2006b). As a result, using proteomics we
identified five proteins to be significantly increased in expression in the p50 (-/+) mice
when compared to the WT. Therefore, the lack of the p50 subunit makes the brain of
mice less susceptible to oxidative stress and also activates the expression of key proteins
involved in energy metabolism and antioxidant activity. Hence, this study has provided
insights into the role of NF-κB and especially the role of the p50 subunit of NF-κB.
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B3 Experimental procedures
Animals and experimental protocols
Male wild type and NF-κB p50 -/+ mice were received from Jackson Laboratory at 4-6
weeks and were sacrificed at 7-9 weeks. They were housed in a temperature and humidity
controlled room with a 12:12 h light: dark cycle, with food and water available ad
libitum. All procedures and protocols were approved by the Institutional Animal Care and
Use Committee. These were performed in Dr Charles Rammasamy’s laboratory at INRSInstitut Armand-Frappier, and INAF, University Laval, Québec, Canada.
Measurement of protein carbonyls
Protein carbonyls are an index of protein oxidation and were determined as
described previously (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein)
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples
were then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30%
glycerol). Derivatized protein samples were then blotted onto a nitrocellulose membrane
with a slot-blot apparatus (250 ng per lane). The membrane was then washed with wash
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by
incubation in the presence of 5% bovine serum albumin, followed by incubation with
rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h.
The membranes were washed with wash buffer and further incubated with alkaline
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion
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Image (PC version of Macintosh-compatible NIH Image) software. No non-specific
background binding of the primary or secondary antibodies was found.
Measurement of 3-nitrotyrosine (3-NT)
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003).
The nitrotyrosine content was determined immunochemically as previously described
(Drake et al., 2003b). Briefly, samples were incubated with Laemmli sample buffer in a
1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) for
20 min. Protein (250 ng) was then blotted onto the nitrocellulose paper using the slot-blot
apparatus and immunochemical methods as described above for protein carbonyls. The
mouse anti-nitrotyrosine antibody (5: 1000 dilutions) was used as the primary antibody
and alkaline phosphatase-conjugated anti-mouse secondary antibody was used for
detection. Blots were then scanned using scion imaging and densitometric analysis of
bands in images of the blots was used to calculate levels of 3-NT. No non-specific
binding of the primary or secondary antibodies was found.
Measurement of 4-hydoxynonenal (HNE)
HNE is a marker of lipid oxidation and the assay was performed as previously
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v)
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus
containing a nitrocellulose membrane under vacuum pressure. The membrane was
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline
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containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in
PBST for 90 min. Following completion of the primary antibody incubation, the
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The
membrane was washed in PBST three times and developed using Sigmafast Tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
by Scion Image. A small background of the primary antibody binding to the membrane
was found, but this was the same in both control and subject blots.
Two-dimensional electrophoresis
Brain samples (200 µg) were incubated with 4 volumes of 2N HCl at room for
electrophoresis. Proteins were then precipitated by the addition of ice-cold 100%
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps,
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v)
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h.
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First dimension electrophoresis
For the first-dimension electrophoresis, 200 µL of sample solution was applied to
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80
°C until the 2nd dimension electrophoresis was to be performed.
Second dimension electrophoresis
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along
with the sample at 200 V for 65 min.
SYPRO ruby staining
After the second dimension electrophoresis, the gels were incubated in fixing
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was
then removed and gels stored in DI water.
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Image analysis
SYPRO ruby-stained gel images were obtained using a STORM phosphoimager
(Ex. 470 nm, Em. 618 nm, Molecular Dynamics, Sunnyvale, CA, USA) and also saved in
TIFF format. PD-Quest (Bio-Rad) imaging software was then used to match and analyze
visualized protein spots among differential 2D gels with one gel for each individual
sample.
In-gel trypsin digestion
Protein spots statistically different that controls were digested in-gel by trypsin
using protocols previously described and modified by (Thongboonkerd et al., 2002).
Briefly, spots of interest were excised using a clean blade and placed in Eppendorf tubes,
which were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room
temperature for 15 min. Acetonitrile was then added to the gel pieces and incubated at
room temperature for 15 min. This solvent mixture was then removed and gel pieces
dried. The protein spots were then incubated with 20 µL of 20 mM DTT in 0.1 M
NH4HCO3 at 56 °C for 45 min. The DTT solution was removed and replaced with 20 µL
of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was then incubated at room
temperature for 30 min. The iodoacetamide was removed and replaced with 0.2 mL of
50 mM NH4HCO3 and incubated at room temperature for 15 min. Acetonitrile (200 µL)
was added. After 15 min incubation, the solvent was removed, and the gel spots were
dried in a flow hood for 30 min. The gel pieces were rehydrated with 20 ng/µL-modified
trypsin (Promega, Madison, WI) in 50 mM NH4HCO3 with the minimal volume enough
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to cover the gel pieces. The gel pieces were incubated overnight at 37 °C in a shaking
incubator.
Mass spectrometry
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen,
Germany) and prepared according to AnchorChip recommendations (AnchorChip
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol:
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.
The TFA droplet was gently blown off the sample spot with compressed air. The
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser
shots. External calibration of the mass axis was used for acquisition and internal
calibration using either trypsin autolysis ions or matrix clusters and was applied post
acquisition for accurate mass determination.
Analysis of peptide sequences
Peptide mass fingerprinting was used to identify proteins from tryptic peptide
fragments by utilizing the MASCOT search engine based on the entire NCBI and
SwissProt protein databases. Database searches were conducted allowing for up to one
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missed trypsin cleavage and using the assumption that the peptides were monoisotopic,
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was
the window of error allowed for matching the peptide mass values (Butterfield and
Castegna, 2003b). Probability-based MOWSE scores were estimated by comparison of
search results against estimated random match population and were reported as 10*log10 (p), where p is the probability that the identification of the protein is a random
event. MOWSE scores greater than 63 were considered to be significant (p < 0.05). All
protein identifications were in the expected size and isoelectric point (pI) range based on
the position in the gel.
Statistical analysis
Statistical analysis of differentially expressed protein levels matched with spots
on 2D-gels from frontal cortex brain samples of the p50 (-/+) and wild type (WT) were
used and carried out using Student's t-tests. Here we report a comparative proteomics
analysis of p50 (-/+) vs. WT. A value of p < 0.05 was considered statistically significant.
Only proteins that are considered significantly different by Student's t-test were subjected
to in-gel trypsin digestion and subsequent proteomic analysis. This is the normal
procedure for proteomics studies, since sophisticated statistical analysis used for micro
array studies are not applicable for proteomics studies (Maurer et al., 2005).
Protein Interacteome
The functional protein interacteome was obtained by using Interaction Explorer
TM

Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist

is software for functional interaction analysis. It allows for the identification and
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visualization of pathways, gene regulation networks and protein interaction maps
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of
data. This data set is then searched against ResNet, a database containing over 500,000
biological interactions built by applying the MedScan text-mining algorithms to all
PubMed abstracts. These interactions are then visualized by building interaction networks
with shortest-path algorithms. This process can graphically identify all known interaction
among the proteins. The information of the function of these proteins and their relevance
to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002).

322

B4 Results
Decreased levels of oxidative stressing p50 (-/+) mice and compared to WT
The levels of protein carbonyls, 3NT and HNE as indicators of oxidative stress
were measured in the frontal cortex of p50 (-/+) mice and compared to WT. Fig.B1
shows total protein oxidation measured by the accumulation of protein carbonyls and
3NT and also the levels of lipid peroxidation as measured by protein-bound HNE. There
was a significant decrease in the levels of all oxidative stress parameter measured in the
p50 (-/+) mice compared to WT.
Increased protein expression levels in p50 (-/+) mice compared to the wild type
Two-dimensional electrophoresis offers an excellent tool for the screening of
abundant protein changes in various disease states (Butterfield, 2004). To assess whether
there were any changes in the proteomic profile in the brain of p50 (-/+) mice in the
present study, we investigated the pattern of protein expression in the frontal cortex from
the p50 (-/+) mice compared to the wild type. Comparing the densitometric intensities of
individual spots on the gels, five proteins were expressed at significantly higher levels in
the frontal cortex of p50 (-/+) mice compared to the wild type. Fig A2 shows SYPRO
ruby stained 2D gels of the p50 (-/+) mice (A) vs. wild type (B) groups, with identified
protein boxed and labeled. The brain proteins identified with increased expression in the
p50 (-/+) mice were: ATP synthase gamma chain, Ubiquinol-cyt-C reductase, Heat shock
protein (Hsp10), Fructose Bisphosphate aldolase C, and NADH-ubiquinone
oxidoreductase. These proteins identified by mass spectrometry are shown in Table A1.
Table A2 provides the changes in protein levels expressed as arbitrary units (A.U) ±
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S.E.M. Table A1 shows that the mowse scores obtained are all highly significant and that
the probability of a random identification using proteomics is exceedingly small in this
study.
Protein interacteome
Fig B3 shows the protein interacteome of proteomics-identified proteins
differentially expressed in the frontal cortex of p50 (-/+) mice. The Interaction Explorer
PathwayAssist (Stratagene) software shows that the proteins identified in this study are
related to regulation of signal transduction, energy metabolism, and chaperone activity
among others. As a result, the present findings suggest that the partial knock out p50
subunit of NF-κB leads to the expression of proteins that are involved in various
pathways that provide normal development and protection against oxidative stress.
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Figure B1
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Figure B1 Shows protein carbonyl, 3NT and HNE levels in the frontal cortex of p50 (-/+)
compared to wild type. There was a significant reduction in the levels of protein
carbonyls, 3NT and HNE in the p50 (-/+) mice compared to the wild type. Data are
represented as % control; error bars indicate the SEM for each group measured (* p<0.05
n=5).
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Figure B2
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Figure B2 Shows SYPRO Ruby-stained 2D-gels maps of frontal cortex brain samples
from Wild-type (A) vs. p50 (-/+) mice (B). Proteins identified by mass spectrometry
showing differential expression are presented as the boxed spots.
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Figure B3

Figure B3 Schematic diagram of a functional interacteome of all proteins identified to be
differentially expressed in the brains of p50 (-/+) compared to wild type. This diagram
was generated by the interaction explorer ™ Pathway Module (Stratagene), indicating
that all the proteins are directly or indirectly associated with cellular process shown.
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B5 Discussion
In the present study we have found that the partial knock out of the p50 subunit
and a stimulus-free experimental set-up, lead to a reduction in the levels of oxidative
damage in the p50 (-/+) mice brain when compared to that of the wild type mouse. We
observed a significant reduction in the levels of oxidative stress biomarkers, i.e., protein
carbonyls, 3NT and lipid peroxidation product HNE. In addition, we carried out a
proteomic profile analysis of the frontal cortex of the p50 (-/+) mice brain and compared
it to the wild type. We found that there was a significant increase in the expression of
proteins related to energy metabolism and antioxidant activity in the p50 (-/+) mice brain
compared to the wild type. These results present an intriguing finding and are discussed
here with relevance to the mechanism of NF-κB transcription factor, and the role of the
p50 subunit in oxidative stress.
NF-κB has been known to transcribe a wide range of genes with different and
sometimes opposite functions. NF-κB is involved in transcribing both pro-apoptotic
genes such as p53, Fas and FasL (Matsui et al., 1998; Kirch et al., 1999) and antiapoptotic genes such as, Bcl-2, Bcl-x and SOD2 (Lipton, 1997; Mattson et al., 1997;
Tamatani et al., 1999). NF-κB activity is regulated by various factors, such as stress and
injury related stimuli, cell type, and organ type among others. The wide range of stressand injury-related stimuli regulated by NF-κB present investigators with extreme
difficulties in trying to elucidate mechanistic pathways of this transcription factor and has
led to the generation of numerous differing findings. An understanding of its dual action
might therefore be possible if we consider its various subunits and their role in regulating
its activation. As mentioned earlier, NF-κB consists of several proteins, which include
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NF-κB1 (p50), NF-κB2 (p52), RelA (p65), c-Rel (Rel), with the heterodimer p50/p65
being the most predominant (Grilli et al., 1993; Ghosh et al., 1998; Santoro et al., 2003).
Usually located in the cytosol, the presence of a stimulus triggers the translocation to the
nucleus where it binds to promoter region of specific genes activating its transcription
(Grilli et al., 1993).
The role of its various subunits and in particular p50 in oxidative stress related
mechanisms is still at question. Though the p50 subunit generated from precursor
molecule p105 lacks a transactivation domain, its disruption in various experimental
settings has generated a number of interesting findings. For example, in a model of
Huntington’s disease p50 (-/-) mice have been shown to have increased oxidative stress,
calcium dysregulation and increased damage to striatal neurons following treatment with
mitochondrial toxin 3-nitropropionic acid (3NP) (Yu et al., 1999). It has also been shown
that lack of p50 negatively modulates learning ability and hippocampal response to brain
injury after chemical-induced lesion (Kassed et al., 2002). In addition, a higher
constitutive expression of cyclooxygenase-2 (COX-2) in p50-/- mice following an acute
inhalation of pulmonary irritant ozone has been observed (Mabley et al., 2002;
Fakhrzadeh et al., 2004). It has also been reported that p50 is increased in neurons
surviving hippocampal injury after middle cerebral artery occlusion (Pennypacker et al.,
2001) and that overexpression of p50 inhibits TNF- α gene expression following
lipopolysaccharide (LPS) on p50-/- splenocytes (Gadjeva et al., 2004). On the other
hand, it has been shown that NF-κB p50-deficient mice show; reduced anxiety-like
behaviors in tests involving exploratory drive and anxiety (Kassed and Herkenham,
2004); reduced ischemic damage (Schneider et al., 1999); resistance to murine
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enecephalomyocarditis virus (EMCV) infections that cause myocarditis and dilated
cardiomyopathy which kill normal healthy mice (Schwarz et al., 1998); and reduced
ventricular rupture and improved cardiac function and survival after myocardial
infarction (MI) (Kawano et al., 2005). In addition to the above, a study by O’Donnell et
al., 2005 showed that following reovirus infection in the CNS, NF-κB p50 (+/+) mice
exhibited significant neuronal apoptosis, while p50 (-/-) mice displayed a minimal
apoptotic response. On the other hand, reovirus infection in the heart induced minimal
apoptosis in the NF-κB p50+/+ mice, while extensive apoptosis occurred in the heart of
p50–/– mice (O'Donnell et al., 2005). This study provided two distinct roles for the NF-κB
p50 subunit in the brain and heart, continuing to confirm the organ and cell type
specificity of the NF-κB activity. The studies mentioned above provide two differing
effects resulting from the disruption of the p50 subunit of NF-κB, hence, presenting
researches with a difficult task of trying to conclusively elucidate the exact mechanisms
of this key transcription factor (Lipton, 1997).
It has been shown that NF-κB is redox regulated and that oxidative stress is an
activator of NF-κB and a known regulator of gene transcription since most agents that
that activate NF-κB, trigger the formation of reactive oxygen species (ROS) or are
oxidants themselves, e.g. superoxide, hydrogen peroxide, hydroxyl radicals and
peroxynitrite (Laskin and Pendino, 1995; Kim et al., 2000b; Chung et al., 2005). In
addition, NF-κB activation can also be triggered by ROS in the absence of any stimulus,
as is the case in the current study. The upstream processes for the activation of NF-κB
have also been shown to involve a series of serine/threonine kinases and phosphatases
that are regulated by the redox status of the cell, further emphasizing the interaction of
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NF-κB and oxidative stress (Flohe et al., 1997). In the present study, we observed a
significant decrease in the levels of oxidative stress as indexed by oxidative stress
biomarkers, i.e., protein carbonyls, 3NT and lipid peroxidation product HNE in the brains
of partially knocked out p50 (-/+) mice compared to those of the WT. It has previously
been shown that 4-hydroxyhexenal (HHE), a reactive aldehdye similar to HNE, activates
NF-κB which further activates p38, MAPK and extracellular signal regulated kinase
(ERK) leading to various signaling cascades (Je et al., 2004). As a result, the reduced
levels of HNE in the p50 (-/+) mice observed in the present study could thus inhibit the
activation of NF-κB leading to a possible protective mechanism.
The partial knock out of p50, i.e., p50 (-/+), generates a dysfunctional subunit,
which as a result could lead to a possible compensatory mechanism from the other
heterodimer member of the classical NF-κB transcription factor, p65. Since p65 has a
transactivation domain and is responsible for the transcriptional activation of target
genes, its compensatory role would therefore bring about a more functional NF-κB
transcription factor and enhance activity (Kato et al., 2002). This proposed compensatory
mechanism phenomenon has previously been documented in cytokine knockout mice
where the redundancy of the cytokine cascade compensates for the deletion of a single
cytokine gene (Kato et al., 2002). Various studies of p50 knockouts also continue to put
forth the possible compensational role of p65. In a study of partial hepatectomy in p50 (/-) mice, there was an increased expression of the p65 protein in the nucleus which was
believed to provide compensation for the absence of p50 leading to normal liver
regeneration and repair following liver injury (Iimuro et al., 1998; Kato et al., 2002). It
has also been shown that gene deletion of p50 does not alter hepatic inflammatory
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response since the increased nuclei level of p65 protein in the p50 (-/-) mice compared to
the p50 (+/+) mice was believed to compensate for sufficient transcriptional activation of
relevant genes (Beg et al., 1995). It is also suggested that both p50 and p65 may have
critical inhibitory functions and that the inhibitory functions of p65 are more clearly
demonstrated in the absence of p50 (Gadjeva et al., 2004). In the same fashion, we
hypothesis that the partial knock out of p50 leads to a dysfunctional heterodimer hence
necessitating a compensatory response from p65 which then leads to the transcriptional of
antioxidant genes and hence a reduction in the levels of oxidative stress.
Other than the compensatory response mechanisms suggested for the reduction in
oxidative stress levels in the p50 (-/+) mice, it is also possible that other pathways could
be involved in activating the NF-κB leading to the observed reduction in the levels of
oxidative stress observed in the present study. One potential pathway could be the
involvement of nuclear factor-erythroid 2–related factor 2 (Nrf2). Just like NF-κB, Nrf2
is also involved in the innate immune response and survival. In particular, Nrf2 regulates
the basal and inducible expression of various antioxidant and other cytoprotective genes
by binding to the antioxidant response element of DNA in conditions of oxidative stress
(Motohashi and Yamamoto, 2004). It has been reported that there could be a possible
cross-talk among redox-sensitive transcription factors NF-κB and Nrf2, in that there is
dependency of key family members of AP-1 and NF-κB on Nrf2 (Yang et al., 2005).
Thus, Nrf2 regulates NF- B activation largely by modulating its upstream signaling
components (Thimmulappa et al., 2006). Under normal conditions, there are low nuclear
levels of Nrf2; under stress conditions there is an increase in the nuclear accumulation of
Nrf2 resulting in its binding to the antioxidant response element leading to enhanced
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transcriptional activation of antioxidant target genes (Thimmulappa et al., 2006). A broad
range of antioxidants has been known to inhibit the activation of NF-κB (Flohe et al.,
1997); however, oxidative stress induced activation of NF-κB leads to the up-regulation
of antioxidant enzymes such as glutathione peroxidase and catalase among others
(Messina et al., 2006). For the present study we believe that with the compensatory effect
of p65, NF-κB could be activated and in turn it would activate Nrf2 leading to the upregulation of antioxidant enzymes resulting into the reduction in the level of oxidative
stress observed. Downstream effects of Nrf2 and NF-κB activity in the p50 (-/+) mice
can be observed in the present study from the proteomics results obtained. In addition to a
reduction in the levels oxidative damage in the p50 (-/+) mice in the current study, we
also observed a significant increase in the expression of key proteins related to energy
metabolism and cytoprotective activities. These proteins identified and their possible
roles in survival are discussed as follows;
Heat shock proteins (HSP) are a family of molecules that are highly conserved
during evolution and involved in many cellular functions, such as protein folding. Some
examples include HSP10, -27, -60, -70, -72 and -90. Mammalian heat shock protein 10
(Hsp10) also known as chaperonin 10 is a mitochondrial protein involved in protein
folding. It has been shown that HSP 10 forms a heptameric lid, which binds to a doublering toroidal structure that is composed of seven Hsp subunit rings (Xu et al., 1997).
Increased expression of HSPs has recently been found to be associated with a number of
neurodegenerative disorders, immunomodulatory activities among others (Flohe et al.,
2003; Poon et al., 2004b). It is believed that HSPs are exported to the plasma membrane
and are released from apoptotic cells as a source of signaling to the innate and adaptive
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immune system (Beg, 2002; Flohe et al., 2003). HSP10 and another chaperone HSP60
interact in a two-step folding mechanism in the mitochondria of prokaryotic and
eukaryotic cells (Beg, 2002) and it is hypothesized that HSP60 and HSP10 could possibly
be a new diagnostic and prognostic tools for certain cancers (Triantafilou and
Triantafilou, 2004). In the present study, we have shown that there is a significant
increase in the expression of HSP10 in the p50 (-/+) mice compared to the wild type. The
increased expression could mean enhanced activity leading to proper folding of proteins
and more protection against oxidative stress and this could possibly contribute to the
significant reduction of oxidative stress observed in these p50 (-/+) mice.
The NADH: ubiquinone oxidoreductase also known as Complex I, couples the
oxidation of NADH and the reduction of ubiquinone, to the generation of a proton
gradient which is then used for generation of ATP in the mitochondria (Weiss et al.,
1991). This complex provides the input to the electron transport chain from the NADlinked dehydrogenases of the citric acid cycle. Dysregulation of this complex has been
associated with various neurodegenerative disorders such as AD among others
(Robinson, 1998; Loeffen et al., 2000). In the current study, we observed a significant
increase in the expression of NADH: ubiquinone oxidoreductase in the p50 (-/+) mice
compared to the wild type. The significance of this could imply increased activity and
also provide an efficient mechanism for the generation of proton gradient that eventually
leads to an increase in the production of ATP.
Fructose Bisphosphate aldolase C (FBP) is a glycolytic enzyme that catalyses the
reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate into
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dihydroxyacetone-phosphate and glyceraldehyde 3-phosphate (Perham, 1990). In
vertebrates, three forms of this enzyme are found: aldolase A is expressed in muscle,
aldolase B in liver, kidney, stomach and intestine, and aldolase C in brain, heart and
ovary. The different isozymes have different catalytic functions: aldolases A and C are
mainly involved in glycolysis, while aldolase B is involved in both glycolysis and
gluconeogenesis (Perham, 1990). In the current study we observed a significant increase
in the expression of FBP in the p50 (-/+) mice compared to the wild type that would lead
to improved glycolytic function and enhanced energy metabolism.
ATP synthase (Complex V) is a mitochondrial enzyme that utilizes the
electrochemical proton gradient established across the inner mitochondrial membrane by
the ETC for synthesis of ATP (Leyva et al., 2003). ATP synthase deficiency has been
associated with an increase in oxidative stress (Basso et al., 2004). Our laboratory has
shown that ATP synthase is oxidatively modified and is inactivated in the gracile axonal
dystrophy (gad) mouse brain (Castegna et al., 2004). In the present study, ATP synthase γ
chain expression was significantly increased in the p50 (-/+) mice compared to the wild
type. The increased expression of this enzyme could presumably result in increased
activity, hence enhancing the crucial cellular process of ATP generation.
Ubiquinol-cytochrome-C reductase also known as the bc1 complex or complex III
is the central redox enzyme in the ETC. This complex catalyzes the oxidation of diverse
quinols by high potential redox-carriers, in the process generating a proton gradient that
is utilized for the generation of ATP (Mulkidjanian, 2005). In the current study the
expression of the Ubiquinol-cytochrome-C reductase core protein 2 also known as
complex III subunit II was found to be significantly increased. This is a component of the
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Ubiquinol-cytochrome c reductase complex and the core protein 2 is required for the
assembly of the Complex III. As a result, the increase in expression of three key proteins
of the ETC, a glycolytic enzyme and a chaperone protein in the present study is very
significant, in that this ensures not only sufficient generation of adequate ATP that would
lead to improved cellular activities and hence survival in the p50 (-/+) mice, but also the
proper folding of proteins.
The present study and those discussed in this dissertation research underscore the
complexity of the mechanism through which NF-κB is activated or repressed. It has been
suggest that the ultimate biological effect of NF-κB activation will be dependent on a
number of reasons; these include the stimulus responsible for this activation or
repression, the subunit composition of the NF-κB, gene targets, the cell type and organ
among many others (Culmsee et al., 2003). With these many variables to consider and
different experimental approaches available, a wide variation in the interpretation of
results will be expected. It should therefore be noted that whereas all these studies
mentioned in this manuscript had various stimuli and the knockouts were homozygous,
the present study had heterozygous knockout mice and there was no stimulus given. We
believe that the differences in the knockout models are very subtle with the major
difference being only on the lack of stimulus, which therefore should not undermine the
importance of the present findings. Though speculative, we believe that the partial knock
out of p50 subunit of NF-κB might be a pre-conditioning step preparing the mice against
oxidative stress induced effects. The effect of various stimuli on the p50 (-/+) mice
showing a reduced oxidative stress warrants further investigation since this might be a
potential avenue for therapeutic interventions. We therefore provide additional insights
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on the complexities of NF-κB activity especially in a stimulus-free environment. We also
suggest that the p50 subunit of NF-κB plays a significant role in the oxidative stressrelated neurodegeneration and that it should be considered as a potential target in the
development of therapeutics strategies involving oxidative stress and nuclear factor kappa
B (NF-κB) activity.
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Appendix C
Data supporting figures and Tables
Figure 4.1A
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Figure 4.1B
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Figure 4.1C
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Figure 4.6
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Table 6.4
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HNE
CH
368.5
502
481.5
595.5
486.875
100
46.609805

IH
802
779
753.5
626.5
740.25
152.04108
39.188912

3NT
CH
394.25
460.5
448
409
427.9375
100
15.695798

IH
604
565
659.5
612
610.125
142.57339
19.397568

Carbonyl
CH
736.66667
698.66667
754
680.66667
717.5
100
16.859715

Table 7.3

Cortex
SSP
3402
5404
6606
6609
3303

Contra
blots/gels
Average
62.2
16.9
1.3
0.02
0.06

Ipsi blot/gels
Average
% Control
228.3
367.1
162.7
962.8
36.7
2742.7
0.06
318.8
1.28
2042.5

Sem
47.2
68.8
85.9
30.0
74.3

Table 7.4
Hippo

Contra
Blots/gels

SSP
3303
4204
6511
6609

Average
0.062485
0.028807
7.174938
0.021081

Ispi Blots/gels
%
Control
Average
0.851117 1362.103
0.351442 1220.004
42.21875 588.4197
0.109313 518.536

348

Sem
38.55067
31.80999
37.7746
27.16987

IH
1003.3333
1142.6667
926.233
890.66667
990.72492
138.08013
55.83915

Figure 7.7
Complex I
Contralateral
Ipsilateral

Mean
92.50
52.90

SEM
0.925
12.5

Complex IV
Contralateral
Ipsilateral

Mean
96.76
73.18

SEM
6.11
3.41

PDH activity
Contralateral
Ipsilateral

Mean
99.50
84.10

SEM
5.22
13.97

Figure A1

Average
Stdev
Sem

Ctrl
336
381
358.5
321
354
365.2
352.6167
21.33639
8.534557

Fe2+/H2O2
589
611
600
599
606
576
596.8333
12.6082
5.043279

349

29
448
412
386
342
378
404
395
35.6595
14.2638

40
540
569
554.5
509
512
523
534.5833
24.12139
9.648558

52
509
472.5
423
462
412
445
453.9167
35.31914
14.12766

Figure A3

Average
Stdev
Sem

Ctrl
336
381
358.5
321
354
365.2
352.6167
21.33639
8.534557

Fe2+/H2O2
589
611
600
599
606
576
596.8333
12.6082
5.043279

D609
225
242
233.5
221.5
263.2
241
237.7
14.97331
5.989324

40 nM
436
509
472.5
462
421
488
464.75
32.57875
13.0315

D609+ 40 nM
DCC
306
293
299.5
311
285.1
279
295.6
12.27273
4.909094

Figure A4

Average
% Control
Stdev
SEM

Ctrl
104
124
65
97.66667
100
30.00556
20.0037

29
107
125
130
120.6667
123.5495
12.09683
8.064554

40
137
171
175
161
164.8464
20.88061
13.92041

Ctrl
182
184
133
166.3333
100
28.88483
16.69643

29
99
146
107
117.3333
70.54108
25.14624
14.5354

40
84
151
157
130.6667
78.55711
40.52571
23.42527

52
114
121
99
111.3333
113.9932
11.23981
7.493207

Figure A5

Average
% Control
Stdev
Sem

350

52
97
139
93
109.6667
65.93186
25.48202
14.72949

Figure A6

Average
%Control
Stdev
Sem

CC
203
196
191
186
194
100
7.25718
3.62859

29nm
228
247
236
214
231.25
119.201
13.88944
6.944722

40nm
309
326
301
316
313
161.3402
10.61446
5.307228

52nm
183
142
153
146
156
80.41237
18.5652
9.2826

Figure A7

Average
% Control
Stdev
Sem

C
401
328
353
336
354.5
100
32.70576
16.35288

Fe2+/H202
538
512
498
502
512.5
144.5698
17.99074
8.995369

370nM
380
371
375
362
372
104.9365
7.615773
3.807887

700nM
333
326
329
336
331
93.37094
4.396969
2.198484

1mM
307
306
298
310
305.25
86.10719
5.123475
2.561738

Figure B1

Average
% Control
Stdev
Sem

Carbonyl
wt
232.5
367.5
271
166
298.5
267.1
100
74.9995
34.090682

ko
171
154
191
170.5
157
168.7
63.159865
14.652645
6.6602931

HNE
wt
379.5
389.5
355
357.5
496.5
395.6
100
58.260621
26.482101

351

ko
301.5
341.5
269
351.5
353
323.3
81.723964
36.852069
16.750941

3NT
wt
534.33333
419
423
443.33333
476.33333
459.2
100
47.740968
21.70044

ko
365.66667
336.33333
432.33333
429.33333
434.66667
399.66667
87.035424
45.659975
20.754534

Figure B2

WT

KO

Fold
change

p value

ATP Synthase

959.14

1367.02

1.42526

0.0562

Ubiquinol cyt c reductase

2113.84

8008.46

3.78858

0.01624

HSP10

1340.64

2671.24

1.99251

0.04613

FBP

1343.66

1609.08

1.19754

0.01913

NADH-ubiquinone

345.9

780.54

2.25655

0.05324
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